Ie Esc Guideline

European Heart Journal (2015) 36, 3075–3123 ESC GUIDELINES
doi:10.1093/eurheartj/ehv319
2015 ESC Guidelines for the management

of infective endocarditis
The Task Force for the Management of Infective Endocarditis of the
European Society of Cardiology (ESC)
Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Endorsed by: European Association for Cardio-Thoracic Surgery
(EACTS), the European Association of Nuclear Medicine (EANM)
Authors/Task Force Members: Gilbert Habib* (Chairperson) (France),
Patrizio Lancellotti* (co-Chairperson) (Belgium), Manuel J. Antunes (Portugal),
Maria Grazia Bongiorni (Italy), Jean-Paul Casalta (France), Francesco Del Zotti (Italy),
Raluca Dulgheru (Belgium), Gebrine El Khoury (Belgium), Paola Anna Erbaa (Italy),
Bernard Iung (France), Jose M. Mirob (Spain), Barbara J. Mulder (The Netherlands),
Edyta Plonska-Gosciniak (Poland), Susanna Price (UK), Jolien Roos-Hesselink
(The Netherlands), Ulrika Snygg-Martin (Sweden), Franck Thuny (France),
Pilar Tornos Mas (Spain), Isidre Vilacosta (Spain), and Jose Luis Zamorano (Spain)
Document Reviewers: Çetin Erol (CPG Review Coordinator) (Turkey), Petros Nihoyannopoulos (CPG Review
Coordinator) (UK), Victor Aboyans (France), Stefan Agewall (Norway), George Athanassopoulos (Greece),
Saide Aytekin (Turkey), Werner Benzer (Austria), Héctor Bueno (Spain), Lidewij Broekhuizen (The Netherlands),
Scipione Carerj (Italy), Bernard Cosyns (Belgium), Julie De Backer (Belgium), Michele De Bonis (Italy),
Konstantinos Dimopoulos (UK), Erwan Donal (France), Heinz Drexel (Austria), Frank Arnold Flachskampf (Sweden),
Roger Hall (UK), Sigrun Halvorsen (Norway), Bruno Hoenb (France), Paulus Kirchhof (UK/Germany),
* Corresponding authors: Gilbert Habib, Service de Cardiologie, C.H.U. De La Timone, Bd Jean Moulin, 13005 Marseille, France, Tel: +33 4 91 38 75 88, Fax: +33 4 91 38 47 64,
Email: gilbert.habib2@gmail.com
Patrizio Lancellotti, University of Liège Hospital, GIGA Cardiovascular Sciences, Departments of Cardiology, Heart Valve Clinic, CHU Sart Tilman, Liège, Belgium – GVM Care and
Research, E.S. Health Science Foundation, Lugo (RA), Italy, Tel: +3243667196, Fax: +3243667194, Email: plancellotti@chu.ulg.ac.be
ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix
ESC entities having participated in the development of this document:
ESC Associations: Acute Cardiovascular Care Association (ACCA), European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Association of
Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
ESC Councils: Council for Cardiology Practice (CCP), Council on Cardiovascular Nursing and Allied Professions (CCNAP), Council on Cardiovascular Primary Care (CCPC).
ESC Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Grown-up Congenital Heart Disease, Myocardial and Pericardial Diseases, Pulmonary Circulation
and Right Ventricular Function, Thrombosis, Valvular Heart Disease.
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford Uni-
versity Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at
the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recom-
mendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encour-
aged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or
therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and
accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor
do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent
public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the
health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
& The European Society of Cardiology 2015. All rights reserved. For permissions please email: journals.permissions@oup.com.
3076 ESC Guidelines
Mitja Lainscak (Slovenia), Adelino F. Leite-Moreira (Portugal), Gregory Y.H. Lip (UK), Carlos A. Mestresc
(Spain/United Arab Emirates), Massimo F. Piepoli (Italy), Prakash P. Punjabi (UK), Claudio Rapezzi (Italy),
Raphael Rosenhek (Austria), Kaat Siebens (Belgium), Juan Tamargo (Spain), and David M. Walker (UK)
The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website
http://www.escardio.org/guidelines.
a
Representing the European Association of Nuclear Medicine (EANM); bRepresenting the European Society of Clinical Microbiology and Infectious Diseases (ESCMID); and
c
Representing the European Association for Cardio-Thoracic Surgery (EACTS).
Online publish-ahead-of-print 29 August 2015
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Keywords Endocarditis † Cardiac imaging † Valve disease † Echocardiography † Prognosis † Guidelines † Infection †
Nuclear imaging † Cardiac surgery † Cardiac device † Prosthetic heart valves † Congenital heart disease †
Pregnancy † Prophylaxis † Prevention
Table of Contents
Abbreviations and acronyms . . . . . . . . . . . . . . . . . . . . . . . .3077 7.3 Penicillin-resistant oral streptococci and Streptococcus bovis
1. Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3078 group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3092
2. Justification/scope of the problem . . . . . . . . . . . . . . . . . . .3079 7.4 Streptococcus pneumoniae, beta-haemolytic streptococci
3. Prevention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3079 (groups A, B, C, and G) . . . . . . . . . . . . . . . . . . . . . . . . .3092
3.1 Rationale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3079 7.5 Granulicatella and Abiotrophia (formerly nutritionally
3.2 Population at risk . . . . . . . . . . . . . . . . . . . . . . . . . .3080 variant streptococci) . . . . . . . . . . . . . . . . . . . . . . . . . . .3094
3.3 Situations and procedures at risk . . . . . . . . . . . . . . . .3081 7.6 Staphylococcus aureus and coagulase-negative
3.3.1 Dental procedures . . . . . . . . . . . . . . . . . . . . . .3081 staphylococci . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3094
3.3.2 Other at-risk procedures . . . . . . . . . . . . . . . . . .3081 7.7 Methicillin-resistant and vancomycin-resistant
3.4 Prophylaxis for dental procedures . . . . . . . . . . . . . . .3081 staphylococci . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3094
3.5 Prophylaxis for non-dental procedures . . . . . . . . . . . .3082 7.8 Enterococcus spp. . . . . . . . . . . . . . . . . . . . . . . . . .3094
3.5.1 Respiratory tract procedures . . . . . . . . . . . . . . . .3082 7.9 Gram-negative bacteria . . . . . . . . . . . . . . . . . . . . . .3096
3.5.2 Gastrointestinal or genitourinary procedures . . . . .3082 7.9.1 HACEK-related species . . . . . . . . . . . . . . . . . . .3096
3.5.3 Dermatological or musculoskeletal procedures . . . .3082 7.9.2 Non-HACEK species . . . . . . . . . . . . . . . . . . . . .3097
3.5.4 Body piercing and tattooing . . . . . . . . . . . . . . . .3082 7.10 Blood culture– negative infective endocarditis . . . . . . .3097
3.5.5 Cardiac or vascular interventions . . . . . . . . . . . . .3082 7.11 Fungi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3097
3.5.6 Healthcare-associated infective endocarditis . . . . . .3082 7.12 Empirical therapy . . . . . . . . . . . . . . . . . . . . . . . . .3097
4. The ‘Endocarditis Team’ . . . . . . . . . . . . . . . . . . . . . . . . .3083 7.13 Outpatient parenteral antibiotic therapy for infective
5. Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3084 endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3098
5.1 Clinical features . . . . . . . . . . . . . . . . . . . . . . . . . . .3084 8. Main complications of left-sided valve infective endocarditis and
5.2 Laboratory findings . . . . . . . . . . . . . . . . . . . . . . . . .3084 their management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3099
5.3 Imaging techniques . . . . . . . . . . . . . . . . . . . . . . . . .3084 8.1 Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3099
5.3.1 Echocardiography . . . . . . . . . . . . . . . . . . . . . . .3084 8.1.1 Heart failure in infective endocarditis . . . . . . . . . .3099
5.3.2 Multislice computed tomography . . . . . . . . . . . . .3086 8.1.2 Indications and timing of surgery in the presence of
5.3.3 Magnetic resonance imaging . . . . . . . . . . . . . . . .3087 heart failure in infective endocarditis . . . . . . . . . . . . . . .3100
5.3.4 Nuclear imaging . . . . . . . . . . . . . . . . . . . . . . . .3087 8.2 Uncontrolled infection . . . . . . . . . . . . . . . . . . . . . . .3100
5.4 Microbiological diagnosis . . . . . . . . . . . . . . . . . . . . .3087 8.2.1 Persisting infection . . . . . . . . . . . . . . . . . . . . . .3100
5.4.1 Blood culture– positive infective endocarditis . . . . .3087 8.2.2 Perivalvular extension in infective endocarditis . . . .3100
5.4.2 Blood culture– negative infective endocarditis . . . . .3088 8.2.3 Indications and timing of surgery in the
5.4.3 Histological diagnosis of infective endocarditis . . . .3088 presence of uncontrolled infection in infective
5.4.4 Proposed strategy for a microbiological diagnostic endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3101
algorithm in suspected IE . . . . . . . . . . . . . . . . . . . . . .3088 8.2.3.1 Persistent infection . . . . . . . . . . . . . . . . . . .3101
5.5 Diagnostic criteria . . . . . . . . . . . . . . . . . . . . . . . . .3089 8.2.3.2 Signs of locally uncontrolled infection . . . . . . .3101
6. Prognostic assessment at admission . . . . . . . . . . . . . . . . . .3090 8.2.3.3 Infection by microorganisms at low likelihood of
7. Antimicrobial therapy: principles and methods . . . . . . . . . . .3091 being controlled by antimicrobial therapy . . . . . . . . . .3101
7.1 General principles . . . . . . . . . . . . . . . . . . . . . . . . .3091 8.3 Prevention of systemic embolism . . . . . . . . . . . . . . . .3101
7.2 Penicillin-susceptible oral streptococci and Streptococcus 8.3.1 Embolic events in infective endocarditis . . . . . . . . .3101
bovis group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3092 8.3.2 Predicting the risk of embolism . . . . . . . . . . . . . .3101
ESC Guidelines 3077
8.3.3 Indications and timing of surgery to prevent embolism 12.8.2 Infective endocarditis associated with cancer . . . .3115
in infective endocarditis . . . . . . . . . . . . . . . . . . . . . . .3101 13. To do and not to do messages from the guidelines . . . . . . .3115
9. Other complications of infective endocarditis . . . . . . . . . . .3102 14. Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3116
9.1 Neurological complications . . . . . . . . . . . . . . . . . . .3102 15. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3117
9.2 Infectious aneurysms . . . . . . . . . . . . . . . . . . . . . . . .3103
9.3 Splenic complications . . . . . . . . . . . . . . . . . . . . . . .3103
9.4 Myocarditis and pericarditis . . . . . . . . . . . . . . . . . . .3104
9.5 Heart rhythm and conduction disturbances . . . . . . . . .3104
Abbreviations and acronyms
9.6 Musculoskeletal manifestations . . . . . . . . . . . . . . . . .3104
9.7 Acute renal failure . . . . . . . . . . . . . . . . . . . . . . . . .3104 3D three-dimensional
10. Surgical therapy: principles and methods . . . . . . . . . . . . . .3105 AIDS acquired immune deficiency syndrome
b.i.d. bis in die (twice daily)

10.1 Operative risk assessment . . . . . . . . . . . . . . . . . . .3105
10.2 Preoperative and perioperative management . . . . . . .3105 BCNIE blood culture-negative infective endocarditis
10.2.1 Coronary angiography . . . . . . . . . . . . . . . . . . .3105 CDRIE cardiac device-related infective endocarditis
10.2.2 Extracardiac infection . . . . . . . . . . . . . . . . . . . .3105 CHD congenital heart disease
10.2.3 Intraoperative echocardiography . . . . . . . . . . . .3105 CIED cardiac implantable electronic device
10.3 Surgical approach and techniques . . . . . . . . . . . . . . .3105 CoNS coagulase-negative staphylococci
10.4 Postoperative complications . . . . . . . . . . . . . . . . . .3106 CPG Committee for Practice Guidelines
11. Outcome after discharge: follow-up and long-term prognosis 3106 CRP C-reactive protein
11.1 Recurrences: relapses and reinfections . . . . . . . . . . .3106 CT computed tomography
11.2 Short-term follow-up . . . . . . . . . . . . . . . . . . . . . . .3107 E. Enterococcus
11.3 Long-term prognosis . . . . . . . . . . . . . . . . . . . . . . .3107 ESC European Society of Cardiology
12. Management of specific situations . . . . . . . . . . . . . . . . . .3107 ESR erythrocyte sedimentation rate
12.1 Prosthetic valve endocarditis . . . . . . . . . . . . . . . . . .3107 EuroSCORE European System for Cardiac Operative
12.1.1 Definition and pathophysiology . . . . . . . . . . . . .3107 Risk Evaluation
12.1.2 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . .3107 FDG fluorodeoxyglucose
12.1.3 Prognosis and treatment . . . . . . . . . . . . . . . . . .3108 HF heart failure
12.2 Infective endocarditis affecting cardiac implantable HIV human immunodeficiency virus
electronic devices . . . . . . . . . . . . . . . . . . . . . . . . . . . .3108 HLAR high-level aminoglycoside resistance
12.2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . .3108 i.m. intramuscular
12.2.2 Definitions of cardiac device infections . . . . . . . .3108 i.v. intravenous
12.2.3 Pathophysiology . . . . . . . . . . . . . . . . . . . . . . .3108 ICE International Collaboration on Endocarditis
12.2.4 Risk factors . . . . . . . . . . . . . . . . . . . . . . . . . .3109 ICU intensive care unit
12.2.5 Microbiology . . . . . . . . . . . . . . . . . . . . . . . . .3109 ID infectious disease
12.2.6 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . .3109 IE infective endocarditis
12.2.7 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . .3109 Ig immunoglobulin
12.2.8 Antimicrobial therapy . . . . . . . . . . . . . . . . . . .3109 IVDA intravenous drug abuser
12.2.9 Complete hardware removal (device and lead MIC minimum inhibitory concentration
extraction) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3109 MR magnetic resonance
12.2.10 Reimplantation . . . . . . . . . . . . . . . . . . . . . . .3110 MRI magnetic resonance imaging
12.2.11 Prophylaxis . . . . . . . . . . . . . . . . . . . . . . . . .3110 MRSA methicillin-resistant Staphylococcus aureus
12.3 Infective endocarditis in the intensive care unit . . . . . .3111 MSCT multislice computed tomography
12.3.1 Organisms . . . . . . . . . . . . . . . . . . . . . . . . . . .3111 MSSA methicillin-susceptible Staphylococcus aureus
12.3.2 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . .3111 NBTE non-bacterial thrombotic endocarditis
12.3.3 Management . . . . . . . . . . . . . . . . . . . . . . . . .3111 NICE National Institute for Health and Care Excellence
12.4 Right-sided infective endocarditis . . . . . . . . . . . . . . .3111 NVE native valve endocarditis
12.4.1 Diagnosis and complications . . . . . . . . . . . . . . .3112 OPAT outpatient parenteral antibiotic therapy
12.4.2 Prognosis and treatment . . . . . . . . . . . . . . . . . .3112 PBP penicillin binding protein
12.4.2.1 Antimicrobial therapy . . . . . . . . . . . . . . . . .3112 PCR polymerase chain reaction
12.4.2.2 Surgery . . . . . . . . . . . . . . . . . . . . . . . . . .3112 PET positron emission tomography
12.5 Infective endocarditis in congenital heart disease . . . . .3113 PVE prosthetic valve endocarditis
12.6 Infective endocarditis during pregnancy . . . . . . . . . . .3113 SOFA Sequential Organ Failure Assessment
12.7 Antithrombotic therapy in infective endocarditis . . . . .3114 SPECT single-photon emission computed tomography
12.8 Non-bacterial thrombotic endocarditis and endocarditis TOE transoesophageal echocardiography
associated with cancers . . . . . . . . . . . . . . . . . . . . . . . . .3114 TTE transthoracic echocardiography
12.8.1 Non-bacterial thrombotic endocarditis . . . . . . . .3114 WBC white blood cell
3078 ESC Guidelines
management options were weighed and graded according to prede-

1. Preamble fined scales, as outlined in Tables 1 and 2.
Guidelines summarize and evaluate all available evidence on a par- The experts of the writing and reviewing panels provided declara-
ticular issue at the time of the writing process, with the aim of assist- tions of interest forms for all relationships that might be perceived as
ing health professionals in selecting the best management strategies real or potential sources of conflicts of interest. These forms were
for an individual patient with a given condition, taking into account compiled into one file and can be found on the ESC website (http://
the impact on outcome, as well as the risk –benefit ratio of particu- www.escardio.org/guidelines). Any changes in declarations of inter-
lar diagnostic or therapeutic means. Guidelines and recommenda- est that arise during the writing period must be notified to the ESC
tions should help health professionals to make decisions in their and updated. The Task Force received its entire financial support
daily practice. However, the final decisions concerning an individual from the ESC without any involvement from the healthcare
patient must be made by the responsible health professional(s) in industry.
consultation with the patient and caregiver as appropriate.

The ESC CPG supervises and coordinates the preparation of new
A great number of Guidelines have been issued in recent years by Guidelines produced by task forces, expert groups or consensus pa-
the European Society of Cardiology (ESC) as well as by other soci- nels. The Committee is also responsible for the endorsement pro-
eties and organisations. Because of the impact on clinical practice, cess of these Guidelines. The ESC Guidelines undergo extensive
quality criteria for the development of guidelines have been estab- review by the CPG and external experts. After appropriate revi-
lished in order to make all decisions transparent to the user. The re- sions the Guidelines are approved by all the experts involved in
commendations for formulating and issuing ESC Guidelines can be the Task Force. The finalized document is approved by the CPG
found on the ESC website (http://www.escardio.org/Guidelines- for publication in the European Heart Journal. The Guidelines
&-Education/Clinical-Practice-Guidelines/Guidelines-development/ were developed after careful consideration of the scientific and
Writing-ESC-Guidelines). ESC Guidelines represent the official pos- medical knowledge and the evidence available at the time of
ition of the ESC on a given topic and are regularly updated. their dating.
Members of this Task Force were selected by the ESC to re- The task of developing ESC Guidelines covers not only integra-
present professionals involved with the medical care of patients tion of the most recent research, but also the creation of education-
with this pathology. Selected experts in the field undertook a al tools and implementation programmes for the recommendations.
comprehensive review of the published evidence for management To implement the guidelines, condensed pocket guidelines versions,
(including diagnosis, treatment, prevention and rehabilitation) of summary slides, booklets with essential messages, summary cards
a given condition according to ESC Committee for Practice for non-specialists, and an electronic version for digital applications
Guidelines (CPG) policy. A critical evaluation of diagnostic and (smartphones, etc.) are produced. These versions are abridged and
therapeutic procedures was performed, including assessment of thus, if needed, one should always refer to the full text version,
the risk –benefit ratio. Estimates of expected health outcomes for which is freely available on the ESC website. The National Societies
larger populations were included, where data exist. The level of of the ESC are encouraged to endorse, translate and implement all
evidence and the strength of the recommendation of particular ESC Guidelines. Implementation programmes are needed because it
Table 1 Classes of recommendations
Classes of Suggested wording to use

recommendations
Class I Evidence and/or general Is recommended/is

agreement that a given treatment indicated
or procedure is beneficial, useful,
effective.
Class II Conflicting evidence and/or a

divergence of opinion about the
usefulness/efficacy of the given
treatment or procedure.
Class IIa Weight of evidence/opinion is in Should be considered

favour of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well May be considered

established by evidence/opinion.
Class III Evidence or general agreement Is not recommended

that the given treatment or
procedure is not useful/effective,
and in some cases may be harmful.
ESC Guidelines 3079
has been shown that the outcome of disease may be favourably in- The main objective of the current Task Force was to provide clear
fluenced by the thorough application of clinical recommendations. and simple recommendations, assisting healthcare providers in their
Surveys and registries are needed to verify that real-life daily prac- clinical decision making. These recommendations were obtained by
tice is in keeping with what is recommended in the guidelines, thus expert consensus after thorough review of the available literature.
completing the loop between clinical research, writing of guidelines, An evidence-based scoring system was used, based on a classifica-
disseminating them and implementing them into clinical practice. tion of the strength of recommendations and the levels of evidence.
Health professionals are encouraged to take the ESC Guidelines
fully into account when exercising their clinical judgment, as well as
in the determination and the implementation of preventive, diagnos- 3. Prevention
tic or therapeutic medical strategies. However, the ESC Guidelines
do not override in any way whatsoever the individual responsibility 3.1 Rationale

of health professionals to make appropriate and accurate decisions The principle of antibiotic prophylaxis for IE was developed on the
in consideration of each patient’s health condition and in consult- basis of observational studies and animal models and aimed at pre-
ation with that patient and the patient’s caregiver where appropriate venting the attachment of bacteria onto the endocardium after tran-
and/or necessary. It is also the health professional’s responsibility to sient bacteraemia following invasive procedures. This concept led to
verify the rules and regulations applicable to drugs and devices at the the recommendation for antibiotic prophylaxis in a large number of
time of prescription. patients with predisposing cardiac conditions undergoing a wide
range of procedures.13
The restriction of indications for antibiotic prophylaxis was in-
Table 2 Levels of evidence itiated in 2002 because of changes in pathophysiological concep-
tions and risk– benefit analyses as follows:14
Level of Data derived from multiple randomized † Low-grade but repeated bacteraemia occurs more frequently dur-
evidence A clinical trials or meta-analyses.
ing daily routine activities such as toothbrushing, flossing or chew-
Level of
Data derived from a single randomized ing, and even more frequently in patients with poor dental health.15
clinical trial or large non-randomized The accountability of low-grade bacteraemia was demonstrated in
evidence B
studies.
an animal model.16 The risk of IE may therefore be related more to
Consensus of opinion of the experts and/ cumulative low-grade bacteraemia during daily life rather than spor-
Level of
or small studies, retrospective studies,
evidence C adic high-grade bacteraemia after dental procedures.
registries.
† Most case –control studies did not report an association between
invasive dental procedures and the occurrence of IE.17 – 19
† The estimated risk of IE following dental procedures is very low.
Antibiotic prophylaxis may therefore avoid only a small number
of IE cases, as shown by estimations of 1 case of IE per 150 000
dental procedures with antibiotics and 1 per 46 000 for proce-
2. Justification/scope of the dures unprotected by antibiotics.20
problem † Antibiotic administration carries a small risk of anaphylaxis, which
may become significant in the event of widespread use. However,
Infective endocarditis (IE) is a deadly disease.1,2 Despite improve-
the lethal risk of anaphylaxis seems very low when using oral
ments in its management, IE remains associated with high mortality
amoxicillin.21
and severe complications. Until recently, guidelines on IE were
† Widespread use of antibiotics may result in the emergence of
mostly based on expert opinion because of the low incidence of
resistant microorganisms.13
the disease, the absence of randomized trials and the limited num-
† The efficacy of antibiotic prophylaxis on bacteraemia and the oc-
ber of meta-analyses.3 – 7
currence of IE has only been proven in animal models. The effect
The 2009 ESC Guidelines on the prevention, diagnosis and treat-
on bacteraemia in humans is controversial.15
ment of IE8 introduced several innovative concepts, including limita-
† No prospective randomized controlled trial has investigated the
tion of antibiotic prophylaxis to the highest-risk patients, a focus on
efficacy of antibiotic prophylaxis on the occurrence of IE and it is
healthcare-associated IE and identification of the optimal timing for
unlikely that such a trial will be conducted given the number of
surgery. However, several reasons justify the decision of the ESC to
subjects needed.22
update the previous guidelines: the publication of new large series of
IE, including the first randomized study regarding surgical therapy;9 These points have been progressively taken into account in most
important improvements in imaging procedures,10 particularly in the guidelines, including the 2009 ESC guidelines,5,8,23 – 26 and led to
field of nuclear imaging; and discrepancies between previous guide- the restriction of antibiotic prophylaxis to the highest-risk patients
lines.5 – 8 In addition, the need for a collaborative approach involving (patients with the highest incidence of IE and/or highest risk of
primary care physicians, cardiologists, surgeons, microbiologists, adverse outcome from IE).
infectious disease (ID) specialists and frequently other specialists— In 2008 the National Institute for Health and Care Excellence
namely the ‘Endocarditis Team’—has been underlined recently11,12 (NICE) guidelines went a step further and advised against any anti-
and will be developed in these new guidelines. biotic prophylaxis for dental and non-dental procedures whatever
3080 ESC Guidelines
the patient’s risk.27 The authors concluded there was an absence of higher mortality from IE and more often develop complications
benefit of antibiotic prophylaxis, which was also highly cost- of the disease than patients with native valves and an identical
ineffective. These conclusions have been challenged since estima- pathogen.37 This also applies to transcatheter-implanted pros-
tions of the risks of IE are based on low levels of evidence due to theses and homografts.
multiple extrapolations.28,29 (2) Patients with previous IE: they also have a greater risk of new IE,
Four epidemiological studies have analysed the incidence of IE fol- higher mortality and higher incidence of complications than pa-
lowing restricted indications for antibiotic prophylaxis. The analysis tients with a first episode of IE.38
of 2000–2010 national hospital discharge codes in the UK did not (3) Patients with untreated cyanotic congenital heart disease
show an increase in the incidence of streptococcal IE after the re- (CHD) and those with CHD who have postoperative palliative
lease of NICE guidelines in 2008.30 The restriction of antibiotic shunts, conduits or other prostheses.39,40 After surgical repair
prophylaxis was seen in a 78% decrease in antibiotic prescriptions with no residual defects, the Task Force recommends prophy-

before dental care. However, residual prescriptions raised concerns laxis for the first 6 months after the procedure until endothelia-
regarding a persisting use of antibiotic prophylaxis. A survey lisation of the prosthetic material has occurred.
performed in 2012 in the UK showed that the majority of cardiolo-
gists and cardiac surgeons felt that antibiotic prophylaxis was
necessary in patients with valve prosthesis or prior IE.31 Recently Table 3 Cardiac conditions at highest risk of infective
an analysis of UK data collected from 2000 to 2013 showed a signifi- endocarditis for which prophylaxis should be
cant increase in the incidence of IE in both high-risk and lower-risk considered when a high-risk procedure is performed
patients in the UK starting in 2008.32 However, this temporal relation-
ship should not be interpreted as a direct consequence of the NICE
Recommendations Classa Levelb
guidelines. These findings may be influenced by confounding factors,
in particular changes in the number of patients at risk of hospitaliza- Antibiotic prophylaxis should be considered for
patients at highest risk for IE:
tions and healthcare-associated IE. Moreover, microbiological data
(1) Patients with any prosthetic valve, including a
were not available. Thus we cannot know whether that increase is transcatheter valve, or those in whom any
due to the microbiological species covered by antibiotic prophylaxis. prosthetic material was used for cardiac valve
A repeated prospective 1-year population-based French survey repair.
did not show an increase in the incidence of IE, in particular strepto- (2) Patients with a previous episode of IE.
(3) Patients with CHD: IIa C
coccal IE, between 1999 and 2008, whereas antibiotic prophylaxis
(a) Any type of cyanotic CHD.
had been restricted for native valve disease since 2002.33 (b) Any type of CHD repaired with a
Two studies from the USA did not find a negative impact of the prosthetic material, whether placed
abandonment of antibiotic prophylaxis in native valve disease in the surgically or by percutaneous techniques,
2007 American Heart Association guidelines.34,35 A more recent up to 6 months after the procedure or
lifelong if residual shunt or valvular
analysis on an administrative database found an increase in the inci-
regurgitation remains.
dence of IE hospitalizations between 2000 and 2011, with no signifi-
cant change after the change of American guidelines in 2007.36 The Antibiotic prophylaxis is not recommended in
III C
increase in IE incidence was observed for all types of microorgan- other forms of valvular or CHD.
isms, but was significant for streptococci after 2007.36 It was not sta-
ted whether this was due to oral streptococci and if intermediate- CHD ¼ congenital heart disease; IE ¼ infective endocarditis.
a
Class of recommendation.
or high-risk patients were involved. b
Level of evidence.
The present guidelines maintain the principle of antibiotic c
Reference(s) supporting recommendations.
prophylaxis in high-risk patients for the following reasons:
† The remaining uncertainties regarding estimations of the risk of

IE, which play an important role in the rationale of NICE
Although American Heart Association/American College of
guidelines.
Cardiology guidelines recommend prophylaxis in cardiac transplant
† The worse prognosis of IE in high-risk patients, in particular those
recipients who develop cardiac valvulopathy, this is not supported
with prosthetic IE.
by strong evidence5,25,41 and is not recommended by the ESC
† The fact that high-risk patients account for a much smaller num-
Task Force.
ber than patients at intermediate risk, thereby reducing potential
Antibiotic prophylaxis is not recommended for patients at
harm due to adverse events of antibiotic prophylaxis.
intermediate risk of IE, i.e. any other form of native valve disease
(including the most commonly identified conditions: bicuspid
3.2 Population at risk aortic valve, mitral valve prolapse and calcific aortic stenosis).
Nevertheless, both intermediate- and high-risk patients should
Patients with the highest risk of IE can be placed in three categories
(Table 3): be advised of the importance of dental and cutaneous hygiene13
(Table 4). These measures of general hygiene apply to patients
(1) Patients with a prosthetic valve or with prosthetic material used and healthcare workers and should ideally be applied to the general
for cardiac valve repair: these patients have a higher risk of IE, a population, as IE frequently occurs without known cardiac disease.
ESC Guidelines 3081
Table 4 Non-specific prevention measures to be Table 5 Continued

followed in high-risk and intermediate-risk patients

These measures should ideally be applied to the general
population and particularly reinforced in high-risk patients: B. Respiratory tract proceduresc
• Strict dental and cutaneous hygiene. Dental follow-up should be † Antibiotic prophylaxis is not recommended
performed twice a year in high-risk patients and yearly in the others. for respiratory tract procedures, including
III C
• Disinfection of wounds. bronchoscopy or laryngoscopy, or transnasal
or endotracheal intubation
• Eradication or decrease of chronic bacterial carriage: skin, urine.
C. Gastrointestinal or urogenital procedures or TOEc
• Curative antibiotics for any focus of bacterial infection.
† Antibiotic prophylaxis is not recommended

• No self-medication with antibiotics.
for gastroscopy, colonoscopy, cystoscopy, III C
• Strict infection control measures for any at-risk procedure. vaginal or caesarean delivery or TOE
• Discourage piercing and tattooing. D. Skin and soft tissue proceduresc
• Limit the use of infusion catheters and invasive procedure when
† Antibiotic prophylaxis is not recommended
possible. Favour peripheral over central catheters, and systematic III C
for any procedure
replacement of the peripheral catheter every 3–4 days. Strict
adherence to care bundles for central and peripheral cannulae
should be performed. TOE ¼ transoesophageal echocardiography.
a
b
Level of evidence.
c
For management when infections are present, please refer to Section 3.5.3.
3.3 Situations and procedures at risk

3.3.1 Dental procedures
At-risk procedures involve manipulation of the gingival or periapical 3.3.2 Other at-risk procedures
region of the teeth or perforation of the oral mucosa (including scal- There is no compelling evidence that bacteraemia resulting from re-
ing and root canal procedures) (Table 5).15,20 The use of dental im- spiratory tract procedures, gastrointestinal or genitourinary proce-
plants raises concerns with regard to potential risk due to foreign dures, including vaginal and caesarean delivery, or dermatological or
material at the interface between the buccal cavity and blood. musculoskeletal procedures causes IE (Table 5).
Very few data are available.42 The opinion of the Task Force is
that there is no evidence to contraindicate implants in all patients 3.4 Prophylaxis for dental procedures
at risk. The indication should be discussed on a case-by-case basis. Antibiotic prophylaxis should only be considered for patients at
The patient should be informed of the uncertainties and the need highest risk for endocarditis, as described in Table 3, undergoing at-
for close follow-up. risk dental procedures listed in Table 5, and is not recommended in
other situations. The main targets for antibiotic prophylaxis in these
patients are oral streptococci. Table 6 summarizes the main regimens
Table 5 Recommendations for prophylaxis of of antibiotic prophylaxis recommended before dental procedures.
infective endocarditis in the highest-risk patients Fluoroquinolones and glycopeptides are not recommended due to
according to the type of at-risk procedure their unclear efficacy and the potential induction of resistance.

Table 6 Recommended prophylaxis for high-risk
A. Dental procedures
dental procedures in high-risk patients
† Antibiotic prophylaxis should only be
considered for dental procedures requiring Single-dose 30–60 minutes
manipulation of the gingival or periapical IIa C Situation Antibiotic before procedure
region of the teeth or perforation of the oral Adults Children
mucosa
No allergy to Amoxicillin or 2 g orally or i.v. 50 mg/kg orally
† Antibiotic prophylaxis is not recommended penicillin or ampicillina or i.v.
for local anaesthetic injections in non-infected ampicillin
tissues, treatment of superficial caries, Allergy to Clindamycin 600 mg orally 20 mg/kg orally
removal of sutures, dental X-rays, placement penicillin or or i.v. or i.v.
III C ampicillin
or adjustment of removable prosthodontic or
orthodontic appliances or braces or following
a
the shedding of deciduous teeth or trauma to Alternatively, cephalexin 2 g i.v. for adults or 50 mg/kg i.v. for children, cefazolin or
the lips and oral mucosa ceftriaxone 1 g i.v. for adults or 50 mg/kg i.v. for children.
Cephalosporins should not be used in patients with anaphylaxis, angio-oedema, or
urticaria after intake of penicillin or ampicillin due to cross-sensitivity.
Continued
3082 ESC Guidelines
Cephalosporins should not be used in patients with anaphylaxis, should be considered due to the increased risk and adverse
angio-oedema or urticaria after intake of penicillin or ampicillin due outcome of an infection45 – 49 (Table 7). The most frequent microor-
to cross-sensitivity. ganisms underlying early (1 year after surgery) prosthetic valve
infections are coagulase-negative staphylococci (CoNS) and
Staphylococcus aureus. Prophylaxis should be started immediately be-
3.5 Prophylaxis for non-dental fore the procedure, repeated if the procedure is prolonged and ter-
procedures minated 48 h afterwards. A randomized trial has shown the efficacy
Systematic antibiotic prophylaxis is not recommended for non- of 1 g intravenous (i.v.) cefazolin on the prevention of local and sys-
dental procedures. Antibiotic therapy is only needed when invasive temic infections before pacemaker implantation.45 Preoperative
procedures are performed in the context of infection. screening of nasal carriage of S. aureus is recommended before elect-
ive cardiac surgery in order to treat carriers using local mupirocin
and chlorhexidine.46,47 Rapid identification techniques using gene

3.5.1 Respiratory tract procedures amplification are useful to avoid delaying urgent surgery. Systematic
Patients listed in Table 3 who undergo an invasive respiratory tract local treatment without screening is not recommended. It is strongly
procedure to treat an established infection (i.e. drainage of an ab- recommended that potential sources of dental sepsis should be
scess) should receive an antibiotic regimen that contains an anti- eliminated at least 2 weeks before implantation of a prosthetic valve
staphylococcal drug. or other intracardiac or intravascular foreign material, unless the lat-
ter procedure is urgent.48
3.5.2 Gastrointestinal or genitourinary procedures
In the case of an established infection or if antibiotic therapy is in-
dicated to prevent wound infection or sepsis associated with a Table 7 Recommendations for antibiotic
gastrointestinal or genitourinary tract procedure in patients de- prophylaxis for the prevention of local and systemic
scribed in Table 3, it is reasonable that the antibiotic regimen in- infections before cardiac or vascular interventions
cludes an agent active against enterococci (i.e. ampicillin,
amoxicillin or vancomycin; only in patients unable to tolerate beta-
lactams). The use of intrauterine devices was regarded as contra- Recommendations Classa Levelb Ref.c
indicated, but this was based on low levels of evidence. Use of an Preoperative screening of nasal carriage of
intrauterine device is now considered acceptable, in particular Staphylococcus aureus is recommended
I A 46,47
when other contraceptive methods are not possible and in women before elective cardiac surgery in order to
treat carriers
at low risk of genital infections.43
Perioperative prophylaxis is
recommended before placement of a
3.5.3 Dermatological or musculoskeletal procedures I B 45
pacemaker or implantable cardioverter
For patients described in Table 3 undergoing surgical procedures defibrillator
involving infected skin (including oral abscesses), skin structure or
Potential sources of sepsis should be
musculoskeletal tissue, it is reasonable that the therapeutic regimen eliminated ≥2 weeks before implantation
contains an agent active against staphylococci and beta-haemolytic of a prosthetic valve or other intracardiac IIa C
streptococci. or intravascular foreign material, except in
urgent procedures
3.5.4 Body piercing and tattooing Perioperative antibiotic prophylaxis
These growing societal trends are a cause for concern, particularly should be considered in patients
for individuals with CHD who are at increased susceptibility for the undergoing surgical or transcatheter
IIa C
implantation of a prosthetic valve,
acquisition of IE. Case reports of IE after piercing and tattooing are
intravascular prosthetic or other foreign
increasing, particularly when piercing involves the tongue,44 al- material
though publication bias may over- or underestimate the problem.
Systematic local treatment without
Currently no data are available on the incidence of IE after such pro- III C
screening of S. aureus is not recommended
cedures and the efficacy of antibiotics for prevention. Education of
patients at risk of IE is paramount. They should be informed about a
the hazards of piercing and tattooing and these procedures should b
Level of evidence.
c
be discouraged not only in high-risk patients, but also in those with Reference(s) supporting recommendations.
native valve disease. If undertaken, procedures should be performed
under strictly sterile conditions, though antibiotic prophylaxis is not
recommended. 3.5.6 Healthcare-associated infective endocarditis
Healthcare-associated IE represents up to 30% of all cases of IE and
3.5.5 Cardiac or vascular interventions is characterized by an increasing incidence and a severe prognosis,
In patients undergoing implantation of a prosthetic valve, any type of thus presenting an important health problem.50,51 Although routine
prosthetic graft or pacemakers, perioperative antibiotic prophylaxis antimicrobial prophylaxis administered before most invasive
ESC Guidelines 3083
procedures is not recommended, aseptic measures during the inser- in the management of valve disease11 (the ‘Heart Valve Clinic’),
tion and manipulation of venous catheters and during any invasive particularly in the selection of patients for transcatheter aortic valve
procedures, including in outpatients, are mandatory to reduce the implantation procedures (‘Heart Team’ approach).55 In the field of
rate of this healthcare-associated IE.52 IE, the team approach adopted in France, including standardized
In summary, these guidelines propose continuing to limit antibiot-
medical therapy, surgical indications following guideline recommen-
ic prophylaxis to patients at high risk of IE undergoing the dations and 1 year of close follow-up, has been shown to significant-
highest-risk dental procedures. They highlight the importance of ly reduce the 1-year mortality, from 18.5% to 8.2%.12 Other authors
hygiene measures, in particular oral and cutaneous hygiene. Epi- have recently reported similar results.56 Taking these reports to-
demiological changes are marked by an increase in IE due to
gether, such a team approach has been recommended recently as
staphylococcus and of healthcare-associated IE, thereby high-
lighting the importance of non-specific infection control mea-
class IB in the 2014 American Heart Association/American College
sures.51,53 This should concern not only high-risk patients, but of Cardiology guideline for the management of patients with valvular
heart disease.25

should also be part of routine care in all patients since IE occur-
ring in patients without previously known heart disease now ac-
counts for a substantial and increasing incidence. This means The present Task Force on the management of IE of the ESC
that although antibiotic prophylaxis should be restricted to the strongly supports the management of patients with IE in refer-
highest-risk patients, preventive measures should be maintained ence centres by a specialized team (the ‘Endocarditis Team’).
or extended to all patients with cardiac disease. The main characteristics of the Endocarditis Team and the
Although this section of the guidelines on IE prophylaxis is referring indications are summarized in Tables 8 and 9.
based on weak evidence, they have been strengthened recently
by epidemiological surveys, most of which did not show an in-
creased incidence of IE due to oral streptococci. 33 – 35 Their ap-
Table 8 Characteristics of the ‘Endocarditis Team’
plication by patients should follow a shared decision-making
process. Future challenges are to gain a better understanding
of the mechanisms associated with valve infection, the When to refer a patient with IE to an ‘Endocarditis Team’
adaptation of prophylaxis to the ongoing epidemiological in a reference centre
changes and the performance of specific prospective surveys 1. Patients with complicated IE (i.e. endocarditis with HF, abscess, or
on the incidence and characteristics of IE. embolic or neurological complication or CHD), should be referred
early and managed in a reference centre with immediate surgical
facilities.
2. Patients with non-complicated IE can be initially managed in a non-
reference centre, but with regular communication with the reference
4. The ‘Endocarditis Team’ centre, consultations with the multidisciplinary ‘Endocarditis Team’, and,
when needed, with external visit to the reference centre.
IE is a disease that needs a collaborative approach for the following Characteristics of the reference centre
reasons: 1. Immediate access to diagnostic procedures should be possible,
including TTE,TOE, multislice CT, MRI, and nuclear imaging.
† First, IE is not a single disease, but rather may present with very 2. Immediate access to cardiac surgery should be possible during the
different aspects depending on the first organ involved, the early stage of the disease, particularly in case of complicated IE (HF,
abscess, large vegetation, neurological, and embolic complications).
underlying cardiac disease (if any), the microorganism involved, 3. Several specialists should be present on site (the ‘Endocarditis Team’),
the presence or absence of complications and the patient’s char- including at least cardiac surgeons, cardiologists, anaesthesiologists, ID
acteristics.8 No single practitioner will be able to manage and specialists, microbiologists and, when available, specialists in valve
treat a patient in whom the main clinical symptoms might be car- diseases, CHD, pacemaker extraction, echocardiography and other
cardiac imaging techniques, neurologists, and facilities for
diac, rheumatological, infectious, neurological or other. neurosurgery and interventional neuroradiology .
† Second, a very high level of expertise is needed from practitioners
Role of the ‘Endocarditis Team’
from several specialties, including cardiologists, cardiac surgeons, 1. The ‘Endocarditis Team’ should have meetings on a regular basis in
ID specialists, microbiologists, neurologists, neurosurgeons, ex- order to discuss cases, take surgical decisions, and define the type of
follow-up.
perts in CHD and others. Echocardiography is known to have a
2. The ‘Endocarditis Team’ chooses the type, duration, and mode of
major importance in the diagnosis and management of IE. How- follow up of antibiotic therapy, according to a standardized protocol,
ever, other imaging techniques, including magnetic resonance im- following the current guidelines.
aging (MRI), multislice computed tomography (MSCT), and 3. The ‘Endocarditis Team’ should participate in national or international
registries, publicly report the mortality and morbidity of their centre,
nuclear imaging, have also been shown to be useful for diagnosis,
and be involved in a quality improvement programme, as well as in a
follow-up and decision making in patients with IE.10 Including all of patient education programme.
these specialists in the team is becoming increasingly important. 4. The follow-up should be organized on an outpatient visit basis at a
† Finally, about half of the patients with IE undergo surgery during frequency depending on the patient’s clinical status (ideally at 1, 3,
6, and 12 months after hospital discharge, since the majority of events
the hospital course.54 Early discussion with the surgical team is occur during this period57).
important and is considered mandatory in all cases of compli-
cated IE [i.e. endocarditis with heart failure (HF), abscess or em-
CHD ¼ Congenital heart disease; CT ¼ computed tomography; HF ¼ heart
bolic or neurological complications]. failure; ID ¼ Infectious disease; IE ¼ infective endocarditis; MRI ¼ magnetic
resonance imaging; TOE ¼ transoesophageal echocardiography; TTE ¼
Therefore the presence of an Endocarditis Team is crucial. This transthoracic echocardiography.
multidisciplinary approach has already been shown to be useful
3084 ESC Guidelines
However, these signs lack specificity and have not been integrated
Table 9 Recommendations for referring patients to into current diagnostic criteria. Atypical presentation is common in
the reference centre elderly or immunocompromised patients,59 in whom fever is less
common than in younger individuals. A high index of suspicion and
Recommendations Classa Levelb Ref.c low threshold for investigation are therefore essential in these and
other high-risk groups, such as those with CHD or prosthetic valves,
Patients with complicated IE should be
evaluated and managed at an early stage in to exclude IE or avoid delays in diagnosis.
a reference centre, with immediate
surgical facilities and the presence of a
IIa B 12,56
5.2 Laboratory findings
multidisciplinary ‘Endocarditis Team’, In addition to specialized microbiological and imaging investigations,
including an ID specialist, a microbiologist,
a number of laboratory investigations and biomarkers have been
a cardiologist, imaging specialists, a cardiac

surgeon and, if needed, a specialist in CHD evaluated in sepsis/sepsis syndromes and endocarditis. The large
number of proposed potential biomarkers reflects the complex
For patients with uncomplicated IE
managed in a non-reference centre, early pathophysiology of the disease process, involving pro- and anti-
and regular communication with the IIa B 12,56 inflammatory processes, humoral and cellular reactions and both
reference centre and, when needed, visits circulatory and end-organ abnormalities.60 However, owing to their
to the reference centre should be made poor positive predictive value for the diagnosis of sepsis and lack of
specificity for endocarditis, these biomarkers have been excluded
CHD ¼ congenital heart disease; ID ¼ infectious disease; IE ¼ infective from being major diagnostic criteria and are only used to facilitate
endocarditis.
a risk stratification.
b
Level of evidence. Sepsis severity may be indicated by the demonstration of a number
c
Reference(s) supporting recommendations. of laboratory investigations, including the degree of leucocytosis/leu-
copoenia, the number of immature white cell forms, concentrations
of CRP and procalcitonin, ESR and markers of end-organ dysfunction
(lactataemia, elevated bilirubin, thrombocytopaenia and changes in
5. Diagnosis serum creatinine concentration); however, none are diagnostic for
IE.61 Further, certain laboratory investigations are used in surgical
5.1 Clinical features scoring systems relevant to risk stratification in patients with IE, in-
The diverse nature and evolving epidemiological profile of IE ensure cluding bilirubin, creatinine and platelet count [Sequential Organ Fail-
that it remains a diagnostic challenge. The clinical history of IE is ure Assessment (SOFA) score] and creatinine clearance [European
highly variable according to the causative microorganism, the pres- System for Cardiac Operative Risk Evaluation (EuroSCORE) II]. Final-
ence or absence of pre-existing cardiac disease, the presence or ably, the pattern of increase in inflammatory mediators or immune
sence of prosthetic valves or cardiac devices and the mode of complexes may support, but not prove, the diagnosis of IE, including
presentation. Thus IE should be suspected in a variety of very differ- the finding of hypocomplementaemia in the presence of elevated
ent clinical situations. It may present as an acute, rapidly progressive antineutrophil cytoplasmic antibody in endocarditis-associated vas-
infection, but also as a subacute or chronic disease with low-grade culitis or, where lead infection is suspected clinically, the laboratory
fever and non-specific symptoms that may mislead or confuse initial finding of a normal procalcitonin and white cell count in the presence
assessment. Patients may therefore present to a variety of specialists of significantly elevated CRP and/or ESR.62
who may consider a range of alternative diagnoses, including chronic
infection; rheumatological, neurological and autoimmune diseases; 5.3 Imaging techniques
or malignancy. The early involvement of a cardiologist and an ID Imaging, particularly echocardiography, plays a key role in both the
specialist to guide management is highly recommended. diagnosis and management of IE. Echocardiography is also useful
Up to 90% of patients present with fever, often associated with sys- for the prognostic assessment of patients with IE, for its follow-up
temic symptoms of chills, poor appetite and weight loss. Heart mur- under therapy and during and after surgery.63 Echocardiography is
murs are found in up to 85% of patients. Up to 25% of patients have particularly useful for initial assessment of the embolic risk and in
embolic complications at the time of diagnosis. Therefore IE has to be decision making in IE. Transoesophageal echocardiography (TOE)
suspected in any patient presenting with fever and embolic phenom- plays a major role both before and during surgery (intraoperative
ena. Classic signs may still be seen in the developing world in subacute echocardiography). However, the evaluation of patients with IE
forms of IE, although peripheral stigmata of IE are increasingly uncom- is no longer limited to conventional echocardiography, but
mon elsewhere, as patients generally present at an early stage of the should include several other imaging techniques such as MSCT,
disease. However, vascular and immunological phenomena such as MRI, 18F-fluorodeoxyglucose (FDG) positron emission tomography
splinter haemorrhages, Roth spots and glomerulonephritis remain (PET)/computed tomography (CT) or other functional imaging
common. Emboli to the brain, lung or spleen occur in 30% of patients modalities.10
and are often the presenting feature.58 In a febrile patient, diagnostic
suspicion may be strengthened by laboratory signs of infection, such 5.3.1 Echocardiography
as elevated C-reactive protein (CRP) or erythrocyte sedimentation Echocardiography, either transthoracic echocardiography (TTE) or
rate (ESR), leucocytosis, anaemia and microscopic haematuria. TOE, is the technique of choice for the diagnosis of IE, and plays a
ESC Guidelines 3085
key role in the management and monitoring of these patients.64,65

Echocardiography must be performed as soon as IE is suspected. Table 10 Continued
TOE must be performed in case of negative TTE when there is a
high index of suspicion for IE, particularly when TTE is of suboptimal Recommendations Classa Levelb Ref.c
quality. TOE should also be performed in patients with positive TTE
† Repeat TTE and/or TOE should be
to rule out local complications. The indications of echocardiograph- considered during follow-up of
ic examination for diagnosis and follow-up of patients with sus- uncomplicated IE, in order to detect
pected IE are summarized in Table 10 and Figure 1. In patients new silent complications and
with S. aureus bacteraemia, echocardiography is justified in view of monitor vegetation size. The timing IIa B 64,72
and mode (TTE or TOE) of repeat
the frequency of IE in this setting, the virulence of this organism
examination depend on the initial
and its devastating effects once intracardiac infection is estab- findings, type of microorganism, and
lished.66,67 In these patients, TTE or TOE should be considered ac-

initial response to therapy.
cording to individual patient risk factors and the mode of acquisition C. Intraoperative echocardiography
of S. aureus bacteraemia.66,67
† Intraoperative echocardiography is
recommended in all cases of IE I B 64,73
requiring surgery.
Table 10 Role of echocardiography in infective D. Following completion of therapy
endocarditis † TTE is recommended at completion
of antibiotic therapy for evaluation
I C
of cardiac and valve morphology and
Recommendations Classa Levelb Ref.c function.
A. Diagnosis
† TTE is recommended as the HF ¼ heart failure; IE ¼ infective endocarditis; TOE ¼ transoesophageal
first-line imaging modality in I B 64,65 echocardiography; TTE ¼ transthoracic echocardiography.
a
suspected IE. b
Level of evidence.
c
† TOE is recommended in all Reference(s) supporting recommendations.
patients with clinical suspicion 64,
I B
of IE and a negative or 68 – 71
non-diagnostic TTE.
† TOE is recommended in patients
with clinical suspicion of IE,
when a prosthetic heart I B 64,71
valve or an intracardiac device is
Clinical suspicion of IE
present.
† Repeat TTE and /or TOE within
5 –7 days is recommended in case TTE
of initially negative examination I C
when clinical suspicion of IE
remains high. Prosthetic valve Non-diagnosis Positive Negative
Intracardiac device TTE TTE TTE
† Echocardiography should be
considered in Staphylococcus IIa B 66,67
aureus bacteraemia. Clinical suspicion
of IE
† TOE should be considered in
patients with suspected IE, even
in cases with positive TTE,
except in isolated right-sided High Low
IIa C
native valve IE with good
quality TTE examination and
TOEa Stop
unequivocal echocardiographic
findings.
B. Follow-up under medical therapy If initial TOE is negative but high suspicion for IE remains,
repeat TTE and/or TOE within 5–7 days
† Repeat TTE and/or TOE are
recommended as soon as a
IE = infective endocarditis; TOE = transoesophageal echocardiography; TTE = transthoracic
new complication of IE is echocardiography.
I B 64,72 a
TOE is not mandatory in isolated right-sided native valve IE with good quality TTE examination and
suspected (new murmur,
unequivocal echocardiographic
embolism, persisting fever, HF,
abscess, atrioventricular block).
Figure 1 Indications for echocardiography in suspected infect-
Continued ive endocarditis.
3086 ESC Guidelines
Three echocardiographic findings are major criteria in the diag- The sensitivity of TTE for the diagnosis of abscesses is about 50%,
nosis of IE: vegetation, abscess or pseudoaneurysm and new dehis- compared with 90% for TOE. Specificity higher than 90% has been
cence of a prosthetic valve8,64,65 (see Table 11 for anatomical and reported for both TTE and TOE.64,65 Small abscesses may be diffi-
echocardiographic definitions). Nowadays, the sensitivity for the cult to identify, particularly in the earliest stage of the disease, in the
diagnosis of vegetations in native and prosthetic valves is 70% postoperative period and in the presence of a prosthetic valve. IE
and 50%, respectively, for TTE and 96% and 92%, respectively, must always be suspected in patients with new periprosthetic regur-
for TOE. 64,65 Specificity has been reported to be around 90% gitation, even in the absence of other echocardiographic findings
for both TTE and TOE. Identification of vegetations may be diffi- of IE.64
cult in the presence of pre-existing valvular lesions (mitral valve In cases with an initially negative examination, repeat TTE/TOE
prolapse, degenerative calcified lesions), prosthetic valves, small must be performed 5 – 7 days later if the clinical level of suspicion
vegetations (, 2 – 3 mm), recent embolization and in non- is still high, or even earlier in the case of S. aureus infection.75 Other

vegetant IE. Diagnosis may be particularly challenging in IE affecting imaging techniques should also be used in this situation (see section
intracardiac devices, even with the use of TOE. 5.5). Finally, follow-up echocardiography to monitor complications
False diagnosis of IE may occur, and in some instances it may be and response to treatment is mandatory (Figure 1).
difficult to differentiate vegetations from thrombi, Lambl’s excres- Real-time three-dimensional (3D) TOE allows the analysis of 3D
cences, cusp prolapse, chordal rupture, valve fibroelastoma, de- volumes of cardiac structures in any possible plane. A recent study
generative or myxomatous valve disease, strands, systemic lupus has shown that conventional TOE underestimates vegetation size
(Libman – Sacks) lesions, primary antiphospholipid syndrome, and that 3D TOE is a feasible technique for the analysis of vegetation
rheumatoid lesions or marantic vegetations.74 Therefore the re- morphology and size that may overcome the shortcomings of con-
sults of the echocardiographic study must be interpreted with cau- ventional TOE, leading to a better prediction of the embolic risk in
tion, taking into account the patient’s clinical presentation and the IE.76 3D TOE is particularly useful in the assessment of perivalvular
likelihood of IE. extension of the infection, prosthetic valve dehiscence and valve
perforation.77 Although in clinical practice 3D TOE is increasingly
performed along with conventional TOE in many centres, at present
3D TOE should still be regarded as a supplement to standard echo-
Table 11 Anatomical and echocardiographic
cardiography in most cases.
definitions
Surgery/necropsy Echocardiography 5.3.2 Multislice computed tomography

Vegetation Infected mass attached to Oscillating or non- The potential risks of vegetation embolization and/or haemo-
an endocardial structure oscillating intracardiac
or on implanted mass on valve or other dynamic decompensation during coronary angiography (when in-
intracardiac material. endocardial structures, dicated) have led to proposals to consider MSCT coronary
or on implanted
intracardiac material. angiography as an alternative technique for some patients with
Abscess Perivalvular cavity Thickened, non- endocarditis.78
with necrosis and homogeneous MSCT can be used to detect abscesses/pseudoaneurysms with a
purulent material not perivalvular area
communicating with the with echodense or
diagnostic accuracy similar to TOE, and is possibly superior in the
cardiovascular lumen. echolucent appearance. provision of information regarding the extent and consequences of
Pseudoaneurysm Perivalvular cavity Pulsatile perivalvular any perivalvular extension, including the anatomy of pseudoaneur-
communicating with the echo-free space, with
ysms, abscesses and fistulae.79 In aortic IE, CT may additionally be
cardiovascular lumen. colour-Doppler
detected. useful to define the size, anatomy and calcification of the aortic
Perforation Interruption of endocardial Interruption of valve, root and ascending aorta, which may be used to inform sur-
tissue continuity. endocardial tissue gical planning. In pulmonary/right-sided endocarditis, CT may re-
continuity traversed by
colour-Doppler veal concomitant pulmonary disease, including abscesses and
Fistula Communication between Colour-Doppler infarcts.
two neighbouring cavities communication between In the evaluation of prosthetic valve dysfunction, one recent
through a perforation. two neighbouring
cavities through a study has suggested that MSCT may be equivalent or superior
perforation. to echocardiography for the demonstration of prostheses-related
Valve aneurysm Saccular outpouching of Saccular bulging of vegetations, abscesses, pseudoaneurysms and dehiscence.80 How-
valvular tissue. valvular tissue.
ever, large comparative studies between the two techniques
Dehiscence of a Dehiscence of the Paravalvular
prosthetic valve prosthesis. regurgitation
are missing, and echocardiography should always be performed
by TTE/TOE, with or first.
without rocking motion The higher sensitivity of MRI compared with CT for the detection
of the prosthesis.
of cerebral lesions is well known and has been confirmed in the con-
text of endocarditis. However, in the critically ill patient, CT may be
TOE ¼ transoesophageal echocardiography; TTE ¼ transthoracic
echocardiography. more feasible and practical and is an acceptable alternative when
MRI is not available. MSCT angiography allows complete
ESC Guidelines 3087
visualization of the intracranial vascular tree and carries a lower con- To summarize, cerebral MRI allows for a better lesion character-
trast burden and risk of permanent neurological damage than con- ization in patients with IE and neurological symptoms, whereas its
ventional digital subtraction angiography, with a sensitivity of 90% impact on IE diagnosis is marked in patients with non-definite IE
and specificity of 86%.81 Where subarachnoid and/or intraparench- and without neurological symptoms.
ymal haemorrhage is detected, other vascular imaging (i.e. angiog-
raphy) is required to diagnose or exclude a mycotic aneurysm if 5.3.4 Nuclear imaging
not detected on CT. With the introduction of hybrid equipment for both conventional
Contrast-enhanced MSCT has a high sensitivity and specificity nuclear medicine [e.g. single-photon emission CT (SPECT)/CT]
for the diagnosis of splenic and other abscesses; however, the differ- and PET (i.e. PET/CT), nuclear molecular techniques are evolving
entiation with infarction can be challenging. MSCT angiography pro- as an important supplementary method for patients with sus-
vides a rapid and comprehensive exploration of the systemic arterial pected IE and diagnostic difficulties. SPECT/CT imaging relies on
the use of autologous radiolabelled leucocytes ( 111In-oxine or

bed. Detailed multiplanar and 3D contrast-enhanced angiographic
reconstructions allow vascular mapping with identification and char- 99m
Tc-hexamethylpropyleneamine oxime) that accumulate in a
acterization of peripheral vascular complications of IE and their time-dependent fashion in late images versus earlier images,92
follow-up.82 whereas PET/CT is generally performed using a single acquisition
time point (generally at 1 h) after administration of 18F-FDG, which
5.3.3 Magnetic resonance imaging is actively incorporated in vivo by activated leucocytes, monocyte-
Given its higher sensitivity than CT, MRI increases the likelihood of macrophages and CD4+ T-lymphocytes accumulating at the sites
detecting cerebral consequences of IE. Different studies including of infection.
systematic cerebral MRI during acute IE have consistently reported Several reports have shown promising results for radiolabelled
frequent lesions, in 60 –80% of patients.83 Regardless of neurological white blood cell (WBC) SPECT/CT and 18F-FDG PET/CT imaging
symptoms, most abnormalities are ischaemic lesions (in 50 –80% of in IE. The main added value of using these techniques is the reduc-
patients), with more frequent small ischaemic lesions than larger tion in the rate of misdiagnosed IE, classified in the ‘Possible IE’ cat-
territorial infarcts.84 Other lesions are found in ,10% of patients egory using the Duke criteria, and the detection of peripheral
and are parenchymal or subarachnoidal haemorrhages, abscesses embolic and metastatic infectious events.93 Limitations to the use
or mycotic aneurysms.83 – 86 of 18F-FDG PET/CT are represented by localization of septic emboli
Systematic cerebral MRI has an impact on the diagnosis of IE in the brain, due to the high physiological uptake of this tracer in the
since it adds one minor Duke criterion87 in patients who have brain cortex, and to the fact that at this site, metastatic infections are
cerebral lesions and no neurological symptoms. In one study, find- generally ,5 mm, the spatial resolution threshold of current PET/
ings of cerebral MRI upgraded the diagnosis of IE in 25% of patients CT scanners.
presenting initially with non-definite IE, thereby leading to earlier Caution must be exercised when interpreting 18F-FDG PET/CT
diagnosis.85 results in patients who have recently undergone cardiac surgery,
Cerebral microbleeds are detected only when using gradient as a postoperative inflammatory response may result in non-specific
echo T2* sequences and are found in 50 –60% of patients.85 Micro- 18
F-FDG uptake in the immediate postoperative period. Further-
bleeds represent small areas of haemosiderin deposits and are more, a number of pathological conditions can mimic the pattern
considered as an indicator of small vessel disease. The lack of of focally increased 18F-FDG uptake that is typically observed in
concordance between ischaemic lesions and microbleeds and the IE, such as active thrombi, soft atherosclerotic plaques, vasculitis,
differences in their predictive factors suggest that microbleeds are primary cardiac tumours, cardiac metastasis from a non-cardiac tu-
not of embolic origin.86,88 Therefore, although IE and the presence mour, post-surgical inflammation and foreign body reactions.94
of microbleeds are strongly linked, microbleeds should not be Radiolabelled WBC SPECT/CT is more specific for the detection
considered as a minor criterion in the Duke classification.87 of IE and infectious foci than 18F-FDG PET/CT and should be pre-
Cerebral MRI is, in the majority of cases, abnormal in IE patients ferred in all situations that require enhanced specificity.95 Disadvan-
with neurological symptoms.89 It has a higher sensitivity than CT in tages of scintigraphy with radiolabelled WBC are the requirement
the diagnosis of the culprit lesion, in particular with regards to of blood handling for radiopharmaceutical preparation, the duration
stroke, transient ischaemic attack and encephalopathy. MRI may of the procedure, which is more time consuming than PET/CT, and a
also detect additional cerebral lesions that are not related to clinical slightly lower spatial resolution and photon detection efficiency
symptoms. Cerebral MRI has no impact on the diagnosis of IE in pa- compared with PET/CT.
tients with neurological symptoms, as they already have one minor An additional promising role of 18F-FDG PET/CT may be seen in
Duke criterion, but MRI may impact the therapeutic strategy, par- patients with established IE, in whom it could be employed to moni-
ticularly the timing of surgery.89 In patients without neurological tor response to antimicrobial treatment. However, sufficient data
symptoms, MRI shows cerebral lesions in at least half of the patients, are not available at this time to make a general recommendation.
most often ischaemic lesions.90 Systematic abdominal MRI detects
lesions in one of three patients evaluated, most often affecting the
spleen.91 Ischaemic lesions are most common, followed by ab- 5.4 Microbiological diagnosis
scesses and haemorrhagic lesions. Abdominal MRI findings have 5.4.1 Blood culture–positive infective endocarditis
no incremental impact on the diagnosis of IE when taking into ac- Positive blood cultures remain the cornerstone of diagnosis and pro-
count the findings of cerebral MRI. vide live bacteria for both identification and susceptibility testing. At
3088 ESC Guidelines
least three sets are taken at 30-min intervals, each containing 10 mL of

blood, and should be incubated in both aerobic and anaerobic atmo- Table 12 Investigation of rare causes of blood culture
spheres. Sampling should be obtained from a peripheral vein rather negative infective endocarditis
than from a central venous catheter (because of the risk of contam-
Pathogen Diagnostic procedures
ination and misleading interpretation), using a meticulous sterile tech-
nique. This is virtually always sufficient to identify the usual causative Brucella spp. Blood cultures, serology, culture, immunohistology,
and PCR of surgical material.
microorganisms. The need for culture before antibiotic administra-
tion is self-evident. In IE, bacteraemia is almost constant and has Coxiella burnetii Serology (IgG phase l >1:800), tissue culture,
immunohistology, and PCR of surgical material.
two implications: (i) there is no rationale for delaying blood sampling
Bartonella spp. Blood cultures, serology, culture, immunohistology,
with peaks of fever and (ii) virtually all blood cultures are positive. As a
and PCR of surgical material.
result, a single positive blood culture should be regarded cautiously
Tropheryma Histology and PCR of surgical material.

for establishing the diagnosis of IE. The microbiology laboratory whipplei
should be aware of the clinical suspicion of IE at the time of blood cul-
Mycoplasma spp. Serology, culture, immunohistology, and PCR of
ture sampling. When a microorganism has been identified, blood cul- surgical material.
tures should be repeated after 48–72 h to check the effectiveness of Legionella spp. Blood cultures, serology, culture, immunohistology,
treatment. Automated machines perform continuous monitoring of and PCR of surgical material.
bacterial growth, which ensures quick provision of reports to physi- Fungi Blood cultures, serology, PCR of surgical material.
cians. When a positive blood culture bottle is identified, presumptive
identification is based on Gram staining. This information is immedi-
Ig ¼ immunoglobulin; PCR ¼ polymerase chain reaction.
ately given to clinicians in order to adapt presumptive antibiotic ther-
apy. Complete identification is routinely achieved within 2 days, but
may require longer for fastidious or atypical organisms. Since the de-
lay between blood culture sampling and definitive identification of the When all microbiological assays are negative, the diagnosis of
organism responsible for the bacteraemia and antibiotic susceptibility non-infectious endocarditis should systematically be considered
testing is long, many improvements have been proposed to speed up and assays for antinuclear antibodies as well as antiphospholipid syn-
the process of detection and identification. One of the most recent drome {anticardiolipin antibodies [immunoglobulin (Ig)G] and
procedures for rapid bacterial identification is based on peptide spec- anti-b2-glycoprotein 1 antibodies [IgG and IgM]} should be per-
tra obtained by matrix-assisted laser desorption ionization formed. When all other tests are negative and the patient has a por-
time-of-flight mass spectrometry. This technique has recently de- cine bioprosthesis together with markers of allergic response,
monstrated its usefulness in clinical microbiology; it also has the po- anti-pork antibodies should be sought.99
tential for direct identification of bacterial colonies in the blood
culture bottle supernatant.96
5.4.3 Histological diagnosis of infective endocarditis
Pathological examination of resected valvular tissue or embolic frag-
5.4.2 Blood culture–negative infective endocarditis
ments remains the gold standard for the diagnosis of IE. All tissue
Blood culture – negative IE (BCNIE) refers to IE in which no causa-
samples that are excised during the course of the surgical removal
tive microorganism can be grown using the usual blood culture
of cardiac valves must be collected in a sterile container without
methods. BCNIE can occur in up to 31% of all cases of IE and often
fixative or culture medium. The entire sample should be taken to
poses considerable diagnostic and therapeutic dilemmas. BCNIE
the diagnostic microbiology laboratory for optimal recovery and
most commonly arises as a consequence of previous antibiotic
identification of microorganisms.
administration, underlying the need for withdrawing antibiotics
and repeating blood cultures in this situation. BCNIE can be caused
by fungi or fastidious bacteria, notably obligatory intracellular bac- 5.4.4 Proposed strategy for a microbiological diagnostic
teria. Isolation of these microorganisms requires culturing them on algorithm in suspected IE
specialized media, and their growth is relatively slow. According to A proposed diagnostic scheme is provided in Figure 2. When there is
local epidemiology, systematic serological testing for Coxiella bur- clinical suspicion of IE and blood cultures remain negative at 48 h,
netii, Bartonella spp., Aspergillus spp., Mycoplasma pneumonia, Brucel- liaison with the microbiologist is necessary. A suggested strategy is
la spp. and Legionella pneumophila should be proposed, followed by the use of a diagnostic kit including blood cultures and systematic
specific polymerase chain reaction (PCR) assays for Tropheryma serological testing for C. burnetii, Bartonella spp., Aspergillus spp.,
whipplei, Bartonella spp. and fungi (Candida spp., Aspergillus spp.) L. pneumophila, Brucella spp., M. pneumonia, as well as rheumatoid
from the blood 97 (Table 12). Most studies using blood PCR factor, the serological tests for antiphospholipid syndrome [anticar-
for the diagnosis of BCNIE have highlighted the importance of diolipin (IgG) and anti-b2-glycoprotein 1 (IgG and IgM)], antinuclear
Streptococcus gallolyticus and Streptococcus mitis, enterococci, antibodies and anti-pork antibodies. In addition, cardiac valvular ma-
S. aureus, Escherichia coli and fastidious bacteria, the respective terials obtained at surgery have to be subjected to systematic cul-
prevalence of which varies according to the status and condition ture, histological examination and PCR aimed at documenting the
of the patient.98 presence of fastidious organisms.
ESC Guidelines 3089
Suspected IE
Blood cultures
+ - BCNIE
Identification by mass spectrometry

Coxiella burnetiia
Bartonella henseleaa

Bartonella Quintana
Legionella Pneumophila
Brucella spp
Mycoplasma spp
Antibiotic resistance Agar culture Serologies
Aspergillus spp
and agar culture
Microbiological identification Blood PCRa Specific PCRa

Staphylococcus aureus, Tropheryma whipplei,
Fungi, Escherichia coli, Streptococcus gallolyticus
Mass spectrometry Streptococcus mitis, Enterococci
OR
Routine identification
Antinuclear antibodiesb
Antimicrobial Antimicrobial Anti phospholipid antibodies b
susceptibility testing susceptibility testing Anti-Pork antibodies b
BCNIE = blood culture-negative infective endocarditis; IE = infective endocarditis; PCR = polymerase chain reaction.
a
microbiological laboratory
b
Immunological laboratory
Figure 2 Microbiological diagnostic algorithm in culture-positive and culture-negative IE.
5.5 Diagnostic criteria

Besides the pathological aspect obtained after valve surgery, in clinical Table 13 Definition of infective endocarditis
practice the diagnosis of IE usually relies on the association between according to the modified Duke criteria (adapted from
an infective syndrome and recent endocardial involvement. This is the Li et al. 87)
cornerstone of the various criteria proposed to facilitate the difficult
diagnosis of this disease. Thus, in 2000, the modified Duke criteria
were recommended for diagnostic classification (Table 13). These cri- Pathological criteria
teria are based on clinical, echocardiographic and biological findings, as • Microorganisms demonstrated by culture or on histological
examination of a vegetation, a vegetation that has embolized, or an
well as the results of blood cultures and serologies.87 This classifica- intracardiac abscess specimen; or
tion has a sensitivity of approximately 80% overall when the criteria • Pathological lesions; vegetation or intracardiac abscess by
are evaluated at the end of patient follow-up in epidemiological stud- histological examination showing active endocarditis
Clinical criteria
ies.100 However, the modified Duke criteria show a lower diagnostic
• 2 major criteria; or
accuracy for early diagnosis in clinical practice, especially in the case of • 1 major criterion and 3 minor criteria; or
prosthetic valve endocarditis (PVE) and pacemaker or defibrillator • 5 minor criteria
lead IE, for which echocardiography is normal or inconclusive in up Possible IE
to 30% of cases.101,102 Recent advances in imaging techniques have re- • 1 major criterion and 1 minor criterion; or
sulted in an improvement in identification of endocardial involvements • 3 minor criteria
and extracardiac complications of IE.10,103 Thus recent works have de- Rejected IE
monstrated that cardiac/whole-body CT scan, cerebral MRI, 18F-FDG • Firm alternate diagnosis; or
• Resolution of symptoms suggesting IE with antibiotic therapy for
PET/CT and radiolabelled leucocyte SPECT/CT might improve the ≤4 days; or
detection of silent vascular phenomena (embolic events or infectious • No pathological evidence of IE at surgery or autopsy, with antibiotic
aneurysms) as well as endocardial lesions.79,80,83 – 85,93,94,104 – 108 The therapy for ≤4 days; or
• Does not meet criteria for possible IE, as above
addition of the results of these imaging modalities may improve the
sensitivity of the modified Duke criteria in difficult cases.
3090 ESC Guidelines
Given the recent published data, the Task Force proposes the and blood cultures. When the diagnosis remains only ‘possible’ or
addition of three further points in the diagnostic criteria (Table 14): even ‘rejected’ but with a persisting high level of clinical suspicion,
echocardiography and blood culture should be repeated and other
(1) The identification of paravalvular lesions by cardiac CT should
imaging techniques should be used, either for diagnosis of cardiac
be considered a major criterion.
involvement (cardiac CT, 18F-FDG PET/CT or radiolabelled leuco-
(2) In the setting of the suspicion of endocarditis on a prosthetic
cyte SPECT/CT) or for imaging embolic events (cerebral MRI,
valve, abnormal activity around the site of implantation de-
whole-body CT and/or PET/CT). The results of these new investi-
tected by 18F-FDG PET/CT (only if the prosthesis was im-
gations should then be integrated in the ESC 2015 modified diagnos-
planted for .3 months) or radiolabelled leucocyte SPECT/
tic criteria.
CT should be considered a major criterion.
(3) The identification of recent embolic events or infectious aneur-
ysms by imaging only (silent events) should be considered a min-

or criterion.
Clinical suspicion of IE
Modified Duke criteria (Li)

Table 14 Definitions of the terms used in the
European Society of Cardiology 2015 modified criteria Possible/rejected IE but Rejected IE
Definite IE
high suspicion Low suspicion
for the diagnosis of infective endocarditis
Native Prosthetic
Major criteria valve valve
1. Blood cultures positive for IE
a. Typical microorganisms consistent with IE from 2 separate blood 1 - Repeat echo 1 - Repeat echo (TTE + TOE)/microbiology
cultures: (TTE + TOE)/microbiology 2 - 18 F-FDG PET/CT or Leucocytes labeled SPECT/CT
2 - Imaging for embolic eventsa 3 - Cardiac CT
• Viridans streptococci, Streptococcus gallolyticus (Streptococcus
3 - Cardiac CT 4 - Imaging for embolic eventsa
bovis), HACEK group, Staphylococcus aureus; or
• Community-acquired enterococci, in the absence of a primary
focus; or ESC 2015 modified diagnostic criteriab
b. Microorganisms consistent with IE from persistently positive blood
cultures:
• ≥2 positive blood cultures of blood samples drawn >12 h apart; or Definite IE Possible IE Rejected IE
• All of 3 or a majority of ≥4 separate cultures of blood (with
and last samples drawn ≥1 h apart); or
c. Single positive blood culture for Coxiella burnetii or phase I IgG
antibody titre >1:800 CT = computed tomography; FDG = IE = infective endocarditis;
PET = positron emission tomography; SPECT = single photon emission computerized tomography;
2. Imaging positive for IE TOE = transoesophageal echocardiography;TTE = transthoracic echocardiography.
a. Echocardiogram positive for IE: a
May include cerebral MRI, whole body CT, and/or PET/CT.
• Vegetation; b
See Table 14.
•Abscess, pseudoaneurysm, intracardiac
• Valvular perforation or aneurysm;
• New partial dehiscence of prosthetic valve. Figure 3 European Society of Cardiology 2015 algorithm for
b. Abnormal activity around the site of prosthetic valve implantation
detected by 18F-FDG PET/CT (only if the prosthesis was implanted
diagnosis of infective endocarditis.
for >3 months) or radiolabelled leukocytes SPECT/CT.
paravalvular lesions by cardiac CT.
Minor criteria
Finally, 18F-FDG PET/CT and radiolabelled leucocyte SPECT/CT
1. Predisposition such as predisposing heart condition, or injection
drug use. have proven their role in the diagnosis of cardiovascular electronic
2. Fever as temperature >38°C. implanted devices,108 but the data are not sufficient for them to be
3. Vascular phenomena (including those detected by imaging only):
major arterial emboli, septic pulmonary infarcts, infectious (mycotic) included in the diagnostic criteria of the specific topic of IE on pace-
aneurysm, intracranial haemorrhage, conjunctival haemorrhages, and maker or defibrillator leads.
Janeway’s lesions.
4. Immunological phenomena: glomerulonephritis, Osler’s nodes, Roth’s In summary, echocardiography (TTE and TOE), positive blood cul-
spots, and rheumatoid factor.
tures and clinical features remain the cornerstone of IE diagnosis.
5. Microbiological evidence: positive blood culture but does not meet
a major criterion as noted above or serological evidence of active When blood cultures are negative, further microbiological studies
infection with organism consistent with IE. are needed. The sensitivity of the Duke criteria can be improved
by new imaging modalities (MRI, CT, PET/CT) that allow the diag-
nosis of embolic events and cardiac involvement when TTE/TOE
CT ¼ computed tomography; FDG ¼ fluorodeoxyglucose; HACEK ¼
Haemophilus parainfluenzae, H. aphrophilus, H. paraphrophilus, H. influenzae,
findings are negative or doubtful. These criteria are useful, but
Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella they do not replace the clinical judgement of the Endocarditis Team.
corrodens, Kingella kingae, and K. denitrificans; IE ¼ infective endocarditis; Ig ¼
immunoglobulin; PET ¼ positron emission tomography; SPECT ¼ single photon
emission computerized tomography. Adapted from Li et al.87
6. Prognostic assessment at
Figure 3 presents the proposed ESC diagnostic algorithm including
admission
the ESC 2015 modified diagnostic criteria. The diagnosis of IE is still The in-hospital mortality rate of patients with IE varies from 15% to
based on the Duke criteria, with a major role of echocardiography 30%.109 – 114 Rapid identification of patients at highest risk of death
ESC Guidelines 3091
may offer the opportunity to change the course of the disease (i.e. are predictors of mortality.112,120,124 Predictably, patients with an in-
emergency or urgent surgery) and improve prognosis.115 Prognosis dication for surgery who cannot proceed due to prohibitive surgical
in IE is influenced by four main factors: patient characteristics, the risk have the worst prognosis.125
presence or absence of cardiac and non-cardiac complications, In summary, prognostic assessment at admission can be performed
the infecting organism and the echocardiographic findings (Table 15). using simple clinical, microbiological and echocardiographic para-
The risk of patients with left-sided IE has been formally assessed ac- meters and should be used to select the best initial approach. Pa-
cording to these variables.116,117 Patients with HF, periannular com- tients with persistently positive blood cultures 48 – 72 h after
starting antibiotics have a worse prognosis.
plications and/or S. aureus infection are at highest risk of death and
need for surgery in the active phase of the disease.117 When three of
these factors are present, the risk reaches 79%.117 Therefore these
patients with complicated IE should be referred early and managed 7. Antimicrobial therapy:

in a reference centre with surgical facilities and preferably by an
Endocarditis Team.118 A high degree of co-morbidity, diabetes, sep-
principles and methods
tic shock, moderate-to-severe ischaemic stroke, brain haemorrhage
7.1 General principles
or the need for haemodialysis are also predictors of poor in-hospital
Successful treatment of IE relies on microbial eradication by anti-
outcome.111 – 115,119 – 122 Persistence of positive blood cultures
microbial drugs. Surgery contributes by removing infected material
48–72 h after initiation of antibiotic treatment indicates a lack of in-
and draining abscesses. Host defences are of little help. This explains
fection control and is an independent risk factor for in-hospital
why bactericidal regimens are more effective than bacteriostatic
mortality.123
therapy, both in animal experiments and in humans.126,127 Amino-
glycosides synergize with cell-wall inhibitors (i.e. beta-lactams and
glycopeptides) for bactericidal activity and are useful for shortening
Table 15 Predictors of poor outcome in patients with the duration of therapy (e.g. oral streptococci) and eradicating prob-
infective endocarditis lematic organisms (e.g. Enterococcus spp.).
One major hindrance to drug-induced killing is bacterial antibiotic
Patient characteristics tolerance. Tolerant microbes are not resistant (i.e. they are still sus-
• Older age
ceptible to growth inhibition by the drug) but escape drug-induced
• Prosthetic valve IE
• Diabetes mellitus killing and may resume growth after treatment discontinuation.
• Comorbidity (e.g., frailty, immunosuppression, renal or pulmonary Slow-growing and dormant microbes display phenotypic tolerance
disease) towards most antimicrobials (except rifampin to some extent).
Clinical complications of IE They are present in vegetations and biofilms (e.g. in PVE) and justify
• Heart failure the need for prolonged therapy (6 weeks) to fully sterilize infected
• Renal failure
• >Moderate area of ischaemic stroke heart valves. Some bacteria carry mutations rendering them tolerant
• Brain haemorrhage during both active growth and stationary (dormant) phases. Bacteri-
• Septic shock cidal drug combinations are preferred to monotherapy against tol-
Microorganism erant organisms.
• Staphylococcus aureus Drug treatment of PVE should last longer (at least 6 weeks) than
• Fungi
• Non-HACEK Gram-negative bacilli
that of native valve endocarditis (NVE) (2– 6 weeks), but is other-
wise similar, except for staphylococcal PVE, where the regimen
• Periannular complications should include rifampin whenever the strain is susceptible.
• Severe left-sided valve regurgitation In NVE needing valve replacement by a prosthesis during antibiot-
• Low left ventricular ejection fraction ic therapy, the postoperative antibiotic regimen should be that re-
• Pulmonary hypertension
commended for NVE, not for PVE. In both NVE and PVE, the
• Large vegetations
• Severe prosthetic valve dysfunction duration of treatment is based on the first day of effective antibiotic
• Premature mitral valve closure and other signs of elevated diastolic therapy (negative blood culture in the case of initial positive blood
pressures culture), not on the day of surgery. A new full course of treatment
should only start if valve cultures are positive, with the choice of
HACEK ¼ Haemophilus parainfluenzae, H. aphrophilus, H. paraphrophilus, antibiotic being based on the susceptibility of the latest recovered
H. influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis,
Eikenella corrodens, Kingella kingae, and K. denitrificans; IE ¼ infective
bacterial isolate.
endocarditis. Finally, there are six important considerations in the current
recommendations:
(1) The indications and pattern of use of aminoglycosides have
changed. They are no longer recommended in staphylococcal
Nowadays, 40 – 50% of patients undergo cardiac surgery during NVE because their clinical benefits have not been demon-
hospitalization.37,109 – 114 Surgical mortality in IE strongly depends strated, but they can increase renal toxicity;128 when they are
on its indication. Among patients who need emergency or urgent indicated in other conditions, aminoglycosides should be given
surgery, septic shock, persistent signs of infection and renal failure in a single daily dose to reduce nephrotoxicity.129
3092 ESC Guidelines
(2) Rifampin should be used only in foreign body infections such as (MIC ≥4 mg/L). However, some guidelines consider an MIC
PVE after 3 – 5 days of effective antibiotic therapy, once the .0.5 mg/L as fully resistant.6,8,135 Such resistant streptococci are in-
bacteraemia has been cleared. The rationale supporting this creasing in number. Large strain collections have reported .30% of
recommendation is based on the likely antagonistic effect of intermediate- and fully resistant Streptococcus mitis and Streptococcus
the antibiotic combinations with rifampin against planktonic/ oralis.142,143 Conversely, .99% of digestive streptococci remain
replicating bacteria,130 the synergy seen against dormant bac- penicillin susceptible.
teria within the biofilms and prevention of rifampin-resistant Treatment guidelines for penicillin-resistant streptococcal
variants.131 IE rely on retrospectives series. Compiling four of them, 47 of
(3) Daptomycin and fosfomycin have been recommended for 60 patients (78%) were treated with penicillin or ceftriaxone,
treating staphylococcal endocarditis and netilmicin for treat- mostly combined with aminoglycosides, and some with either
ing penicillin-susceptible oral and digestive streptococci, but clindamycin or aminoglycosides alone. 144 – 147 Most penicillin
MICs were ≥1 mg/L. Fifty patients (83%) were cured and 10

they are considered alternative therapies in these guidelines
because they are not available in all European countries. (17%) died. Death was not related to resistance, but to the pa-
When daptomycin is indicated, it must be given at high doses tients’ underlying conditions. 146 Treatment outcomes were
(≥10 mg/kg once daily132) and combined with a second anti- similar in PVE and NVE. 145 Hence antibiotic therapy for
biotic to increase activity and avoid the development of penicillin-resistant and penicillin-susceptible oral streptococci is
resistance.133,134 qualitatively similar (Table 16). However, in penicillin-resistant cases,
(4) Only published antibiotic efficacy data from clinical trials and aminoglycoside treatment must be given for at least 2 weeks and
cohort studies in patients with endocarditis (or bacteraemia if short-term therapy regimens are not recommended. Little ex-
there are no endocarditis data) have been considered in these perience exists with highly resistant isolates (MIC ≥4 mg/L), but
guidelines. Data from experimental endocarditis models have vancomycin might be preferred in such circumstances (combined
not been taken into account in most cases. with aminoglycosides). There is very limited experience with
(5) We are still using the Clinical and Laboratory Standards Institute daptomycin.
minimum inhibitory concentration (MIC) breakpoints instead of
the European Committee on Antimicrobial Susceptibility Test-
ing ones because most endocarditis data are derived from stud-
7.4 Streptococcus pneumoniae,
ies using the former breakpoints. beta-haemolytic streptococci
(6) Although a consensus was obtained for the majority of antibiot- (groups A, B, C, and G)
ic treatments, the optimal treatment of staphylococcal IE and IE due to S. pneumoniae has become rare since the introduction
the empirical treatment are still debated. of antibiotics. It is associated with meningitis in up to 30% of
cases, 149 which requires special consideration in cases with
7.2 Penicillin-susceptible oral penicillin resistance. Treatment of penicillin-susceptible strains
(MIC ≤0.06 mg/L) is similar to that of oral streptococci (Table 16),
streptococci and Streptococcus bovis group
except for the use of short-term 2-week therapy, which has not
Recommended regimens against susceptible streptococci (penicil-
been formally investigated. The same holds true for penicillin inter-
lin MIC ≤0.125 mg/L) are summarized in Table 16.6,8,135,136 The
mediate (MIC 0.125 – 2 mg/L) or resistant strains (MIC ≥4 mg/L)
cure rate is expected to be .95%. In uncomplicated cases, short-
without meningitis, although for resistant strains some authors
term 2-week therapy can be administered by combining penicillin
recommend high doses of cephalosporins (e.g. cefotaxime or ceftri-
or ceftriaxone with gentamicin or netilmicin.137,138 Gentamicin
axone) or vancomycin. In cases with meningitis, penicillin must be
and netilmicin can be given once daily in patients with IE due to
avoided because of its poor penetration of the cerebrospinal fluid,
susceptible streptococci and normal renal function. Ceftriaxone
and should be replaced with ceftriaxone or cefotaxime alone or in as-
alone or combined with gentamicin or netilmicin given once a
sociation with vancomycin150 according to the antibiotic susceptibility
day is particularly convenient for outpatient therapy.137 – 139 If
pattern.
desensitization cannot be performed, patients allergic to beta-
IE due to group A, B, C, or G streptococci—including Streptococ-
lactam should receive vancomycin. Teicoplanin has been proposed
cus anginosus group (S. constellatus, S. anginosus, and S. intermedius)—
as an alternative,8 but requires loading doses (6 mg/kg/12 h for
is relatively rare.151 Group A streptococci are uniformly susceptible
3 days) followed by 6 – 10 mg/kg/day. Loading is critical because
to beta-lactams (MIC ≤0.12 mg/L), whereas other serogroups
the drug is highly bound (≥98%) to serum proteins and penetrates
may display some degree of resistance. IE due to group B strepto-
slowly into vegetations.140 However, only limited retrospective
cocci was once associated with the peripartum period, but it now
studies have assessed its efficacy in streptococcal141 and entero-
occurs in other adults, especially the elderly. Group B, C, and G
coccal142 IE.
streptococci and S. anginosus produce abscesses and thus may re-
quire adjunctive surgery.151 Mortality from group B PVE is very
7.3 Penicillin-resistant oral streptococci high and cardiac surgery is recommended.152 Antibiotic treatment
and Streptococcus bovis group is similar to that of oral streptococci (Table 16), except that short-
Penicillin-resistant oral streptococci are classified as inter- term therapy is not recommended. Gentamicin should be given for
mediate resistant (MIC 0.25 – 2 mg/L) and fully resistant 2 weeks.
ESC Guidelines 3093
Table 16 Antibiotic treatment of infective endocarditis due to oral streptococci and Streptococcus bovis groupa
Antibiotic Dosage and route Duration Classb Levelc Ref.d Comments

(weeks)
Strains penicillin-susceptible (MIC ≤ 0.125 mg/L) oral and digestive streptococci
Standard treatment: 4-week duration
Penicillin G 12 –18 million U/day i.v. either in 4– 6 doses or continuously 4 I B 6,8, Preferred in patients . 65 years
or 135 – or with impaired renal or VIII
Amoxicilline 4 I B 139 (vestibulocochlear) cranial nerve
100 –200 mg/kg/day i.v. in 4– 6 doses
functions.
or
6-week therapy recommended
Ceftriaxonef 2 g/day i.v. or i.m. in 1 dose

4 I B for patients with PVE
Paediatric doses:g
Penicillin G 200,000 U/kg/day i.v. in 4 –6 divided doses
Amoxicillin 300 mg/kg/day i.v. in 4 –6 equally divided doses
Ceftriaxone 100 mg/kg/day i.v. or i.m. in 1 dose
Standard treatment: 2-week duration
Penicillin G 12 –18 million U/day i.v. either in 4– 6 doses or continuously 2 I B 6,8, Only recommended in patients
or 127, with non-complicated NVE with
Amoxicilline 100 –200 mg/kg/day i.v. in 4– 6 doses 2 I B 135 – normal renal function.
or 138
Ceftriaxonef 2 g/day i.v. or i.m. in 1 dose 2 I B
combined with
Gentamicinh 3 mg/kg/day i.v. or i.m. in 1 dose 2 I B
or
Netilmicin 4 –5 mg/kg/day i.v. in 1 dose 2 I B Netilmicin is not available in all
European countries.
g
Paediatric doses:
Penicillin G, amoxicillin, and ceftriaxone as above
Gentamicin 3 mg/kg/day i.v. or i.m. in 1 dose or 3 equally divided
doses
In beta-lactam allergic patientsi
Vancomycinj 30 mg/kg/day i.v. in 2 doses 4 I C 6-week therapy recommended
for patients with PVE
Paediatric doses:g
Vancomycin 40 mg/kg/day i.v. in 2 or 3 equally divided doses
Strains relatively resistant to penicillin (MIC 0.250 – 2 mg/l)k
Standard treatment
Penicillin G 24 million U/day i.v. either in 4– 6 doses or continuously 4 I B 6,8, 6-week therapy recommended
or 135, for patients with PVE
Amoxicilline 200 mg/kg/day i.v. in 4– 6 doses 4 I B 136
or
Ceftriaxonef 2 g/day i.v. or i.m. in 1 dose 4 I B
combined with
Gentamicinh 3 mg/kg/day i.v. or i.m. in 1 dose 2 I B
i
In beta-lactam allergic patients
Vancomycinj 30 mg/kg/day i.v. in 2 doses 4 I C 6-week therapy recommended
with for patients with PVE
Gentamicink 3 mg/kg/day i.v. or i.m. in 1 dose 2 I C
Paediatric doses: g
As above
Cmin ¼ minimum concentration; IE ¼ infective endocarditis; i.m. ¼ intramuscular; i.v. ¼ intravenous; MIC ¼ minimum inhibitory concentration; NVE ¼ native valve
endocarditis; PVE ¼ prosthetic valve endocarditis; U ¼ units.
a
Refer to text for other streptococcal species; bClass of recommendation; cLevel of evidence; dReference(s) supporting recommendations; eOr ampicillin, same dosages as
amoxicillin; fPreferred for outpatient therapy; gPaediatric doses should not exceed adult doses; hRenal function and serum gentamicin concentrations should be monitored once a
week. When given in a single daily dose, pre-dose (trough) concentrations should be , 1 mg/L and post-dose (peak; 1 hours after injection) serum concentrations should be
10 –12 mg/L.148; iPenicillin desensitization can be attempted in stable patients; jSerum vancomycin concentrations should achieve 10 –15 mg/L at pre-dose (trough) level,
although some experts recommend to increase the dose of vancomycin to 45 –60 mg/kg/day i.v. in 2 or 3 divided doses to reach serum trough vancomycin levels (Cmin) of 15 –
20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/d unless serum levels are monitored and can be adjusted to obtain a peak plasma
concentration of 30 –45 mg/mL 1 hour after completion of the i.v. infusion of the antibiotic; kPatients with penicillin-resistant strains (MIC . 2 mg/L) should be treated as
enterococcal endocarditis (see Table 18).
3094 ESC Guidelines
7.5 Granulicatella and Abiotrophia antibiotics, leaving only vancomycin and daptomycin to treat severe
(formerly nutritionally variant infections. However, vancomycin-intermediate S. aureus (MIC 4 –
8 mg/L) and hetero-vancomycin-intermediate S. aureus (MIC
streptococci) ≤2 mg/L, but with subpopulations growing at higher concentra-
Granulicatella and Abiotrophia produce IE with a protracted course, tions) have emerged worldwide and are associated with IE treat-
which is associated with large vegetations (.10 mm), higher rates ment failures.165,166 Moreover, some highly vancomycin-resistant
of complications and valve replacement (around 50%),153,154 S. aureus strains have been isolated from infected patients in recent
possibly due to delayed diagnosis and treatment. Antibiotic recom- years, requiring new approaches to treatment. In addition, a system-
mendations include penicillin G, ceftriaxone or vancomycin for atic review and meta-analysis of studies published between 1996 and
6 weeks, combined with an aminoglycoside for at least the first 2011 in patients with MRSA bacteraemia with vancomycin-
2 weeks.153,154 susceptible strains (MIC ≤2 mg/L)167 showed that a high vancomy-

cin MIC (≥1.5 mg/L) was associated with higher mortality.
7.6 Staphylococcus aureus and Daptomycin is a lipopeptide antibiotic approved for S. aureus
coagulase-negative staphylococci bacteraemia and right-sided IE.168 Cohort studies of S. aureus
Staphylococcus aureus is usually responsible for acute and destructive and CoNS IE132,168 – 170 have shown that daptomycin is at least
IE, whereas CoNS produce more protracted valve infections as effective as vancomycin, and in two cohort studies of MRSA
(except S. lugdunensis155 and some cases of S. capitis).156,157 Table 17 bacteraemia with high vancomycin MICs (.1 mg/L),171,172 dapto-
summarizes treatment recommendations for methicillin-susceptible mycin was associated with better outcomes (including survival)
and methicillin-resistant S. aureus and CoNS in both native and pros- compared with vancomycin. Importantly, daptomycin needs to
thetic valve IE. Of note, the addition of an aminoglycoside in be administered in appropriate doses and combined with other
staphylococcal native valve IE is no longer recommended because antibiotics to avoid further resistance in patients with IE.168,173
it increases renal toxicity.128,158 Short-term (2-week) and oral treat- For this reason, daptomycin should be given at high doses
ments have been proposed for uncomplicated right-sided native (≥10 mg/kg), and most experts recommend it be combined with
valve methicillin-susceptible S. aureus (MSSA) IE (see also section beta-lactams133 or fosfomycin134 [beta-lactams (and probably fos-
12.4.2), but these regimens cannot be applied to left-sided IE. For fomycin) increase membrane daptomycin binding by decreasing
penicillin-allergic patients with MSSA IE, penicillin desensitization the positive surface charge] for NVE and with gentamicin and ri-
can be attempted in stable patients since vancomycin is inferior to fampin for PVE.168,173,174
beta-lactams159 and should not be given. If beta-lactams cannot be Other alternatives include fosfomycin plus imipenem,175 newer
given, where available, daptomycin should be chosen and given in beta-lactams with relatively good PBP2a affinity such as ceftaroline,176
combination with another effective antistaphylococcal drug to quinupristin–dalfopristin with or without beta-lactams,177,178 beta-
increase activity and avoid the development of resistance. Some lactams plus oxazolidinones (linezolid),179 beta-lactams plus vanco-
experts have recommended a combination of high doses of mycin180 and high doses of trimethoprim/sulfamethoxazole and
cotrimoxazole plus clindamycin as an alternative for S. aureus clindamycin.160 Such cases warrant collaborative management with
IE.160 S. lugdunensis is always methicillin susceptible and can be trea- an ID specialist.
ted with cloxacillin.155
Staphylococcus aureus PVE carries a very high risk of mortality
7.8 Enterococcus spp.
(.45%)161 and often requires early valve replacement. Other dif- Enterococcal IE is primarily caused by Enterococcus faecalis (90% of
ferences in comparison with NVE include the overall duration of cases) and, more rarely, by Enterococcus faecium (5% of cases) or
therapy, the use of aminoglycosides and the addition of rifampin other species.181 They pose two major problems. First, entero-
after 3–5 days of effective antibiotic therapy once the bacteraemia cocci are highly resistant to antibiotic-induced killing, and eradica-
has been cleared. The rationale supporting this recommendation is tion requires prolonged administration (up to 6 weeks) of
based on the antagonistic effect of the antibiotic combinations with synergistic bactericidal combinations of two cell wall inhibitors
rifampin against planktonic/replicating bacteria and the synergy (ampicillin plus ceftriaxone, which synergize by inhibiting comple-
seen against dormant bacteria within the biofilm, as it has been mentary PBPs) or one cell wall inhibitor with aminoglycosides
demonstrated in foreign body infection models and clinically in (Table 18). Second, they may be resistant to multiple drugs, includ-
prosthetic orthopaedic and vascular infections. Although the le- ing aminoglycosides [high-level aminoglycoside resistance
vel of evidence is poor, adding rifampin to the treatment of (HLAR)], beta-lactams (via PBP5 modification and sometimes
staphylococcal PVE is standard practice, although treatment beta-lactamases) and vancomycin.182
may be associated with microbial resistance, hepatotoxicity and Fully penicillin-susceptible strains (penicillin MIC ≤8 mg/L) are
drug interactions.164 treated with penicillin G or ampicillin (or amoxicillin) combined
with gentamicin. Ampicillin (or amoxicillin) might be preferred since
MICs are two to four times lower. Gentamicin resistance is frequent
7.7 Methicillin-resistant and in both E. faecalis and E. faecium.182 An aminoglycoside MIC
vancomycin-resistant staphylococci .500 mg/L (HLAR) is associated with the loss of bactericidal syner-
Methicillin-resistant S. aureus (MRSA) produces low-affinity penicil- gism with cell wall inhibitors, and aminoglycosides should not be
lin binding protein 2a (PBP2a), which confers cross-resistance to used in such conditions. Streptomycin may remain active in such
most beta-lactams. MRSA are usually resistant to multiple cases and is a useful alternative.
ESC Guidelines 3095
Table 17 Antibiotic treatment of infective endocarditis due to Staphylococcus spp.
Antibiotic Dosage and route Duration Classi Levelj Ref.k Comments

(weeks)
Native valves
Methicillin-susceptible staphylococci
(Flu)cloxacillin or oxacillin 12 g/day i.v. in 4–6 doses 6,8, Gentamicin addition is not recommended because clinical
128, benefit has not been demonstrated and there is increased
4 –6 I B 135, renal toxicity
136,
158
Paediatric doses: g

200 –300 mg/kg/day i.v. in 4–6 equally divided
doses
Alternative therapy*
Cotrimoxazolea Sulfamethoxazole 4800 mg/day and 1 i.v. + 5 IIb C *for Stahylococcus aureus
Trimethoprim 960 mg/day (i.v. in 4 –6 doses) oral intake
with
1 IIb C
Clindamycin 1800mg/day i.v. in 3 doses
Paediatric doses: g
Sulfamethoxazole 60 mg/kg/day and
Trimethoprim 12 mg/kg/day (i.v. in 2 doses)
Clindamycin 40 mg/kg/day (i.v. in 3 doses)
Penicillin-allergic patientsh or methicillin-resistant staphylococci
Vancomycinb ** 30 –60 mg/kg/day i.v. in 2–3 doses 6,8, Cephalosporins (cefazolin 6 g/day or cefotaxime 6 g/day
4 –6 I B 135, i.v. in 3 doses) are recommended for penicillin-allergic
136 patients with non-anaphylactic reactions with
methicillin-susceptible endocarditis
Paediatric doses:g
40 mg/kg/day i.v. in 2–3 equally divided doses
Alternative therapy**:
Daptomycinc,d 10 mg/kg/day i.v. once daily 4 –6 IIa C Daptomycin is superior to vancomycin for MSSA and
MRSA bacteraemia with vancomycin MIC . 1 mg/L
Paediatric doses: g
10 mg/kg/day i.v. once daily
Alternative therapy*
Cotrimoxazolea Sulfamethoxazole 4800 mg/day and 1 i.v. + 5 IIb C
*for Stahylococcus aureus
Trimethoprim 960 mg/day (i.v. in 4 –6 doses) oral intake
with
Clindamycin 1800mg/day IV in 3 doses 1 IIb C
Prosthetic valves
Methicillin-susceptible staphylococci
(Flu)cloxacillin 12 g/day i.v. in 4–6 doses ≥6 I B 6,8,
or 135,
oxacillin 136
with Starting rifampin 3– 5 days later than vancomycin and
Rifampine 900 –1200 mg i.v. or orally in 2 or 3 divided ≥6 I B gentamicin has been suggested by some experts.
and doses
f Gentamicin can be given in a single daily dose in order to
Gentamicin 3 mg/kg/day i.v. or i.m. in 1 or 2 doses 2 I B reduce renal toxicity
Paediatric doses: g
Oxacillin and (flu)cloxacillin as above
Rifampin 20 mg/kg/day i.v. or orally in 3
equally divided doses
Penicillin-allergic patientsh and methicillin-resistant staphylococci
Vancomycinb 30 –60 mg/kg/day i.v. in 2–3 doses ≥6 I B 6,8, Cephalosporins (cefazolin 6 g/day or cefotaxime 6 g/day
with 135, i.v. in 3 doses) are recommended for penicillin-allergic
Rifampine 900 –1200 mg i.v. or orally in 2 or 3 divided 136 patients with non-anaphylactic reactions with
≥6 I B
doses methicillin-susceptible endocarditis.
and
Starting rifampin 3– 5 days later than vancomycin and
Gentamicinf 3 mg/kg/day i.v. or i.m. in 1 or 2 doses 2 I B gentamicin has been suggested by some experts.
Gentamicin can be given in a single daily dose in order to
g
Paediatric dosing: reduce renal toxicity
As above
AUC ¼ area under the curve; Cmin ¼ minimum concentration; IE ¼ infective endocarditis; MIC ¼ minimum inhibitory concentration; MRSA ¼ methicillin-resistant
Staphylococcus aureus; MSSA ¼ methicillin-susceptible S. aureus; PVE ¼ prosthetic valve endocarditis.
a
Renal function, serum Cotrimoxazole concentrations should be monitored once/week (twice/week in patients with renal failure); bSerum trough vancomycin levels (Cmin)
should be ≥20 mg/L. A vancomycin AUC/MIC .400 is recommended for MRSA infections; cMonitor plasma CPK levels at least once a week. Some experts recommend adding
cloxacillin (2 g/4 h i.v.) or fosfomycin (2 g/6 h i.v.) to daptomycin in order to increase activity and avoid the development of daptomycin resistance; dDaptomycin and fosfomycin
are not available in some European countries; eRifampin is believed to play a special role in prosthetic device infection because it helps eradicate bacteria attached to foreign
material.157 The sole use of rifampin is associated with a high frequency of microbial resistance and is not recommended. Rifampin increases the hepatic metabolism of warfarin
and other drugs; fRenal function and serum gentamicin concentrations should be monitored once/week (twice/week in patients with renal failure); gPaediatric doses should not
exceed adult doses; hPenicillin desensitization can be attempted in stable patients; iClass of recommendation; jLevel of evidence; kReference(s) supporting recommendations.
** No clinical benefit of adding rifampicin or gentamicin
3096 ESC Guidelines
Table 18 Antibiotic treatment of infective endocarditis due to Enterococcus spp.
Antibiotic Dosage and route Duration, Classg Levelh Ref.i Comments

weeks
Beta-lactam and gentamicin-susceptible strains (for resistant isolates see a,b,c)
Amoxicillin* 200 mg/kg/day i.v. in 4 –6 doses 6,8, 6-week therapy recommended for patients with .3
4 –6 I B 129, months symptoms or PVE
with
135,
Gentamicind 3 mg/kg/day i.v. or i.m. in 1 dose 2 –6** I B 136,
186
Paediatric doses:e

Ampicillin 300 mg/kg/day i.v. in 4– 6
equally divided doses Gentamicin 3 mg/kg/
day i.v. or i.m. in 3 equally divided doses
Ampicillin 200 mg/kg/day i.v. in 4 –6 doses 6 I B 183– This combination is active against Enterococcus faecalis
with 185 strains with and without HLAR, being the
Ceftriaxone 4 g/day i.v. or i.m. in 2 doses 6 I B combination of choice in patients with HLAR
E. faecalis endocarditis.
Paediatric doses:e
Amoxicillin as above Ceftriaxone 100 mg/ This combination is not active against E. faecium
kg/12 h i.v. or i.m.
Vancomycinf 30 mg/kg/day i.v. in 2 doses 6 I C
with
Gentamicind 3 mg/kg/day i.v. or i.m. in 1 dose 6 I C
e
Paediatric doses:
Vancomycin 40 mg/kg/day i.v. in 2– 3
equally divided doses. Gentamicin as
above
HLAR: high-level aminoglycoside resistance; IE: infective endocarditis; MIC: minimum inhibitory concentration; PBP: penicillin binding protein; PVE: prosthetic valve endocarditis.
a
High-level resistance to gentamicin (MIC .500 mg/L): if susceptible to streptomycin, replace gentamicin with streptomycin 15 mg/kg/day in two equally divided doses.
b
Beta-lactam resistance: (i) if due to beta-lactamase production, replace ampicillin with ampicillin –sulbactam or amoxicillin with amoxicillin – clavulanate; (ii) if due to PBP5
alteration, use vancomycin-based regimens.
c
Multiresistance to aminoglycosides, beta-lactams and vancomycin: suggested alternatives are (i) daptomycin 10 mg/kg/day plus ampicillin 200 mg/kg/day i.v. in four to six doses;
(ii) linezolid 2 × 600 mg/day i.v. or orally for ≥8 weeks (IIa, C) (monitor haematological toxicity); (iii) quinupristin–dalfopristin 3 × 7.5 mg/kg/day for ≥8 weeks. Quinupristin–
dalfopristin is not active against E. faecalis; (iv) for other combinations (daptomycin plus ertapenem or ceftaroline), consult infectious diseases specialists.
d
Monitor serum levels of aminoglycosides and renal function as indicated in Table 16.
e
Paediatric doses should not exceed adult doses.
f
Monitor serum vancomycin concentrations as stated in Table 16.
g
h
Level of evidence.
i
*Or ampicillin, same dosages as amoxicillin.
**Some experts recommend giving gentamicin for only 2 weeks (IIa, B).
There have been two important advances in recent years. First is against E. faecalis), linezolid, daptomycin (combined with ampicillin,
the demonstration, in several cohort studies of E. faecalis IE including ertapenem or ceftaroline) and tigecycline. Again, these situations
hundreds of cases, that ampicillin plus ceftriaxone is as effective as require the expertise of an ID specialist.
ampicillin plus gentamicin for non-HLAR E. faecalis IE. It is also safer,
without any nephrotoxicity.183 – 185 In addition, this is the combin- 7.9 Gram-negative bacteria
ation of choice for treating HLAR E. faecalis IE. Second, the total dai- 7.9.1 HACEK-related species
ly dose of gentamicin can be given in a single daily dose instead of the HACEK Gram-negative bacilli are fastidious organisms and the la-
two or three divided doses recommended up to now, and the length boratory should be made aware that infection with these agents is
of the treatment for non-HLAR E. faecalis IE may be safely shortened under consideration, as specialist investigations may be required
from 4–6 weeks to 2 weeks, reducing the rates of nephrotoxicity to (see also section 5). Because they grow slowly, standard MIC tests
very low levels.129,186,187 may be difficult to interpret. Some HACEK-group bacilli produce
Beta-lactam and vancomycin resistance are mainly observed in beta-lactamases, and ampicillin is therefore no longer the first-line
E. faecium. Since dual resistance is rare, beta-lactam might be used option. Conversely, they are susceptible to ceftriaxone, other
against vancomycin-resistant strains and vice versa. Varying results third-generation cephalosporins and quinolones; the standard
have been reported with quinupristin – dalfopristin (not active treatment is ceftriaxone 2 g/day for 4 weeks in NVE and for 6
ESC Guidelines 3097
weeks in PVE. If they do not produce beta-lactamase, ampicillin Aspergillus spp. predominate, the latter resulting in BCNIE.199,200
(12 g/day i.v. in four or six doses) plus gentamicin (3 mg/kg/day di- Mortality is very high (.50%), and treatment necessitates combined
vided into two or three doses) for 4–6 weeks is an option. Cipro- antifungal administration and surgical valve replacement.135,198 – 200
floxacin (400 mg/8 – 12 h i.v. or 750 mg/12 h orally) is a less Antifungal therapy for Candida IE includes liposomal amphotericin
well-validated alternative.188,189 B (or other lipid formulations) with or without flucytosine or an
echinocandin at high doses; and for Aspergillus IE, voriconazole is
7.9.2 Non-HACEK species the drug of choice and some experts recommend the addition of
The International Collaboration on Endocarditis (ICE) reported an echinocandin or amphotericin B.135,198,200,201 Suppressive long-
non-HACEK Gram-negative bacteria in 49 of 2761 (1.8%) IE term treatment with oral azoles (fluconazole for Candida and
cases.190 Recommended treatment is early surgery plus long-term voriconazole for Aspergillus) is recommended, sometimes for
(at least 6 weeks) therapy with bactericidal combinations of beta- life.135,198,201 Consultation with an ID specialist from the Endocardi-

lactams and aminoglycosides, sometimes with additional quino- tis Team is recommended.
lones or cotrimoxazole. In vitro bactericidal tests and monitoring
of serum antibiotic concentrations may be helpful. Because of their 7.12 Empirical therapy
rarity and severity, these conditions should be discussed by the Treatment of IE should be started promptly. Three sets of blood cul-
Endocarditis Team or with an ID specialist. tures should be drawn at 30-min intervals before initiation of anti-
biotics.202 The initial choice of empirical treatment depends on
7.10 Blood culture–negative infective several considerations:
endocarditis (1) Whether the patient has received previous antibiotic therapy.
The main causes of BCNIE are summarized in section 5.4.2.191,192 (2) Whether the infection affects a native valve or a prosthesis
Treatment options are summarized in Table 19. 192,193 Con- [and if so, when surgery was performed (early vs. late PVE)].
sultation with an ID specialist from the Endocarditis Team is (3) The place of the infection (community, nosocomial, or non-
recommended. nosocomial healthcare-associated IE) and knowledge of the lo-
cal epidemiology, especially for antibiotic resistance and specific
7.11 Fungi genuine culture-negative pathogens (Table 19).
Fungi are most frequently observed in PVE and in IE affecting i.v. drug (4) Cloxacillin/cefazolin administration is associated with
abusers (IVDAs) and immunocompromised patients.198 Candida and lower mortality rates than other beta-lactams, including
Table 19 Antibiotic treatment of blood culture-negative infective endocarditis (adapted from Brouqui et al. 193)
Pathogens Proposed therapy a Treatment outcome

Brucella spp. Doxycycline (200 mg/24 h) Treatment success as an antibody titre <1:60.
plus cotrimoxazole (960 mg/12 h) Some authors recommend adding gentamicin for the
plus rifampin (300–600/24 h) 3 weeks.
for ≥3–6 monthsb orally
C. burnetii Doxycycline (200 mg/24 h) Treatment success as anti-phase I IgG titre
(agent of Q fever) plus hydroxychloroquine (200–600 mg/24 h)c orally <1:200, and IgA and IgM titres <1:50.
(>18 months of treatment)
Bartonella spp.d Doxycycline 100 mg/12 h orally for 4 weeks Treatment success expected in ≥90%.
plus gentamicin (3 mg/24 h) i.v. for 2 weeks
Legionella spp. (500 mg/12 h) i.v. or orally for ≥6 weeks Optimal treatment unknown.
or clarithromycin (500 mg/12 h) i.v. for 2 weeks, then
orally for 4 weeks
plus rifampin (300–1200 mg/24 h)
Mycoplasma spp. (500 mg/12 h) i.v. or orally for ≥6 monthse Optimal treatment unknown.
T. whipplei Doxycycline (200 mg/24 h) Long-term treatment, optimal duration unknown.
(agent of Whipple’s disease)f plus hydroxychloroquine (200–600 mg/24 h)c orally for
≥18 months
ID ¼ infectious disease; IE ¼ infective endocarditis; Ig ¼ immunoglobulin; i.v. ¼ intravenous; U ¼ units.

a
Owing to the lack of large series, the optimal duration of treatment of IE due to these pathogens is unknown. The presented durations are based on selected case reports.
Consultation with an ID specialist is recommended.
b
Addition of streptomycin (15 mg/kg/24 h in 2 doses) for the first few weeks is optional.
c
Doxycycline plus hydroxychloroquine (with monitoring of serum hydroxychloroquine levels) is significantly superior to doxycycline.194
d
Several therapeutic regimens have been reported, including aminopenicillins (ampicillin or amoxicillin, 12 g/24 h i.v.) or cephalosporins (ceftriaxone, 2 g/24 h i.v.) combined with
aminoglycosides (gentamicin or netilmicin).195 Dosages are as for streptococcal and enterococcal IE (Tables 16 and 18).196,197
e
Newer fluoroquinolones (levofloxacin, moxifloxacin) are more potent than ciprofloxacin against intracellular pathogens such as Mycoplasma spp., Legionella spp., and Chlamydia spp.
f
Treatment of Whipple’s IE remains highly empirical. In the case of central nervous system involvement, sulfadiazine 1.5 g/6 h orally must be added to doxycycline. An alternative
therapy is ceftriaxone (2 g/24 h i.v.) for 2–4 weeks or penicillin G (2 million U/4 h) and streptomycin (1 g/24 h) i.v. for 2– 4 weeks followed by cotrimoxazole (800 mg/12 h) orally.
Trimethoprim is not active against T. whipplei. Successes have been reported with long-term therapy (.1 year).
3098 ESC Guidelines
Table 20 Proposed antibiotic regimens for initial empirical treatment of infective endocarditis in acute severely ill
patients (before pathogen identification)a
Antibiotic Dosage and route Classb Levelc Comments

Community-acquired native valves or late prosthetic valves (≥12 months post surgery) endocarditis
Ampicillin 12 g/day i.v. in 4– 6 doses Patients with BCNIE should be treated in consultation with an ID specialist.
with
(Flu)cloxacillin or 12 g/day i.v. in 4– 6 doses
oxacillin IIa C
with
Gentamicind 3 mg/kg/day i.v. or i.m. in 1

dose
Vancomycind 30–60 mg/kg/day i.v. in 2– 3 For penicillin-allergic patients
doses
with
IIb C
Gentamicind 3 mg/kg/day i.v. or i.m. in 1
dose
Early PVE (<12 months post surgery) or nosocomial and non-nosocomial healthcare associated endocarditis
Vancomycind 30 mg/kg/day i.v. in 2 doses Rifampin is only recommended for PVE and it should be started 3 –5 days later than
with vancomycin and gentamicin has been suggested by some experts. In healthcare
Gentamicind 3 mg/kg/day i.v. or i.m. in 1 associated native valve endocarditis, some experts recommend in settings with a
dose IIb C prevalence of MRSA infections .5% the combination of cloxacillin plus
with vancomycin until they have the final S. aureus identification
Rifampin 900–1200 mg i.v. or orally
in 2 or 3 divided doses
BCNIE ¼ blood culture-negative infective endocarditis; ID ¼ infectious disease; i.m. ¼ intramuscular; i.v. ¼ intravenous; PVE ¼ prosthetic valve endocarditis.
a
If initial blood cultures are negative and there is no clinical response, consider BCNIE aetiology (see Section 7.10) and maybe surgery for molecular diagnosis and treatment, and
extension of the antibiotic spectrum to blood culture-negative pathogens (doxycycline, quinolones) must be considered.
b
c
Level of evidence.
d
Monitoring of gentamicin or vancomycin dosages is as described in Tables 16 and 17.
amoxicillin/clavulanic acid or ampicillin/sulbactam, 203 and

vancomycin for empirically treating MSSA bacteraemia/ Table 21 Criteria that determine suitability of
endocarditis.159 outpatient parenteral antibiotic therapy for infective
endocarditis (adapted from Andrews et al. 205)
Suggested regimens for empirical treatment in acute patients Phase of

are summarized in Table 20. NVE and late PVE regimens should Guidelines for use
treatment
cover staphylococci, streptococci and enterococci. Early PVE or Critical phase • Complications occur during this phase
healthcare-associated IE regimens should cover methicillin-resistant (weeks 0–2) • Preferred inpatient treatment during this phase
staphylococci, enterococci and, ideally, non-HACEK Gram-negative • Consider OPAT if: oral streptococci or
Streptococcus bovis,a native valve,b patient stable,
pathogens. Once the pathogen is identified (usually in ,48 h), the
no complications
antibiotic treatment must be adapted to its antimicrobial susceptibil-
Continuation • Consider OPAT if medically stable
ity pattern. phase • Do not consider OPAT if: HF, concerning
(beyond week 2) echocardiographic features, neurological signs, or
renal impairment
7.13 Outpatient parenteral antibiotic
Essential for • Educate patient and staff
therapy for infective endocarditis OPAT • Regular post-discharge evaluation (nurses 1/day,
Outpatient parenteral antibiotic therapy (OPAT) is used to consoli- physicianc in charge 1 or 2/week)d
• Prefer physician-directed programme, not home-
date antimicrobial therapy once critical infection-related complica-
infusion model
tions are under control (e.g. perivalvular abscesses, acute HF, septic
emboli and stroke).204 – 207 Two different phases may be identified
HF ¼ heart failure; ID ¼ infectious disease; IE ¼ infective endocarditis; OPAT ¼
during the course of antibiotic therapy: (i) a first critical phase outpatient parenteral antibiotic therapy; PVE ¼ prosthetic valve endocarditis.
(the first 2 weeks of therapy), during which OPAT has a restricted a
For other pathogens, consultation with an ID specialist is recommended.
b
indication; and (ii) a second, continuation phase (beyond 2 weeks of For patients with late PVE, consultation with an ID specialist is recommended.
c
Preferably from the Endocarditis Team.
therapy), where OPAT may be feasible. Table 21 summarizes the d
General physician can see the patient once a week, if needed.
salient questions to address when considering OPAT for IE.205
ESC Guidelines 3099
8. Main complications of left-sided important objective of the ‘Heart Team’. Each case must be indivi-
dualized and all factors associated with increased risk identified at
valve infective endocarditis and the time of diagnosis. Frequently the need for surgery will be deter-
their management mined by a combination of several high-risk features.211
In some cases, surgery needs to be performed on an emergency
Surgical treatment is required in approximately half of the patients (within 24 h) or urgent (within a few days, ,7 days) basis, irrespect-
with IE because of severe complications.54 Reasons to consider ive of the duration of antibiotic treatment. In other cases, surgery
early surgery in the active phase (i.e. while the patient is still receiv- can be postponed to allow 1 or 2 weeks of antibiotic treatment un-
ing antibiotic treatment) are to avoid progressive HF and irrevers- der careful clinical and echocardiographic observation before an
ible structural damage caused by severe infection and to prevent elective surgical procedure is performed.63,115 The three main indi-
systemic embolism.6,54,115,208 – 210 On the other hand, surgical ther- cations for early surgery in IE are HF, uncontrolled infection and
apy during the active phase of the disease is associated with signifi- prevention of embolic events212 – 216 (Table 22).

cant risk. Surgery is justified in patients with high-risk features that
make the possibility of cure with antibiotic treatment unlikely and
who do not have co-morbid conditions or complications that 8.1 Heart failure
make the prospect of recovery remote. Age per se is not a contra- 8.1.1 Heart failure in infective endocarditis
indication to surgery.211 HF is the most frequent complication of IE and represents the most
Early consultation with a cardiac surgeon is recommended in or- common indication for surgery in IE.54 HF is observed in 42 –60% of
der to determine the best therapeutic approach. Identification of pa- cases of NVE and is more often present when IE affects the aortic
tients requiring early surgery is frequently difficult and is an rather than the mitral valve.111,208,212 HF is mainly caused by new
Table 22 Indications and timing of surgery in left-sided valve infective endocarditis (native valve endocarditis and
prosthetic valve endocarditis)
Indications for surgery Timinga Classb Levelc Ref.d

1. Heart failure
Aortic or mitral NVE or PVE with severe acute regurgitation, obstruction or fistula causing refractory Emergency 111,115,
I B
pulmonary oedema or cardiogenic shock 213,216
Aortic or mitral NVE or PVE with severe regurgitation or obstruction causing symptoms of HF or Urgent 37,115,
echocardiographic signs of poor haemodynamic tolerance I B 209,216,
220,221
2. Uncontrolled infection
Locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation) Urgent 37,209,
I B
216
Infection caused by fungi or multiresistant organisms Urgent/

I C
elective
Persisting positive blood cultures despite appropriate antibiotic therapy and adequate control of Urgent
IIa B 123
septic metastatic foci
PVE caused by staphylococci or non-HACEK gram-negative bacteria Urgent/
IIa C
elective
3. Prevention of embolism
Aortic or mitral NVE or PVE with persistent vegetations .10 mm after one or more embolic Urgent 9,58,72,
I B
episode despite appropriate antibiotic therapy 113,222
Aortic or mitral NVE with vegetations .10 mm, associated with severe valve stenosis or Urgent
IIa B 9
regurgitation, and low operative risk
Aortic or mitral NVE or PVE with isolated very large vegetations (.30 mm) Urgent IIa B 113
Aortic or mitral NVE or PVE with isolated large vegetations (.15 mm) and no other indication for Urgent
IIb C
surgerye
HACEK ¼ Haemophilus parainfluenzae, Haemophilus aphrophilus, Haemophilus paraphrophilus, Haemophilus influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis,
Eikenella corrodens, Kingella kingae and Kingella denitrificans; HF ¼ heart failure; IE ¼ infective endocarditis; NVE ¼ native valve endocarditis; PVE ¼ prosthetic valve endocarditis.
a
Emergency surgery: surgery performed within 24 h; urgent surgery: within a few days; elective surgery: after at least 1– 2 weeks of antibiotic therapy.
b
c
Level of evidence.
d
e
Surgery may be preferred if a procedure preserving the native valve is feasible.
3100 ESC Guidelines
or worsening severe aortic or mitral regurgitation, although intra- In summary, HF is the most frequent and among the most severe
cardiac fistulae213 and, more rarely, valve obstruction may also complications of IE. Unless severe co-morbidity exists, the pres-
ence of HF is an indication for early surgery in NVE and PVE,
lead to HF.
even in patients with cardiogenic shock.
Valvular regurgitation in native IE may occur as a result of mitral
chordal rupture, leaflet rupture (flail leaflet), leaflet perforation or
interference of the vegetation mass with leaflet closure. A particular 8.2 Uncontrolled infection
situation is infection of the anterior mitral leaflet secondary to an in- Uncontrolled infection is one of the most feared complications of IE
fected regurgitant jet of a primary aortic IE.214 Resultant aneurysm and is the second most frequent cause for surgery.54 Uncontrolled
formation on the atrial side of the mitral leaflet may later lead to infection is considered to be present when there is persisting infec-
mitral perforation.215 tion and when there are signs of locally uncontrolled infection. Infec-
Clinical presentation of HF may include dyspnoea, pulmonary oe- tion due to resistant or very virulent organisms often results in
dema and cardiogenic shock.111,120 Among the large ICE Prospect- uncontrolled infection.

ive Cohort Study patients with HF and IE, 66% were in New York
Heart Association class III or IV.216 In addition to clinical findings, 8.2.1 Persisting infection
TTE is of crucial importance for initial evaluation and follow-up.64 The definition of persisting infection is arbitrary and consists of fever
Valve perforation, secondary mitral lesions and aneurysms are and persisting positive cultures after 7– 10 days of antibiotic treat-
best assessed using TOE.64,65,214 Echocardiography is also useful ment. Persisting fever is a frequent problem observed during treat-
to evaluate the haemodynamic consequences of valvular dysfunc- ment of IE. Usually, temperature normalizes within 7– 10 days under
tion, measurement of pulmonary artery pressure, detection of peri- specific antibiotic therapy. Persisting fever may be related to several
cardial effusion and assessment and monitoring of left ventricular factors, including inadequate antibiotic therapy, resistant organisms,
systolic function and left and right heart filling pressures.64 B-type infected lines, locally uncontrolled infection, embolic complications
natriuretic peptide has potential use in the diagnosis and monitoring or extracardiac site of infection and adverse reaction to antibiotics.3
of HF in IE.217 Both elevated levels of cardiac troponins and B-type Management of persisting fever includes replacement of i.v. lines, re-
natriuretic peptide are associated with adverse outcomes in peat laboratory measurements, blood cultures, echocardiography,
IE.218,219 Moderate to severe HF is the most important predictor and the search for an intracardiac or extracardiac focus of infection.
of in-hospital, 6-month and 1-year mortality.52,109,111,117,208
8.2.2 Perivalvular extension in infective endocarditis
Perivalvular extension of IE is the most frequent cause of uncon-
8.1.2 Indications and timing of surgery in the presence of trolled infection and is associated with a poor prognosis and high
heart failure in infective endocarditis (Table 22) likelihood of the need for surgery. Perivalvular complications in-
Identification of surgical candidates and timing of surgery decisions clude abscess formation, pseudoaneurysms and fistulae (defined in
should preferably be made by the Endocarditis Team.118 The pres- Table 11).223,224
ence of HF indicates surgery in the majority of patients with IE and is Perivalvular abscess is more common in aortic IE (10 – 40% in
the principal indication for urgent surgery.115,124 Surgery is indicated NVE)3,225 – 227 and is frequent in PVE (56 –100%).3,6 In mitral IE, peri-
in patients with HF caused by severe aortic or mitral regurgitation, valvular abscesses are usually located posteriorly or laterally.228 In
intracardiac fistulae or valve obstruction caused by vegetations. Sur- aortic IE, perivalvular extension occurs most frequently in the
gery is also indicated in patients with severe acute aortic or mitral mitral-aortic intervalvular fibrosa.229 Serial echocardiographic stud-
regurgitation without clinical HF but with echocardiographic signs ies have shown that abscess formation is a dynamic process, starting
of elevated left ventricular end-diastolic pressure (e.g. premature with aortic root wall thickening and extending to the development
closure of the mitral valve), high left atrial pressure or moderate of fistulae.229 In one study, the most important risk factors for peri-
to severe pulmonary hypertension. These rules apply in both NVE valvular complications were prosthetic valve, aortic location and in-
and PVE.37,220,221 fection with CoNS.230
Surgery must be performed on an emergency basis, irrespective Pseudoaneurysms and fistulae are severe complications of IE and
of the status of infection, when patients are in persistent pul- are frequently associated with very severe valvular and perivalvular
monary oedema or cardiogenic shock despite medical therapy.63 damage.213,231 – 233 The frequency of fistula formation in IE has been
Surgery must be performed on an urgent basis when HF is less reported to be 1.6%, with S. aureus being the most commonly asso-
severe. Urgent surgery should also be performed in patients ciated organism (46%).233
with severe aortic or mitral insufficiency with large vegetations, Despite high rates of surgery in this population (87%), hospital
even without HF.9 mortality remains high (41%).213,233,234 Other complications due
In patients with well-tolerated (New York Heart Association to major extension of infection are less frequent and may include
class I or II) severe valvular regurgitation and no other reasons for ventricular septal defect, third-degree atrio-ventricular block and
surgery, medical management with antibiotics under strict clinical acute coronary syndrome.223,224,234
and echocardiographic observation is a good option, although early Perivalvular extension should be suspected in cases with persist-
surgery may be an option in selected patients at low risk for surgery. ent unexplained fever or new atrio-ventricular block. Therefore an
Elective surgery should be considered depending on the tolerance electrocardiogram should be performed frequently during continu-
of the valve lesion and according to the recommendations of the ing treatment, particularly in aortic IE. TOE, MSCT and PET/CT103
ESC Guidelines on the management of valvular heart disease.55 are particularly useful for the diagnosis of perivalvular complications,
ESC Guidelines 3101
while the sensitivity of TTE is ,50%225 – 228 (see section 5). Indeed, increased morbidity and mortality.105 Conversely, embolic events
perivalvular extension is frequently discovered on a systematic TOE. may be totally silent in 20–50% of patients with IE, especially those
However, small abscesses can be missed, even using TOE, particu- affecting the splenic or cerebral circulation, and can be diagnosed by
larly those in a mitral location when there is co-existent annular non-invasive imaging.83,85,242 Thus systematic abdominal and cere-
calcification.101 bral CT scanning may be helpful. However, contrast media should
be used with caution in patients with renal impairment or haemo-
8.2.3 Indications and timing of surgery in the presence of dynamic instability because of the risk of worsening renal impair-
uncontrolled infection in infective endocarditis (Table 22) ment in combination with antibiotic nephrotoxicity.
The results of surgery when the reason for the procedure is uncon- Overall, embolic risk is very high in IE, with embolic events occur-
trolled infection are worse than when surgery is performed for ring in 20 – 50% of patients.72,242 – 249 However, the risk of new
other reasons.124,235 events (occurring after initiation of antibiotic therapy) is only 6 –
21%.72,115,243 A study from the ICE group250 demonstrated that

8.2.3.1 Persistent infection the incidence of stroke in patients receiving appropriate antimicro-
In some cases of IE, antibiotics alone are insufficient to eradicate the bial therapy was 4.8/1000 patient-days in the first week of therapy,
infection. Surgery has been indicated when fever and positive blood falling to 1.7/1000 patient-days in the second week, and further
cultures persist for several days (7–10 days) despite an appropriate thereafter.
antibiotic regimen and when extracardiac abscesses (splenic, verte-
bral, cerebral or renal) and other causes of fever have been
excluded. However, the best timing for surgery in this difficult situ- 8.3.2 Predicting the risk of embolism
ation is unclear. Recently it has been demonstrated that persistent Echocardiography plays a key role in predicting embolic
blood cultures 48–72 h after initiation of antibiotics are an independ- events,72,115,246 – 252 although prediction remains difficult in the indi-
ent risk factor for hospital mortality.123 These results suggest that sur- vidual patient. Several factors are associated with increased risk of
gery should be considered when blood cultures remain positive after embolism, including the size and mobility of vegetations,72,242,246 – 253
3 days of antibiotic therapy, after the exclusion of other causes of per- the location of the vegetation on the mitral valve,72,246 – 249 the in-
sistent positive blood cultures (adapted antibiotic regimen). creasing or decreasing size of the vegetation under antibiotic ther-
apy,72,253 particular microorganisms (S. aureus,72 S. bovis,254 Candida
8.2.3.2 Signs of locally uncontrolled infection spp.), previous embolism,72 multivalvular IE246 and biological mar-
Signs of locally uncontrolled infection include increasing vegetation kers.255 Among these, the size and mobility of the vegetations are
size, abscess formation, false aneurysms, and the creation of fistu- the most potent independent predictors of a new embolic event.253
lae.213,236,237 Persistent fever is also usually present and surgery is Patients with vegetations .10 mm in length are at higher risk of em-
recommended as soon as possible. Rarely when there are no other bolism,58,253 and this risk is even higher in patients with larger
reasons for surgery and fever is easily controlled with antibiotics, (.15 mm) and mobile vegetations, especially in staphylococcal IE
small abscesses or false aneurysms can be treated conservatively un- affecting the mitral valve.219 A recent study113 found that the risk
der close clinical and echocardiographic follow-up. of neurological complications was particularly high in patients with
very large (.30 mm length) vegetations.
8.2.3.3 Infection by microorganisms at low likelihood of being controlled Several factors should be taken into account when assessing em-
by antimicrobial therapy bolic risk. In a recent study of 847 patients with IE, the 6-month in-
Surgery is indicated in fungal IE,238,239 in cases of multiresistant or- cidence of new embolism was 8.5%.222 Six factors (age, diabetes,
ganisms (e.g. MRSA or vancomycin-resistant enterococci) or in the atrial fibrillation, previous embolism, vegetation length and
rare infections caused by Gram-negative bacteria. Surgery should S. aureus infection) were associated with an increased embolic risk
also be considered in PVE caused by staphylococci or non-HACEK and were used to create an ‘embolic risk calculator’.222
Gram-negative bacteria. In NVE caused by S. aureus, surgery is indi- Whatever the risk factors observed in an individual patient, it must
cated if a favourable early response to antibiotics is not be re-emphasized that the risk of new embolism is highest during the
achieved161,240,241 (Table 22). Finally, surgery should be performed first days following initiation of antibiotic therapy and rapidly de-
in patients with PVE and S. aureus infection. creases thereafter, particularly beyond 2 weeks,58,72,243,250 although
In summary, uncontrolled infection is most frequently related to
some risk persists indefinitely while vegetations remain present, par-
perivalvular extension or ‘difficult-to-treat’ organisms. Unless se- ticularly for very large vegetations.113 For this reason, the benefits of
vere co-morbidity exists, the presence of locally uncontrolled in- surgery to prevent embolism are greatest during the first 2 weeks of
fection is an indication for early surgery in patients with IE. antibiotic therapy, when embolic risk peaks.
8.3 Prevention of systemic embolism 8.3.3 Indications and timing of surgery to prevent
8.3.1 Embolic events in infective endocarditis embolism in infective endocarditis (Table 22)
Embolic events are a frequent and life-threatening complication of IE Avoiding embolic events is difficult since the majority occur before
related to the migration of cardiac vegetations. The brain and spleen admission.222 The best means to reduce the risk of an embolic event
are the most frequent sites of embolism in left-sided IE, while pul- is the prompt institution of appropriate antibiotic therapy.38 While
monary embolism is frequent in native right-sided and pacemaker promising,256,257 the addition of antiplatelet therapy did not reduce
lead IE. Stroke is a severe complication and is associated with the risk of embolism in the only published randomized study.258
3102 ESC Guidelines
The exact role of early surgery in preventing embolic events re- with IE caused by other bacteria. Vegetation length and mobility also
mains controversial. In the Euro Heart Survey, vegetation size was correlate with embolic tendency.88,242 Neurological complications are
one of the reasons for surgery in 54% of patients with NVE and in associated with an excess mortality, as well as sequelae, particularly in
25% of those with PVE,54 but was rarely the only reason. The value the case of stroke.113,259 Rapid diagnosis and initiation of appropriate
of early surgery in an isolated large vegetation is controversial. A re- antibiotics are of major importance to prevent a first or recurrent
cent randomized trial demonstrated that early surgery in patients neurological complication.250 Early surgery in high-risk patients is the
with large vegetations significantly reduced the risk of death and em- second mainstay of embolism prevention, while antithrombotic drugs
bolic events compared with conventional therapy.9 However, the have no role (see section 12.7).
patients studied were at low risk and there was no significant differ- Successful management of IE requires a combined medical and
ence in all-cause mortality at 6 months in the early surgery and surgical approach in a substantial proportion of patients. Following
conventional-treatment groups. a neurological event, the indication for cardiac surgery often remains

Finally, the decision to operate early for prevention of embolism or is strengthened, but must be balanced with perioperative risk and
must take into account the presence of previous embolic events, postoperative prognosis. Randomized studies are not possible and
other complications of IE, the size and mobility of the vegetation, cohort studies suffer from bias that can only be partly compensated
the likelihood of conservative surgery and the duration of antibiotic for by statistical methods.115,260 – 262 However, the risk of post-
therapy.115 The overall benefits of surgery should be weighed operative neurological deterioration is low after a silent cerebral
against the operative risk and must consider the clinical status and emboli or transient ischaemic attack, and surgery is recommended
co-morbidity of the patient. without delay if an indication remains.105 After an ischaemic stroke,
The main indications and timing of surgery to prevent embolism cardiac surgery is not contraindicated unless the neurological progno-
are given in Table 22. Surgery is indicated in patients with persisting sis is judged too poor.263 Evidence regarding the optimal time interval
vegetations .10 mm after one or more clinical or silent embolic between stroke and cardiac surgery is conflicting, but recent data fa-
events despite appropriate antibiotic treatment.58 Surgery may be vour early surgery.9,115 If cerebral haemorrhage has been excluded by
considered in patients with large (.15 mm) isolated vegetations cranial CT and neurological damage is not severe (i.e. coma), surgery
on the aortic or mitral valve, although this decision is more difficult indicated for HF, uncontrolled infection, abscess or persistent high
and must be very carefully individualized according to the probabil- embolic risk should not be delayed and can be performed with a
ity of conservative surgery.58 low neurological risk (3 – 6%) and good probability of complete
Surgery undertaken for the prevention of embolism must be per- neurological recovery.105,263 Conversely, in cases with intracranial
formed very early, during the first few days following initiation of haemorrhage, neurological prognosis is worse and surgery should
antibiotic therapy (urgent surgery), as the risk of embolism is highest generally be postponed for at least 1 month,264,265 although one re-
at this time.58,72 cent study has reported a relatively low risk of neurological deterior-
In summary, embolism is very frequent in IE, complicating 20 –
ation in IE patients undergoing surgery within 2 weeks after an
50% of cases of IE, but falling to 6– 21% after initiation of antibiot- intracranial haemorrhage.266 The Task Force has thus decided to
ic therapy. The risk of embolism is highest during the first 2 weeks adapt the level of evidence to a class IIa. If urgent cardiac surgery is
of antibiotic therapy and is clearly related to the size and mobility needed, close cooperation with the neurosurgical team and the
of the vegetation, although other risk factors exist. The decision
Endocarditis Team is mandatory. Table 23 and Figure 4 summarize
to operate early to prevent embolism is always difficult and spe-
cific for the individual patient. Governing factors include the size the recommended management of neurological complications in IE.
and mobility of the vegetation, previous embolism, type of micro- Cerebral imaging is mandatory for any suspicion of neurological
organism and duration of antibiotic therapy. complication of IE. CT scanning, with or without contrast agent, is
most often performed. The higher sensitivity of MRI, with or with-
out contrast gadolinium enhancement, allows for better detection
and analysis of cerebral lesions in patients with neurological symp-
9. Other complications of infective toms, and this may have an impact on the timing of surgery89 (see
endocarditis section 5). In patients without neurological symptoms, cerebral
MRI often detects lesions that may change the therapeutic strategy;
9.1 Neurological complications in particular, the indications and timing of surgery.85,90 Cerebral MRI
Symptomatic neurological complications occur in 15–30% of patients often detects microbleeds (round T2* hypointensities with a diam-
with IE and are mainly the consequence of embolism from vegeta- eter ≤10 mm) in patients with IE. The lack of association with par-
tions.110,113,259 Neurological manifestations occur before or at IE diag- enchymal haemorrhage and the absence of postoperative
nosis in a majority of cases, but new or recurrent events can also take neurological complications in patients with microbleeds suggest
place later in the course of IE. Clinical presentation is variable and may that microbleeds should not be interpreted as active bleeding and
include multiple symptoms or signs in the same patient, but focal signs should not lead to postponed surgery when this is indicated.89,90
predominate and ischaemic strokes are most commonly diagnosed.
Transient ischaemic attack, intracerebral or subarachnoidal haemor- In summary, symptomatic neurological events develop in 15–30%
of all patients with IE and additional silent events are frequent.
rhage, brain abscess, meningitis and toxic encephalopathy are also
Stroke (ischaemic and haemorrhagic) is associated with excess
seen, and firm evidence supports that additional clinically silent cere- mortality. Rapid diagnosis and initiation of appropriate antibiotics
bral embolisms occur in 35–60% of IE patients.83,85,90 S. aureus IE is are of major importance to prevent a first or recurrent neurological
more frequently associated with neurological complications compared complication. After a first neurological event, cardiac surgery, if
ESC Guidelines 3103
Table 23 Management of neurological

complications of infective endocarditis
Neurological complication
Recommendations Classa Levelb Ref.c

• Clincal assessment
After a silent embolism or transient • Cerebral CT scan / MRI
• TTE / TOE
ischaemic attack, cardiac surgery, if 105,
I B
indicated, is recommended without 263
delay • Heart failure
• Uncontrolled infection
Neurosurgery or endovascular therapy • Abscess
is recommended for very large, enlarging • High embolic risk No
I C Yes
or ruptured intracranial infectious

aneurysms
• Intracranial haemorrhage
Following intracranial haemorrhage, • Coma Yes
surgery should generally be postponed IIa B 264 – 266 • Severe comorbilities
• Stroke with severe damage
for ≥1 month
No
After a stroke, surgery indicated for HF,
uncontrolled infection, abscess, or
persistent high embolic risk should be Consider surgery Conservative treatment
(see Table 22) and monitoring
considered without any delay as long as IIa B 9,263
coma is absent and the presence of CT = computed tomography; IE = infective endocarditis; MRI = magnetic resonance imaging;
cerebral haemorrhage has been TOE = transoesophageal echocardiography;TTE = transthoracic echocardiography.
excluded by cranial CT or MRI
Intracranial infectious aneurysms should Figure 4 Therapeutic strategies for patients with infective endo-
be looked for in patients with IE and
carditis and neurological complications.
neurological symptoms. CT or MR
angiography should be considered for
267,
diagnosis. If non-invasive techniques are IIa B
268
negative and the suspicion of
intracranial aneurysm remains, Cerebral CT and MRI both reliably diagnose infectious aneurysms
conventional angiography should be
with good sensitivity and specificity.271 However, conventional angi-
considered
ography remains the gold standard and should be performed when
non-invasive techniques are negative and suspicion remains.267
CT ¼ computed tomography; HF ¼ heart failure; IE ¼ infective endocarditis;
MR ¼ magnetic resonance; MRI ¼ magnetic resonance imaging.
Owing to the lack of randomized trials, there is no widely accepted
a
Class of recommendation. standard management for infectious aneurysms. Thus management
b
Level of evidence. should be provided by an Endocarditis Team and tailored to the indi-
c
vidual patient. Some infectious aneurysms may resolve during anti-
biotic treatment, while others require surgical or endovascular
indicated, is generally not contraindicated, except when extensive
intervention depending on the occurrence of rupture and the loca-
brain damage or intracranial haemorrhage is present. tion in the artery bed, as well as the clinical status of the patient.268,269
Regarding intracranial infectious aneurysms, ruptured aneurysms
must be treated immediately by surgical or endovascular procedures.
9.2 Infectious aneurysms Unruptured infectious aneurysms should be followed by serial cere-
Infectious (mycotic) aneurysms result from septic arterial embolism bral imaging under antibiotic therapy. If the size of the aneurysm de-
to the intraluminal space or vasa vasorum or from subsequent spread creases or resolves completely, surgical or endovascular intervention
of infection through the intimal vessels. Infectious aneurysms are typ- is usually unnecessary. However, if the size of the aneurysm increases
ically thin walled and friable and, as such, exhibit a high tendency to or remains unchanged, it is likely that the patient will require interven-
rupture and haemorrhage. No predictor of rupture has been identi- tion. On the other hand, if the infectious aneurysm is voluminous and
fied and, in contrast to non-infectious aneurysms, size does not ap- symptomatic, neurosurgery or endovascular therapy is recom-
pear to be a reliable predictor of potential rupture.268,269 mended.272 Finally, if early cardiac surgery is required, preoperative
An intracranial location is most common and the reported fre- endovascular intervention might be considered before the proced-
quency of 2– 4% is probably an underestimation since some infec- ure, depending on associated cerebral lesions, the haemodynamic sta-
tious aneurysms are clinically silent.267,270 Early detection and tus of the patient and the risk of the procedure.
treatment of infectious aneurysms is essential given the high morbid-
ity and mortality rate secondary to rupture. Clinical presentation is
highly variable (i.e. focal neurological deficit, headache, confusion, 9.3 Splenic complications
seizures), so imaging should be systematically performed to detect Splenic infarcts are common and very often asymptomatic. Persist-
intracranial infectious aneurysms in any case of IE with neurological ent or recurrent fever, abdominal pain and bacteraemia suggest the
symptoms.268 presence of complications (splenic abscess or rupture). Although
3104 ESC Guidelines
splenic emboli are common, splenic abscesses are rare. Persistent or increased embolic risk, as were other factors (age, diabetes, previous
recurrent fever and bacteraemia suggest the diagnosis. These pa- embolism, vegetation length and S. aureus infection).222 Consequently,
tients should be evaluated by abdominal CT, MRI or ultrasound. Re- atrial fibrillation has the potential to increase the risk of both congest-
cently PET has proved useful for the diagnosis of splenic metastasic ive HF and embolism in IE. However, there is no specific study on this
infection in patients with IE.273 Treatment consists of appropriate situation and no international consensus for the care of these patients.
antibiotic regimens. Splenectomy may be considered for splenic The management of anticoagulation therapy in these patients should
rupture or large abscesses, which respond poorly to antibiotics be taken on an individual basis by the Endocarditis Team.
alone, and should be performed before valvular surgery unless the
latter is urgent. Rarely, splenectomy and valvular surgery are per- 9.6 Musculoskeletal manifestations
formed during the same operative time. Percutaneous drainage is Musculoskeletal symptoms (arthralgia, myalgia, back pain) are fre-
an alternative for high-risk surgical candidates.274,275 quent during IE.282,283 Rheumatological manifestations may be the

first manifestations of IE and can delay its diagnosis, especially
9.4 Myocarditis and pericarditis when classic manifestations are less evident and a variety of anti-
bodies (i.e. positive antineutrophil cytoplasmic antibody test) in-
Cardiac failure may be due to myocarditis, which is frequently asso-
duced by infections284,285 are present. Arthralgia occurs in about
ciated with abscess formation or immune reaction. Ventricular arrhyth-
10% of patients, while myalgia is present in 12 – 15%.282,286 Back
mias may indicate myocardial involvement and imply a poor prognosis.
pain is observed in about 13% of cases, and lumbar pain is the
Myocardial involvement is best assessed using TTE and cardiac MRI.
most common symptom in patients with IE and vertebral osteomye-
The inflammatory response, HF, periannular complications or in-
litis.282,283,287,288 Peripheral arthritis occurs in about 14% of
fection itself can cause pericardial effusion, which could be a sign of
cases.282 The prevalence of spondylodiscitis in patients with IE is
more severe IE. Rarely, ruptured pseudoaneurysms or fistulae may
about 1.8 – 15%.282 Pyogenic vertebral osteomyelitis occurs in
communicate with the pericardium, with dramatic and often fatal
4.6 – 19% of IE patients with a high incidence of streptococcal and
consequences. Purulent pericarditis is rare and may necessitate sur-
staphylococcal bacteraemia.283,287 IE can complicate or be compli-
gical drainage.276,277
cated by pyogenic osteomyelitis. The prevalence of IE in vertebral
osteomyelitis is higher288,289 in the presence of Streptococcus viridans
9.5 Heart rhythm and conduction IE. CT, but preferably MRI, of the spine or whole-body 18F-FDG-
disturbances PET/CT290 should be performed in IE patients with back or bone
Conduction disorders are uncommon complications of IE. Accord- pain. Conversely, echocardiography should be performed in
ing to data from patient registries, their frequency is between 1% patients with a definite diagnosis of pyogenic spondylodiscitis/
and 15% of cases and their presence is associated with worse prog- osteomyelitis and underlying cardiac conditions predisposing to IE.
nosis and higher mortality.278 In definite spondylodiscitis and osteomyelitis, prolonged antibiot-
Conduction abnormalities (mainly first-, second-, and third- ic therapy is generally required until no signs of inflammatory activity
degree atrio-ventricular blocks, rarely bundle branch blocks) are are detected by 18FDG PET/CT or MRI. Other musculoskeletal
due to spread of the infection beyond the endocardium, from valves manifestations are less common in IE and include sacroiliitis in about
to the conduction pathways, and are generally associated with peri- 1% of cases, a condition mimicking polymyalgia rheumatica with pain
valvular complications. Complete atrio-ventricular block is most of- and morning stiffness of the shoulders and hips, proximal muscle
ten associated with involvement of the left-sided valves (aortic, 36%; weakness in about 0.9% of cases and cutaneous leucocytoclastic vas-
mitral, 33%).278 This is because of the anatomical relationship with culitis (purpuric skin lesions) in 3.6% of cases.282,289
the atrio-ventricular node, which is close to the non-coronary aortic
cusp and the anterior mitral leaflet. In a study of patients with IE and 9.7 Acute renal failure
complete atrio-ventricular block, pathology workup revealed the Acute renal failure is a common complication of IE and may worsen
presence of an infection, frequently accompanied by abscesses the prognosis of IE. The onset of renal dysfunction is independently
and fistulae, affecting the conduction pathways; in cases of paroxys- associated with increased risk of in-hospital death291,292 and post-
mal atrio-ventricular block, inflammation was observed at this level, operative events.293
which would explain the reversibility of the event.279 Acute renal dysfunction occurs in about 6 – 30% of pa-
The occurrence of conduction abnormalities during electrocar- tients.291,292,294,295 Causes are often multifactorial:296,297 (i) immune
diographic monitoring in patients with endocarditis can therefore complex and vasculitic glomerulonephritis; (ii) renal infarction,
alert physicians to the appearance of perivalvular complications. mostly due to septic emboli, occurring at any time during the course
In the case of embolization of vegetation fragments into a coron- of the disease; (iii) haemodynamic impairment in cases with HF or
ary artery, the resulting myocardial ischaemia can be the substrate severe sepsis or after cardiac surgery; (iv) antibiotic toxicity (acute
for the onset of tachyarrhythmias.280 interstitial nephritis), notably related to aminoglycosides, vancomy-
Atrial fibrillation can be observed in patients with IE and may be cin (synergistic toxicity with aminoglycosides) and even high-dose
present before IE or occur as a complication of IE. Atrial fibrillation penicillin; and (v) nephrotoxicity of contrast agents used for imaging
has been reported to be more frequent in the elderly and to be asso- purposes.
ciated with a poor prognosis.281 More recently, in a large prospective Haemodialysis may be required in some patients with advanced
series of IE, atrial fibrillation was found to be associated with an renal failure and is associated with high mortality.295 Acute renal
ESC Guidelines 3105
failure of a milder degree is often reversible.295 To mitigate this com- 10.2.3 Intraoperative echocardiography
plication, antibiotic doses should be adjusted for creatinine clear- Intraoperative TOE is most useful to determine the exact location
ance with careful monitoring of serum levels (aminoglycosides and and extent of infection, guide surgery, assess the result and help in
vancomycin). Imaging with nephrotoxic contrast agents should be early postoperative follow-up.73
avoided when possible in patients with haemodynamic impairment
or previous renal insufficiency.
10.3 Surgical approach and techniques
The two primary objectives of surgery are total removal of infected
10. Surgical therapy: principles tissues and reconstruction of cardiac morphology, including repair
or replacement of the affected valve(s).
and methods Where infection is confined to the valve cusps or leaflets, any

method to repair or replace the valve may be used. However, valve
10.1 Operative risk assessment
repair is favoured whenever possible, particularly when IE affects the
Few studies have evaluated the utility of operative risk scores in the mitral or tricuspid valve without significant destruction.302 Perfora-
setting of IE. Although EuroSCORE II is frequently used,298 it was de- tions in a single valve cusp or leaflet may be repaired with an untreat-
veloped and validated predominantly for coronary artery bypass ed or glutaraldehyde-treated autologous or bovine pericardial
grafting and valve surgery. Risk scores specific to IE surgery have patch. Isolated or multiple ruptured chordae may be replaced by
been developed: (i) from the Society of Thoracic Surgeons database polytetrafluoroethylene neo-chordae.
using 13 617 patients299 and (ii) an additional NVE risk score from a More extensive destruction of a single leaflet or the presence of
single centre using 440 patients by De Feo et al.300 A study com- an abscess is not necessarily a contraindication for valve repair.302
pared the prognostic utility of these contemporary risk scores for Rather, intraoperative assessment of the valve after debridement
mortality and morbidity after IE surgery in 146 patients.301 Here, al- is of paramount importance in order to evaluate whether the re-
though EuroSCORE II discriminated mortality and postoperative maining tissue is of sufficient quality to achieve a durable repair.
morbidity (in particular, stroke), the Society of Thoracic Surgeons The need for a patch to achieve a competent valve, whether pericar-
endocarditis score and the De Feo et al. score300 performed better dial, tricuspid autograft or a flipped-over mitral patch, has not been
at predicting operative mortality after surgery for active IE. How- associated with worse results in terms of recurrence of IE or mitral
ever, the relevance of these findings is limited by the small number regurgitation when performed by experienced surgeons.303
of patients involved. Similar to previous studies, preoperative use of To avoid paravalvular leaks in complex cases with locally uncon-
inotropes or an intra-aortic balloon pump, prior coronary artery by- trolled infection, total excision of infected and devitalized tissue
pass surgery and renal failure requiring dialysis were independent should be followed by valve replacement and repair of associated
predictors of operative and long-term mortality. defects to secure valve fixation.304
Finally, although no single operative risk score is perfect, pre- Mechanical and biological prostheses have similar operative mor-
operative assessment of operative risk is of utmost importance. tality.305 Therefore the Task Force does not favour any specific valve
Although the theoretical indications for surgery in IE are clear substitute but recommends a tailored approach for each individual
(Table 22), their practical application relies largely on the clinical patient and clinical situation. The use of foreign material should be
status of the patient, the patient’s co-morbidities and the patient’s kept to a minimum. Small abscesses can be closed directly, but larger
operative risk. cavities should be allowed to drain into the pericardium or
circulation.
In mitral valve IE, successful valve repair can be achieved by ex-
10.2 Preoperative and perioperative perienced teams in up to 80% of patients, but such results may
management not be matched in non-specialist centres.306 Moreover, although
10.2.1 Coronary angiography surgery may be deferred if control of the infection by antibiotic ther-
Coronary angiography is recommended according to the ESC apy appears evident in the absence of cardiac failure, early operation
Guidelines on the management of valvular heart disease55 in men has been associated in recent reports with a repair rate of 61–80%
.40 years, in post-menopausal women and in patients with at least and improved in-hospital and long-term survival.209,210,302,303,307 Re-
one cardiovascular risk factor or a history of coronary artery dis- sidual mitral regurgitation should be assessed using intraoperative
ease. Exceptions arise when there are aortic vegetations that may TOE. Mitral subannular, annular or supraannular tissue defects are
be dislodged during catheterization or when emergency surgery is preferably repaired with autologous or bovine pericardium, a pros-
necessary. In these situations, high-resolution CT may be used to thetic valve then being secured to the reconstructed/reinforced an-
rule out significant coronary artery disease in haemodynamically nulus, if necessary. The choice of technique depends on the vertical
stable patients.55 extension of the lesion/tissue defect.308 – 310 The use of mitral valve
homografts and pulmonary autografts (Ross II procedure) has been
10.2.2 Extracardiac infection suggested,311,312 but their application is limited by poor availability
If a primary focus of infection likely to be responsible for IE has been and difficulty of the surgical technique, and the results have not
identified, it must be eradicated before cardiac surgical intervention been consistent.
unless valve surgery is urgent. In any case, it should be eradicated In aortic IE, replacement of the aortic valve using a mechanical or
before the end of antibiotic therapy. biological prosthesis is the technique of choice. Nevertheless, in
3106 ESC Guidelines
centres with great expertise, aortic valve repair in IE can be achieved differentiated in the literature, the term ‘relapse’ refers to a repeat
in up to 33% of patients. However, experience with aortic valve re- episode of IE caused by the same microorganism, while ‘reinfection’
pair in this setting is still very limited and there is no evidence that describes an infection caused by a different microorganism.38 When
repair is associated with improved outcomes compared with re- the same species is isolated during a subsequent episode of IE, there
placement.313,314 Owing to their natural biocompatibility, the use is often uncertainty as to whether the repeat infection is a relapse of
of cryopreserved or sterilized homografts has been suggested to re- the initial infection or a new infection (reinfection). In these cases,
duce the risk of persistent or recurrent infection, especially in the molecular methods including strain-typing techniques should be
presence of annular abscesses.315,316 It is expert opinion and stand- employed.8,38 When these techniques or the identity of both iso-
ard strategy in many institutions that the use of a homograft is to be lates is unavailable, the timing of the second episode of IE may be
favoured over valve prostheses, particularly in the presence of root used to distinguish relapse from reinfection. Thus, although variable,
abscess.316,317 However, mechanical prostheses and xenografts the time between episodes is usually shorter for relapse than for re-

have led to similar results in terms of persistent or recurrent infec- infection. Generally speaking, a recurrence caused by the same spe-
tion and survival if associated with complete debridement of annular cies within 6 months following the initial infection represents
abscesses.313,318 Homografts or stentless xenografts may be pre- relapse, whereas later events suggest reinfection.38 For these pur-
ferred in PVE or in cases where there is extensive aortic root de- poses, storage of IE isolates for at least 1 year is recommended.8,38
struction with aorto-ventricular discontinuity.315,319 The anterior Factors associated with an increased rate of relapse are listed in
mitral leaflet of the aortic homograft can be effectively used for re- Table 24. Relapses are most often due to insufficient duration of ori-
construction of the outflow tract. A monoblock aorto-mitral homo- ginal treatment, suboptimal choice of initial antibiotics or a persist-
graft has been suggested as a surgical option for extensive bivalvular ent focus of infection. When the duration of therapy has been
IE.320 In experienced hands, the Ross procedure may be used in chil- insufficient or the choice of antibiotic incorrect, relapse should be
dren or adolescents to facilitate growth and in young adults for ex- treated for a further 4– 6 weeks depending on the causative micro-
tended durability.321,322 organism and its antibiotic susceptibility (remembering that resist-
Cardiac transplantation may be considered in extreme cases ance may develop in the meantime).
where repeated operative procedures have failed to eradicate per- Patients with previous IE are at risk of reinfection,332 and prophy-
sistent or recurrent PVE.323 lactic measures should be very strict. Reinfection is more frequent in
IVDAs (especially in the year after the initial episode),332,333 in
10.4 Postoperative complications PVE,334 in patients undergoing chronic dialysis326,332 and in those
Postoperative patient management should follow the usual recom- with multiple risk factors for IE.8 Patients with reinfection are at
mendations after valvular surgery324 but should also take into ac- higher risk of death and need for valve replacement.325,332 Paravalv-
count the specificities of IE. Postoperative follow-up should be ular destruction is associated with a higher rate of recurrence and a
particularly cautious given the in-hospital mortality of patients oper- higher operative mortality.331 In a large series of surgically managed
ated on for acute IE on an emergency or urgent basis, which ranges NVE (358 cases), 21% had paravalvular destruction, and freedom
from 10% to 20% in most series,1 and the increased risk of post- from recurrent PVE at 15 years was 78.9%.331
operative complications. The type of valve implanted has no effect on the risk of recurrent
Among the most frequent complications are severe coagulopathy IE.325,331 Aortic valve and root replacement with a prosthetic
requiring treatment with clotting factors, re-exploration of the chest
for bleeding or tamponade, acute renal failure requiring haemodialy- Table 24 Factors associated with an increased rate of
sis, stroke, low cardiac output syndrome, pneumonia and atrio- relapse
ventricular block following radical resection of an aortic root ab-
scess with the need for pacemaker implantation.325 A preoperative • Inadequate antibiotic treatment (agent, dose, duration)
electrocardiogram demonstrating left bundle branch block predicts • Resistant microorganisms, i.e. Brucella spp., Legionella spp., Chlamydia
the need for a postoperative permanent pacemaker.23 When a spp., Mycoplasma spp., Mycobacterium spp., Bartonella spp., Coxiella
patient does not survive surgery, the cause of death is often Burnetii, fungi
multifactorial.325 • Polymicrobial infection in an IVDA
• Empirical antimicrobial therapy for BCNIE
11. Outcome after discharge: • Periannular extension

• Prosthetic valve IE
follow-up and long-term prognosis • Persistent metastatic foci of infection (abscesses)
Following in-hospital treatment, the main complications include re- • Resistance to conventional antibiotic regimens
currence of infection, HF, need for valve surgery and death.57,326,327 • Positive valve culture
• Persistence of fever at the seventh postoperative day
11.1 Recurrences: relapses and
• Chronic dialysis
reinfections
The actual risk of recurrence among survivors of IE varies between BCNIE ¼ blood culture-negative infective endocarditis; IE ¼ infective
2% and 6%.57,326 – 332 Two main types of recurrence are distinguish- endocarditis; IVDA ¼ intravenous drug abuser.
able: relapse and reinfection. Although not systematically
ESC Guidelines 3107
conduit yields results similar to those for homograft root 12. Management of specific
replacement.335,336
situations
11.2 Short-term follow-up
12.1 Prosthetic valve endocarditis
A first episode of IE should not be seen as an ending once the patient
PVE is the most severe form of IE and occurs in 1 –6% of patients
has been discharged. Residual severe valve regurgitation may de-
with valve prostheses,338 with an incidence of 0.3 –1.2% per patient-
compensate left ventricular function, or valve deterioration may
year.216,233,339,340 PVE accounts for 10–30% of all cases of IE341 and
progress despite bacteriological cure, usually presenting with acute
affects mechanical and bioprosthetic valves equally. PVE was ob-
HF. After completion of treatment, recommendations for surgery
served in 16% of cases of IE in a French survey,122 in 26% of cases
follow conventional guidelines.55 As a consequence of increasing
in the Euro Heart Survey54 and in 20% of 2670 patients with definite
rates of surgery during the active phase of infection, the need
IE in the ICE Prospective Cohort Study.340 PVE is still associated

for late valve surgery is low, ranging from 3% to 8% in recent
with difficulties in diagnosis, determination of the optimal therapeut-
series.326 – 328
ic strategy and poor prognosis.
Patients should be educated about the signs and symptoms of IE
after discharge. They should be aware that recurrence could occur
in IE and that new onset of fever, chills or other signs of infection 12.1.1 Definition and pathophysiology
mandate immediate evaluation, including procurement of blood cul- Early PVE is defined as IE occurring within 1 year of surgery and late
tures before empirical use of antibiotics. To monitor the develop- PVE as IE occurring beyond 1 year, because of significant differences be-
ment of secondary HF, an initial clinical evaluation and baseline tween the microbiological profiles observed before and after this time
TTE should be performed at the completion of antimicrobial ther- point.3,342 However, this is an artificial distinction. What is important is
apy and repeated serially, particularly during the first year of not the time from the valve replacement procedure to the onset of IE,
follow-up. but whether IE is acquired perioperatively and which microorganism is
Clinical follow-up should be done by the Endocarditis Team or by involved. A recent large, prospective, multicentre, international registry
a Heart Valve Clinic specialist.11,337 Regular clinical and echocardio- reported that 37% of PVE cases were associated with nosocomial infec-
graphic follow-up should be performed during the first year follow- tion or non-nosocomial healthcare-associated infections in outpatients
ing completion of treatment.8,12 This Task Force also recommends with extensive healthcare contact.340
to take blood samples (i.e. white cell count, CRP, etc.), and blood The pathogenesis of PVE differs according to both the type of
cultures systematically at the initial visit, and otherwise if there is contamination and the type of prosthetic valve. In cases with peri-
clinical suspicion. operative contamination, the infection usually involves the junction
Good oral health maintenance, preventive dentistry and advice between the sewing ring and the annulus, leading to perivalvular ab-
about skin hygiene, including tattoos and skin piercing, are manda- scess, dehiscence, pseudo-aneurysms and fistulae.339,343,344 In late
tory. Deficiencies in dental surveillance contribute to the continu- PVE, additional mechanisms may exist. For example, in late biopros-
ous gradual increase in the incidence of IE. 30,337 This increase thetic PVE, infection is frequently located on the leaflets of the pros-
underlines the need for repeating the principles of IE prevention thesis, leading to vegetations, cusp rupture and perforation. PVE has
at each follow-up visit. recently been reported after transcatheter aortic bioprosthetic
valve implantation, which should be managed in the same manner
as other prosthetic valves.345,346 The risk of prosthetic valve im-
11.3 Long-term prognosis
plantation endocarditis increases with the use of orotracheal intub-
In recent series, the crude long-term survival rates after the comple-
ation and a self-expandable valve system.
tion of treatment were estimated to be 80 –90% at 1 year, 70 –80%
The consequence of PVE is usually new prosthetic regurgitation. Less
at 2 years and 60 – 70% at 5 years.57,326 – 332 The main predictors
frequently, large vegetations may cause prosthetic valve obstruction,
of long-term mortality are older age, co-morbidities, recurrences
which can be diagnosed by TOE and sometimes by TTE or fluoroscopy.
and HF, especially when cardiac surgery cannot be
performed.57,327,330
12.1.2 Diagnosis
Compared with an age- and sex-matched general population, pa-
Diagnosis is more difficult in PVE than in NVE. Clinical presentation
tients surviving a first episode of IE have a significantly worse sur-
is frequently atypical, particularly in the early postoperative period,
vival.57 This excess mortality is especially high within the first few
in which fever and inflammatory syndromes are common in the ab-
years after hospital discharge and can be explained by late complica-
sence of IE. However, persistent fever should trigger the suspicion
tions such as HF, higher risk of recurrences and higher patient vul-
of PVE. As in NVE, diagnosis of PVE is based mainly on the results of
nerability.57,329 In fact, most recurrences and late cardiac surgeries
echocardiography and blood cultures. However, both are more fre-
occurred during this period of time.57,328,329
quently negative in PVE.100 Although TOE is mandatory in suspected
In summary, recurrences are rare following IE and may be asso- PVE (Figure 3), its diagnostic value is lower than in NVE. A negative
ciated with inadequate initial antibiotic therapy, resistant micro-
echocardiogram is frequently observed in PVE2 and does not rule
organisms, persistent focus of infection, i.v. drug abuse and
chronic dialysis. Patients with IE must be informed of the risk of out the diagnosis, but identification of a new periprosthetic leak is
recurrence and educated about how to diagnose and prevent a a major criterion, in which case an additional imaging modality could
new episode of IE. The need for late valve surgery is low. be considered (such as CT or nuclear imaging).
3108 ESC Guidelines
In PVE, staphylococcal and fungal infections are more frequent by HF, severe prosthetic dysfunction, abscess or persistent fever
and streptococcal infection less frequent than in NVE. Staphylo- (Table 22). Emergency surgery is indicated only in cases with refrac-
cocci, fungi and Gram-negative bacilli are the main causes of early tory congestive HF leading to pulmonary oedema or shock, as in
PVE, while the microbiology of late PVE mirrors that of NVE, with NVE. Conversely, patients with uncomplicated non-staphylococcal
staphylococci, oral streptococci, S. bovis and enterococci being the and non-fungal late PVE can be managed conservatively.350,357,358
most frequent organisms, more likely due to community-acquired However, patients who are initially treated medically require close
infections. Staphyloccoci and enteroccoci are the most common follow-up because of the risk of late events.
agents in prosthetic valve implantation endocarditis.345,346 In summary, PVE represents 20% of all cases of IE, with an increas-
The Duke criteria have been shown to be helpful for the diagnosis ing incidence. The diagnosis of PVE is more difficult than for NVE.
of NVE, with a sensitivity of 70–80%,100,347 but are less useful in PVE Complicated PVE and staphylococcal PVE are associated with a
because of their lower sensitivity in this setting.348,349 Recently, nuclear worse prognosis if treated without surgery. These forms of PVE
must be managed aggressively. Patients with uncomplicated, non-
techniques, particularly 18F-FDG PET/CT, have been shown to be use-

staphylococcal late PVE can be managed conservatively with
ful for the diagnosis of PVE.93 The addition of abnormal FDG uptake as close follow-up.
a novel major criterion for PVE has thus been pointed out. An algo-
rithm for evaluation of patients with suspected PVE, including echocar-
diography and PET/CT has been suggested (see Figure 3).93 12.2 Infective endocarditis affecting
cardiac implantable electronic devices
12.1.3 Prognosis and treatment 12.2.1 Introduction
A very high in-hospital mortality rate of 20– 40% has been reported Infection of cardiac implantable electronic devices (CIEDs) is a severe
in PVE.338,341 As in NVE, prognostic assessment is of crucial im- disease associated with high mortality.360 The increased rates of CIED
portance in PVE, as it allows identification of high-risk subgroups implantation coupled with increased implantation in older patients
of patients in whom an aggressive strategy may be necessary. with more co-morbidities have set the stage for higher rates of
Several factors have been associated with poor prognosis in CIED infection and the increasing frequency of IE in these patients.361
PVE,161,216,350 – 353 including older age, diabetes mellitus, healthcare- The reported incidence of permanent pacemaker infection varies
associated infections, staphylococcal or fungal infection, early PVE, widely among studies.362,363 A population-based study found an inci-
HF, stroke and intracardiac abscess. Among these, complicated dence of CIED infection of 1.9 per 1000 device-years and a higher
PVE and staphylococcal infection are the most powerful markers. probability of infection after implantable cardioverter defibrillators
These patients need aggressive management, consisting of antibiotic compared with permanent pacemakers.364 Both diagnosis and thera-
therapy and early radical surgery. peutic strategy are particularly difficult in these patients.365
Antimicrobial therapy for PVE is similar to that for NVE. An ex-
ception is S. aureus PVE, which requires a more prolonged (≥6 12.2.2 Definitions of cardiac device infections
weeks) antibiotic regimen (particularly in association with aminogly- A distinction should be made between local device infection and
cosides) and frequent use of rifampin. cardiac device-related IE (CDRIE). Local device infection is defined
Surgery for PVE follows the general principles outlined for NVE. as an infection limited to the pocket of the cardiac device and is clin-
Radical debridement in these cases means removal of all infected ically suspected in the presence of local signs of inflammation at the
foreign material, including the original prosthesis, and any calcium generator pocket, including erythema, warmth, fluctuance, wound
remaining from previous surgery. Homografts, stentless xenografts dehiscence, erosion, tenderness or purulent drainage.366 CDRIE is
or autografts may be considered in aortic PVE, and homograft or defined as an infection extending to the electrode leads, cardiac
xenograft root replacement is indicated for any abnormality of the valve leaflets or endocardial surface. However, differentiating local
aortic root that distorts the aortic sinuses. Alternatively, a valved device infection and CDRIE is frequently difficult. In one study,367
Dacron conduit336 can be used. culture of intravascular lead segments was positive in 72% of 50 pa-
The best therapeutic option in PVE is still debated.221,354 – 359 Al- tients with manifestations strictly limited to the implantation site.
though surgery is generally considered the best option when PVE However, the possibility of intraoperative contamination of the
causes severe prosthetic dysfunction or HF,220 it was performed in lead tip cannot be excluded in these patients.
only 50% of patients with PVE in the Euro Heart Survey,54 a similar
rate as for patients with NVE. Other groups have reported similar 12.2.3 Pathophysiology
data.221,340 Early surgery was associated with lower in-hospital and The pocket may become infected at the time of implantation, during
1-year mortality in a large cohort of 4166 patients including both na- subsequent surgical manipulation of the pocket or if the generator
tive and prosthetic valve IE complicated by HF.216 Conversely, after or subcutaneous electrodes erode through the skin. Pocket infec-
adjustment for differences in clinical characteristics and survival tion may track along the intravascular portion of the electrode to
bias, early valve replacement was not associated with lower mortality involve the intracardiac portion of the pacemaker or implantable
compared with medical therapy in a large international cohort.37 cardioverter defibrillator. Alternatively, the pocket or intracardiac
However, in these series, surgery was beneficial in the subgroup of portion of the electrode may become infected as a result of haema-
patients with the greatest need for surgery, including valve regurgita- togenous seeding during a bacteraemia secondary to a distant in-
tion, vegetation and dehiscence or paravalvular abscess/fistula.37 fected focus. The consequence may be formation of vegetations,
Therefore a surgical strategy is recommended for PVE in high-risk which can be found anywhere from the insertion vein to the super-
subgroups identified by prognostic assessment, i.e. PVE complicated ior vena cava, on the lead or on the tricuspid valve, as well as on the
ESC Guidelines 3109
right atrial and ventricular endocardium. Septic pulmonary embol- scintigraphy389 and 18F-FDG PET/CT scanning108,390 have been de-
ism is a very frequent complication of CDRIE. scribed as additive tools in the diagnosis of CDRIE and related com-
plications, including pulmonary septic embolism.
12.2.4 Risk factors The Duke criteria are difficult to apply in these patients because
Several factors have been associated with CIED infections.366,367 Patient of lower sensitivity.347 Modifications of the Duke criteria have been
factors include renal failure, corticosteroid use, congestive HF, haema- proposed,382,391 including local signs of infection and pulmonary
toma formation, diabetes mellitus and anticoagulation use.368 – 370 In embolism as major criteria.382
addition, procedural characteristics may also play an important role in
the development of CIED infection. The factors associated with 12.2.7 Treatment
an increased risk of infection include the type of intervention,371,372 CDRIE must be treated by prolonged antibiotic therapy associated
device revisions, the site of intervention, the amount of indwelling with complete hardware removal.360,391

hardware, the use of pre-procedural temporary pacing, failure to ad-
minister perioperative antimicrobial prophylaxis,373 fever within the 12.2.8 Antimicrobial therapy
24 h before implantation and operator experience.374 Antimicrobial therapy for CDRIE should be individualized and based
on culture and susceptibility results if possible (see section 7). Be-
12.2.5 Microbiology cause most CDRIE infections are secondary to staphylococcal species
Staphylococci, and especially CoNS, account for 60 –80% of cases in and, of those, up to 50% are methicillin-resistant,376,392 vancomycin
most reported series.375,376 A variety of CoNS species have been should be administered initially as empirical antibiotic coverage until
described.366,377 Methicillin resistance among staphylococci varies microbiological results are known. Daptomycin, approved for right-
among studies,376,378 but a low frequency of methicillin-resistant side IE and bacteraemia attributable to S. aureus,168 is a promising mol-
CoNS has been reported among individuals with no healthcare ecule to treat CIED infection.393 – 395 Before hardware removal, but
contact, whereas a high rate of methicillin resistance in CoNS after blood cultures, i.v. antibiotics should be initiated. There are no
is associated with a healthcare environment source.379 Polymicro- clinical trial data to define the optimal duration of antimicrobial ther-
bial infection sometimes involves more than one species of apy. The duration of therapy should be 4–6 weeks in most cases.362
CoNS.376,380,381 Corynebacterium spp., Propionibacterium acnes, At least 2 weeks of parenteral therapy is recommended after extrac-
Gram-negative bacilli and Candida spp. are rarely identified as patho- tion of an infected device for patients with bloodstream infection.
gens in CIED infection.366,376,377 Patients with sustained (.24 h) positive blood cultures despite
CIED removal and appropriate antimicrobial therapy should receive
12.2.6 Diagnosis parenteral therapy for at least 4 weeks.362,366
Clinical presentation is frequently misleading, with predominant re-
spiratory and rheumatological symptoms as well as local signs of in- 12.2.9 Complete hardware removal (device and lead
fection.382 CDRIE must be suspected in the presence of unexplained extraction)
fever in a patient with a CIED. Fever is frequently blunted, particu- In the case of definite CDRIE, medical therapy alone has been asso-
larly in elderly patients. As in other forms of IE, echocardiography ciated with high mortality and risk of recurrence.360,363,391 For this
and blood cultures are the cornerstones of diagnosis. S. aureus bac- reason, CIED removal is recommended in all cases of proven CDRIE
teraemia might be the sole manifestation of device infection. and should also be considered when CDRIE is only suspected in the
Echocardiography plays a key role in CDRIE and is helpful for the case of occult infection without any apparent source other than the
diagnosis of both lead vegetations and tricuspid involvement, quanti- device.396
fication of tricuspid regurgitation, sizing of vegetations and follow-up Complete removal of the system is the recommended treatment
after lead extraction. Several prognostic features may be better de- for patients with established CDRIE.363,391,396 Considering the in-
fined on TTE than on TOE, such as pericardial effusion, ventricular herent risk of an open surgical procedure,380 transvenous lead ex-
dysfunction and pulmonary vascular pressure estimations. TOE has traction has become the preferred method. It is essential to
superior sensitivity and specificity to TTE for diagnosis of lead-related remove all hardware to avoid the recurrence of infection.368,397 In
endocarditis.381 – 385 TOE allows visualization of the lead in atypical lo- experienced centres, procedural mortality rates have been shown
cations, such as the proximal superior vena cava, and of regions that to be between 0.1% and 0.6%.396,398 Long-term mortality varies
are difficult to visualize by TTE. In addition, the sensitivity of TOE for among subgroups, but rates are higher in systemic infections.399
left-sided involvement and for perivalvular extension of infection is Transvenous extractions are not without risk, and procedural com-
superior to that of TTE. Considering their complementary role, it is plexity may vary significantly according to lead type and features.
recommended to perform both investigations in suspected CDRIE. Typically ICD leads are more difficult to remove than coronary sinus
In the presence of infective material along the lead course not leads, which are usually removed by simple manual traction.400 – 402
providing typical vegetations of measurable size, both TTE and Transvenous lead extraction should be performed only in centres
TOE may be falsely negative in CDRIE. Intracardiac echocardiog- committed to a procedural volume allowing the maintenance of
raphy was recently found to be feasible and effective in cardiac de- skills of adequately trained teams and able to provide immediate car-
vice patients386 and to have a superior sensitivity for the detection diothoracic surgery backup in the event of emergency thoracotomy
of vegetations in cardiac devices.386 – 388 or sternotomy.396,403
A normal echographic examination does not rule out CDRIE. In Pulmonary embolism as a result of vegetation displacement dur-
difficult cases, other modalities such as radiolabelled leucocyte ing extraction occurs frequently, particularly when vegetations are
3110 ESC Guidelines
large.367,404 However, these episodes are frequently asymptomatic,

and percutaneous extraction remains the recommended method Table 25 Cardiac device-related infective
even in cases of large vegetations,360,391,404 as overall risks are endocarditis: diagnosis, treatment and prevention
even higher with surgical extraction.367,380
Some authors recommend surgery in patients with very large ve- Recommendations Classa Levelb Ref.c
getations.405 Until additional data are available, decisions regarding
A. Diagnosis
percutaneous versus surgical removal of leads with vegetations
.2 cm in diameter should be individualized. 1. Three or more sets of blood
cultures are recommended before
Other indications for a surgical approach to lead removal include I C
prompt initiation of antimicrobial
patients who need a contemporary valve replacement or repair for therapy for CIED infection
IE or patients who have significant retained hardware after attempts
2. Lead-tip culture is indicated when
I C

at percutaneous removal. However, mortality associated with surgi- the CIED is explanted
cal removal is high in these frequently elderly patients with asso-
3. TOE is recommended in patients
ciated co-morbidities.380 with suspected CDRIE with
positive or negative blood
cultures, independent of the I C
12.2.10 Reimplantation
results of TTE, to evaluate
The first step before reimplantation is a re-evaluation of the indica- lead-related endocarditis and heart
tion for CIED implantation.377,403 In a significant number of cases, valve infection
reimplantation is not necessary.366,398 The device should be reim- 4. Intracardiac echocardiography may
planted on the contralateral side. There is no clear recommendation be considered in patients with
concerning the optimal timing of reimplantation. Factors such as suspected CDRIE, positive blood IIb C
persistent bacteraemia, persistent vegetation and pacemaker and cultures and negative TTE and TOE
results
implantable cardioverter defibrillator dependency should be con-
sidered and the decision adapted to the individual patient. Immedi- 5. Radiolabelled leucocyte
ate reimplantation should be avoided, owing to the risk of new scintigraphy and 18F-FDG PET/CT
scanning may be considered
infection.366,377,398,403 Blood cultures should be negative for at least additive tools in patients with IIb C
72 h before placement of a new device. In cases of evidence of suspected CDRIE, positive blood
remnant valvular infection, implantation should be delayed for at cultures and negative
least 14 days.366,406 echocardiography
Temporary pacing is a risk factor for subsequent cardiac device B. Principles of treatment
infection367 and should be avoided if possible. In pacing-dependent 1. Prolonged (i.e. before and after
patients, temporary use of active fixation leads connected to exter- extraction) antibiotic therapy and
nal devices is described as a ‘bridge’,407 permitting earlier mobiliza- complete hardware (device and
tion with a reduced risk of pacing-related adverse events.408 – 410 leads) removal are recommended I C
in definite CDRIE, as well as
in presumably isolated pocket
12.2.11 Prophylaxis infection
Although there are no large controlled studies on this topic, anti- 2. Complete hardware removal
biotic prophylaxis is recommended before implantation.367,368,373 should be considered on the
A first-generation cephalosporin, such as cefazolin (6 g/day for basis of occult infection IIa C
24 – 36 h after the intervention), is usually used as prophylaxis and without another apparent source
of infection
should be parenterally administered 1 h before the procedure.
Vancomycin, teicoplanin and daptomicin may be considered in- 3. In patients with NVE or PVE
and an intracardiac device with
stead of cefazolin in centres where oxacillin resistance among
no evidence of associated
staphylococci is high, in high-risk patients or in patients with contra- IIb C
device infection, complete
indications to cephalosporins. They should always be started before hardware extraction may be
the procedure according to the drug pharmacokinetics. considered
In summary, CDRIE is one of the most difficult forms of IE to diag- C. Mode of device removal
nose and must be suspected in the presence of frequently mislead- 1. Percutaneous extraction is
382,
ing symptoms, particularly in elderly patients. Prognosis is poor, recommended in most patients
probably because of its frequent occurrence in elderly patients I B 391,
with CDRIE, even those with
405
with associated co-morbidities. In the majority of patients, CDRIE vegetations .10 mm
must be treated by prolonged antibiotic therapy and device re-
moval. Table 25 summarizes the main features concerning diag- Continued
nosis, treatment and prevention of CDRIE.
ESC Guidelines 3111
Table 25 Continued Estimation of the number of patients requiring ICU admission for
IE is challenging. In a retrospective, multicentre, observational study
of 4106 patients admitted to four medical ICUs, IE was identified in
Recommendations Classa Levelb Ref.c 0.8% of admissions.416 Reasons for admission to the ICU were con-
2. Surgical extraction should be gestive cardiac failure (64%), septic shock (21%), neurological de-
considered if percutaneous terioration (15%) and cardiopulmonary resuscitation (9%). 416
extraction is incomplete or
IIa C Critical care morbidity is high, with up to 79% of patients requiring
impossible or when there is
associated severe destructive mechanical ventilation, 73% inotropic support and 39% developing
tricuspid IE renal failure.
3. Surgical extraction may be
considered in patients with large IIb C 12.3.1 Organisms
Limited data are available regarding causative organisms for IE in the

vegetations (.20 mm)
D. Reimplantation ICU. Case series have revealed Staphylococci spp. to be the most
common causative agent, accounting for 74% of all nosocomial IE
1. After device extraction,
reassessment of the need for I C cases. Streptococci are the second most common causative organ-
reimplantation is recommended isms. Fungal IE is an increasing problem in the ICU, with Candida IE
2. When indicated, definite
occurring significantly more often in ICU than non-ICU hospitalized
reimplantation should be postponed patients.417 There should be a high index of suspicion for fungal IE in
IIa C
if possible, to allow a few days or the ICU setting, in particular where there is failure to respond to
weeks of antibiotic therapy empirical antimicrobial therapy.
3. A ‘temporary’ ipsilateral active
fixation strategy may be considered 12.3.2 Diagnosis
in pacemaker-dependent patients IIb C The diagnostic criteria for IE in the ICU are identical to those for the
requiring appropriate antibiotic
non-ICU patient population. However, clinical manifestations may be
treatment before reimplantation
atypical and the classic features may be masked by concomitant path-
4. Temporary pacing is not routinely ology and critical care interventions. Thus pyrexia may be attributed
III C
recommended
to co-existing hospital-acquired infections, neurological manifesta-
E. Prophylaxis tions masked by the confounding factors of sedation, ICU-related de-
1. Routine antibiotic prophylaxis is 367, lirium, concomitant multiple pathologies and acute kidney injury
recommended before device I B 368, ascribed to co-existing pathologies. Echocardiography can be chal-
implantation 373
lenging in the intensive care setting, with a reduced sensitivity of
2. Potential sources of sepsis should be TTE for the diagnosis of IE. There should be a relatively low thresh-
eliminated ≥2 weeks before
old for TOE in critically ill patients with S. aureus catheter-related
implantation of an intravascular/ IIa C
cardiac foreign material, except in bloodstream infection because of its high propensity to cause IE,
urgent procedures and also, if negative, this may allow short antibiotic treatment.
CDRIE ¼ cardiac device-related infective endocarditis; CIED ¼ cardiac

12.3.3 Management
implantable electronic device; FDG ¼ fluorodeoxyglucose; IE ¼ infective Patients with severe sepsis or septic shock should be managed ac-
endocarditis; NVE ¼ native valve endocarditis; PET ¼ positron emission cording to protocolised international guidelines.418 Antimicrobial
tomography; PVE ¼ prosthetic valve endocarditis; TOE ¼ transoesophageal
echocardiography; TTE ¼ transthoracic echocardiography.
management and indications for surgery in patients with IE are de-
a
Class of recommendation. scribed in sections 7 and 10, respectively. However, emergency/sal-
b
Level of evidence. vage status accounts for the highest mortality rates in registry data
c
for patients operated on for IE,299 and patients with SOFA scores
.15 on the day of surgery have extremely poor outcomes.125 De-
cision making in this most critically ill patient population where indi-
12.3 Infective endocarditis in the intensive cations and contraindications for cardiac surgery co-exist is
care unit challenging and should be undertaken in the context of the multi-
Admission to the intensive care unit (ICU) is frequently a part of the professional, multidisciplinary Endocarditis Team environment.
normal patient pathway following surgery for IE. In addition, patients
with IE may be admitted to the ICU due to haemodynamic instability 12.4 Right-sided infective endocarditis
related to severe sepsis, overt HF and/or severe valvular pathology or Right-sided IE accounts for 5–10% of IE cases.419,420 Although it may
organ failure from IE-related complications.411,412 The incidence of occur in patients with a pacemaker, ICD, central venous catheter or
nosocomial infection is increasing and patients may develop IE as a re- CHD, this situation is most frequently observed in IVDAs, especially
sult of healthcare-associated infection acquired during hospital or in- in patients with concomitant human immunodeficiency virus (HIV)
tensive care admission. Finally, the diagnosis of IE can be challenging, seropositivity or in immunosuppressed patients.420 – 422 S. aureus is
being made only post-mortem in a number of patients.413 Despite ad- the predominant organism (60–90% of cases),419,423 with methicil-
vances in diagnosis and treatment, mortality remains particularly high lin-resistant strains becoming more prevalent.414 The frequency of
in critically ill patients, ranging from 29% to 84%.411,414,415 polymicrobial infections is also rising.424 The tricuspid valve is most
3112 ESC Guidelines
frequently affected, but other valves—including left-sided—may also † Absence of cardiac and extracardiac complications,
become infected.425 In-hospital mortality is approximately 7%.426 – 429 † Absence of associated prosthetic valve or left-sided valve
infection,
12.4.1 Diagnosis and complications † ,20 mm vegetation, and
The usual manifestations of right-sided IE are persistent fever, bacter- † Absence of severe immunosuppression (,200 CD4 cells/mL)
aemia and multiple septic pulmonary emboli, which may manifest as with or without acquired immune deficiency syndrome (AIDS).
chest pain, cough or haemoptysis. When systemic emboli occur,
Because of limited bactericidal activity, poor penetration into vege-
paradoxical embolism or associated left-sided IE should be consid-
tations and increased drug clearance in IVDAs, glycopeptides
ered. Isolated right HF is rare, but can be caused by pulmonary hyper-
(vancomycin) should not be used in a 2-week treatment. The stand-
tension or severe right-sided valvular regurgitation or obstruction.425
ard 4–6-week regimen must be used in the following situations:
Pulmonary hypertension can be secondary to left-sided IE.
† Slow clinical or microbiological response (. 96 h) to antibiotic

TTE usually allows assessment of tricuspid involvement because
of the anterior location of this valve and usual large vegeta- therapy;426
tions.430,431 Eustachian and pulmonary valves should always be as- † Right-sided IE complicated by right HF, vegetations .20 mm,
sessed. TOE is more sensitive in the detection of pulmonary acute respiratory failure, septic metastatic foci outside the lungs
vegetations432 and associated left-sided involvement. (including empyema) or extracardiac complications, e.g. acute re-
nal failure;426
12.4.2 Prognosis and treatment † Therapy with antibiotics other than penicillinase-resistant
Vegetation length .20 mm and fungal aetiology were the main pre- penicillins;437
dictors of death in a large retrospective cohort of right-sided IE in † IVDA with severe immunosuppression (CD4 count ,200 cells/
IVDAs.433 In HIV-infected patients, a CD4 count ,200 cells/mL mL) with or without AIDS;438 or
has a high prognostic value.420,421 † Associated left-sided IE.
Alternatively, when conventional i.v. route therapy is not possible,
12.4.2.1 Antimicrobial therapy
right-sided S. aureus IE in IVDAs may also be treated with oral cipro-
The choice of empiric antimicrobial therapy depends on the sus-
floxacin [750 mg bis in die (b.i.d.)] plus rifampicin (300 mg b.i.d.) pro-
pected microorganism, type of drug and solvent used by the addict
vided that the strain is fully susceptible to both drugs, the case is
and the infection location.424 In any case, S. aureus must always be
uncomplicated and patient adherence is monitored carefully.439
covered. Initial treatment includes penicillinase-resistant penicillins,
One randomized controlled study has demonstrated the non-
vancomycin or daptomycin, depending on the local prevalence of
inferiority of daptomycin compared with standard therapy in the
MRSA,424 in combination with gentamicin. If the patient is a pentazo-
treatment of S. aureus infections, including right-sided IE.168 When
cine addict, an antipseudomonas agent should be added.434 If an
using daptomycin, most authors recommend using high doses
IVDA uses brown heroin dissolved in lemon juice, Candida spp.
(10 mg/kg/24 h) and combining it with cloxacillin or fosfomycin to
(not Candida albicans) should be considered and antifungal treat-
avoid the development of resistance to this drug.174 Glycopeptides
ment added.435 Once the causative organisms have been isolated,
(e.g. vancomycin) or daptomycin are the agents of choice for MRSA
therapy has to be adjusted.
infections. Vancomycin may have a lower efficacy in infections
Consistent data show that 2-week treatment may be sufficient
caused by MRSA strains with a vancomycin MIC .1 mg/
and that the addition of an aminoglycoside may be unnecessary.436
mL.171,172,440 In these cases, daptomycin would be the drug of
Two-week treatment with oxacillin (or cloxacillin) without gentami-
choice. For organisms other than S. aureus, therapy in IVDAs does
cin is effective for most patients with isolated tricuspid IE if all the
not differ from that in non-IVDAs.
following criteria are fulfilled:
† MSSA, 12.4.2.2 Surgery
† Good response to treatment, Given the high recurrence rate of IE due to continued drug
† Absence of metastatic sites of infection or empyema, abuse, surgery should generally be avoided in IVDAs with right-
Table 26 Indications for surgical treatment of right-sided infective endocarditis
Recommendation Classa Levelb

Surgical treatment should be considered in the following scenarios:
† Microorganisms difficult to eradicate (e.g. persistent fungi) or bacteraemia for . 7 days (e.g. S. aureus, P. aeruginosa) despite adequate
antimicrobial therapy or IIa C
† Persistent tricuspid valve vegetations . 20 mm after recurrent pulmonary emboli with or without concomitant right heart failure or
† Right HF secondary to severe tricuspid regurgitation with poor response to diuretic therapy
HF ¼ heart failure.
a
b
Level of evidence.
ESC Guidelines 3113
sided native IE, but it has to be considered in the following situations As in other groups, the diagnosis of IE is often made too late, high-
(Table 26): lighting the need to consider the diagnosis of IE in any patient with
CHD presenting with ongoing fever or other signs of ongoing infec-
† Right HF secondary to severe tricuspid regurgitation with poor
tion. Blood cultures should be taken before starting antibiotic treat-
response to diuretic therapy;
ment. The principal symptoms, complications and basis for diagnosis
† IE caused by organisms that are difficult to eradicate (e.g. persist-
do not differ from IE in general. However, right-sided IE is more fre-
ent fungi) or bacteraemia for at least 7 days (e.g. S. aureus, Pseudo-
quent in CHD than in acquired cardiac disease. The superiority of
monas aeruginosa) despite adequate antimicrobial therapy;441 and
TOE over TTE has not been systematically studied in this setting.
† Tricuspid valve vegetations .20 mm that persist after recurrent
Nevertheless, complex anatomy and the presence of artificial mater-
pulmonary emboli with or without concomitant right HF.426,433
ial may reduce the rate of detection of vegetations and other features
Cardiac surgery in HIV-infected IVDAs with IE does not worsen the of IE, thus favouring the addition of TOE, particularly in the adult
prognosis of either the IE or the HIV. group.443 However, a negative study does not exclude the diagnosis.

Recent nationwide data have shown that the three most frequent Care of CHD patients with IE, from diagnosis to treatment, is best
surgical strategies for tricuspid valve IE are valvectomy, valve repair provided by specialized CHD centres with expertise in imaging, sur-
and valve replacement.429 Tricuspid valve replacement accounted gery and intensive care. Cardiac surgery is appropriate when med-
for the majority of cases, with most receiving a bioprosthetic valve. ical therapy fails, when serious haemodynamic complications arise
Some authors prefer valve repair (avoiding artificial material when- and when there is a high risk of devastating septic embolism.
ever possible) over valve replacement, but the former did not im- IE in CHD carries a mortality rate of 4–10%.443,451,452,454 This bet-
prove outcomes over valve replacement or valvectomy. 429 ter prognosis compared with acquired heart disease may reflect the
Valvectomy without prosthetic replacement can be done in ex- higher proportion of right-heart IE or the better care in CHD centres.
treme cases, but may be associated with severe postoperative right Primary prevention is vital.455 The importance of good oral,
HF, particularly in patients with pulmonary hypertension. In these dental and skin hygiene has already been emphasized, and antibiotic
cases, the valve can be subsequently replaced once infection has prophylaxis is indicated in high-risk groups as defined in
been cured and drug use discontinued. Pulmonary valve replace- section 3. However, there is also an educational problem, especially
ment should be avoided, but if judged necessary, use of a pulmonary in patients not followed in specialist CHD centres, and awareness of
homograft (or, if unavailable, a xenograft valve) is preferred. the risk of IE and the need for preventive measures are not satisfac-
In summary, right-sided IE is primarily a disease that affects IVDAs torily highlighted in the population with CHD.456 Cosmetic tattoo-
and patients with CHD. Diagnostic features include respiratory ing and piercing, at least involving the tongue and mucous
symptoms and fever. S. aureus is responsible for most cases. membranes, should be discouraged in this group.
TTE is of major value in these patients. Despite relatively low in- Surgical repair of CHD often reduces the risk of IE, provided
hospital mortality, right-sided IE has a high risk of recurrence in
there is no residual lesion.447,457 However, in other cases when arti-
IVDAs and surgery is recommended only for intractable symp-
toms, failure of medical therapy, recurrent septic emboli to the ficial valve substitutes are implanted, the procedure may increase
lungs or paradoxical emboli. the overall risk of IE. There are no scientific data justifying cardiac
surgery or percutaneous interventions (e.g. closure of a patent duc-
12.5 Infective endocarditis in congenital tus arteriosus) with the sole purpose of eliminating the risk of IE.458
heart disease Cardiac repair as a secondary preventive measure to reduce the risk
The population of children and adults with CHD is expanding, and of recurrent IE has been described but not systematically studied.
this is the major substrate for IE in younger patients. However, our In summary, IE in CHD is rare and more frequently affects the right
knowledge of IE in this setting is limited since systematic studies are heart. Care of CHD patients with IE, from diagnosis to treatment, is
few and often retrospective and selection bias associated with stud- best provided by specialist CHD centres with expertise in imaging,
ies from highly specialized centres hampers universal application. surgery and intensive care. This applies to most patients with CHD.
Complex anatomy makes echocardiographic assessment difficult.
The reported incidence of IE in CHD is 15 –140 times higher than
However, the diagnosis should be considered in all CHD patients
that in the general population (the highest estimate originating from with ongoing infection or fever. Prognosis is better than in other forms
a highly specialized unit).442,443 The incidence is lower in children of IE, with a mortality rate of <10%. Preventive measures and patient
(0.04% per year) than in adults with CHD (0.1% per year).444,445 education are of particular importance in this population.
The reported proportion of CHD in patients with IE varies (prob-
ably due to selection bias) by between 2% and 60%,446 – 450 with a
consistent minor male dominance.443,451,452 12.6 Infective endocarditis during
Some simple lesions, such as secundum atrial septal defect and pregnancy
pulmonary valve disease, carry a low risk of IE, while others, such A challenge for the physician during pregnancy in the cardiac patient is
as bicuspid aortic valve, carry higher risk. However, CHD often con- the changing cardiovascular physiology, which can mimic cardiac dis-
sists of multiple cardiac lesions, each contributing to the total risk of ease and confuse the clinical picture.459,460 The incidence of IE during
IE. For example, the incidence of IE is considerably higher in patients pregnancy has been reported to be 0.006%.196 The incidence of IE in
with a ventricular septal defect when there is associated aortic patients with cardiac disease is 0–1.2% and is higher in women with a
regurgitation.453 mechanical prosthetic valve.461 – 464 Therefore IE in pregnancy is ex-
The distribution of causative organisms does not differ from the tremely rare and is either a complication of a pre-existing cardiac lesion
pattern found in acquired heart disease, with streptococci and or the result of i.v. drug abuse. Maternal mortality approaches 33%,
staphylococci being the most common strains.443,451,452 with most deaths relating to HF or an embolic event, while foetal
3114 ESC Guidelines
anticoagulants during IE development may diminish early embolic

Table 27 Recommendations for the use of tendencies.467
antithrombotic therapy The recommendations for management of anticoagulant therapy in
IE patients are based on a low level of evidence, and decisions should
Recommendations Classa Levelb Ref.c be made on an individual basis by the Endocarditis Team. The role of
bridging therapy with unfractionated or low molecular weight heparin
Interruption of antiplatelet therapy is
recommended in the presence of major I B 257
has not been studied in patients with IE, but may have reasonable ad-
bleeding vantages in special situations (i.e. in unstable patients) before surgical
In intracranial haemorrhage, interruption
decisions are made or to avoid drug interactions.
I C Evidence does not support initiation of antiplatelet therapy in pa-
of all anticoagulation is recommended
tients diagnosed with IE,258 despite promising results in experimen-
In ischaemic stroke without haemorrhage,
tal studies.468 Some cohort studies indicate a possible reduction in

replacement of oral anticoagulant
(anti-vitamin K) therapy by unfractionated the rate of embolic complications257 or IE development in sub-
IIa C
or low molecular weight heparin for 1 –2 groups of patients already on antiplatelet therapy,469 but the data
weeks should be considered under close are contradictory.470,471
monitoringd
In patients with intracranial haemorrhage
and a mechanical valve, unfractionated or 12.8 Non-bacterial thrombotic
low molecular weight heparin should be IIa C
reinitiated as soon as possible following
endocarditis and endocarditis associated
multidisciplinary discussion with cancers
In the absence of stroke, replacement of 12.8.1 Non-bacterial thrombotic endocarditis
oral anticoagulant therapy by Non-bacterial thrombotic endocarditis (NBTE) (i.e. marantic endo-
unfractionated or low molecular weight carditis, Libman – Sacks endocarditis or verrucous endocarditis) is
IIa C
heparin for 1– 2 weeks should be characterized by the presence of sterile vegetations consisting of fi-
considered in the case of Staphylococcus
brin and platelet aggregates on cardiac valves. These vegetations are
aureus IE under close monitoring
associated with neither bacteraemia nor with destructive changes of
Thrombolytic therapy is not
III C the underlying valve.472 It is also quite relevant to differentiate true
recommended in patients with IE
NBTE versus patients with negative blood cultures due to previous
antibiotic therapy.473
IE ¼ infective endocarditis.
a
NBTE is a condition associated with numerous diseases such as
b
Level of evidence. cancer, connective tissue disorders (i.e. systemic lupus erythemato-
c
Reference(s) supporting recommendations. sus patients possessing antiphospholipid antibodies, called Libman –
d
There is very limited experience with new oral anticoagulant treatment in the
field of IE.
Sacks endocarditis), autoimmune disorders, hypercoagulable states,
septicaemia, severe burns or chronic diseases such as tuberculosis,
uraemia or AIDS. It is a potentially life-threatening source of
thromboembolism, its main clinical manifestation.
mortality is reported to be about 29%.196 Close attention should be
It is essential to differentiate NBTE from IE. The same initial diag-
paid to any pregnant woman with unexplained fever and a cardiac
nostic workup used for IE is recommended. The diagnosis of NBTE
murmur.
is difficult and relies on strong clinical suspicion in the context of a
Rapid detection of IE and appropriate treatment is important in redu-
disease process known to be associated with NBTE, the presence of
cing the risk of both maternal and foetal mortality.196 Despite the high
a heart murmur, the presence of vegetations not responding to anti-
foetal mortality, urgent surgery should be performed during pregnancy
biotic treatment and evidence of multiple systemic emboli.474
in women who present with HF due to acute regurgitation.
The presence of a new murmur or a change in a pre-existing mur-
mur, although infrequent, in the setting of a predisposing disease
should alert the clinician to consider NBTE.
12.7 Antithrombotic therapy in infective Valvular vegetations in NBTE are usually small, broad based and
endocarditis irregularly shaped. They have little inflammatory reaction at the site
Indications for anticoagulant and antiplatelet therapy are the same in of attachment, which make them more friable and detachable. Fol-
IE patients as in other patients, and evidence does not support the lowing embolization, small remnants on affected valves (≤3 mm)
initiation of medications interfering with the coagulation system as may result in false-negative echocardiography results. TOE should
adjunctive therapy for IE.258 Thrombolytic therapy is generally con- be ordered when there is a high suspicion of NTBE. Left-sided (mi-
traindicated and has sometimes resulted in severe intracranial haem- tral more than aortic) and bilateral vegetations are more consistent
orrhage,465 but thrombectomy could be an alternative in selected with NTBE than with IE.475 When an early TOE examination is per-
patients with ischaemic stroke related to IE (see section 9.1). formed, the prognosis of NTBE is improved.476
The risk of intracranial haemorrhage may be increased in patients Comprehensive haematological and coagulation studies should be
already on oral anticoagulants when IE is diagnosed, especially in pa- performed to search for a potential cause. Multiple blood cultures
tients with S. aureus PVE.113,466 On the other hand, ongoing oral should be undertaken to rule out IE, although negative blood cultures
ESC Guidelines 3115
can be observed in IE (i.e. previous antibiotic therapy, HACEK group, 13. To do and not to do messages
fungi, etc.). Immunological assays for antiphospholipid syndrome (i.e.
lupus anticoagulant, anticardiolipin antibodies, and anti-b2- from the guidelines
glycoprotein 1 antibodies; at least one must be positive for the diag-
nosis of antiphospholipid syndrome on at least two occasions 12
weeks apart) should be undertaken in patients presenting with recur-
rent systemic emboli or known systemic lupus erythematous.477 Recommendations Classa Levelb
NTBE is first managed by treating the underlying pathology. 1. Prophylaxis/prevention
If there is no contraindication, these patients should be anti- Antibiotic prophylaxis should be considered for
coagulated with unfractioned or low molecular weight heparin or patients at highest risk for IE:
warfarin, although there is little evidence to support this strategy. a. Patients with any prosthetic valve, including
transcatheter valve, or those in whom any

In NTBE, the use of direct thrombin or factor Xa inhibitors has
prosthetic material was used for cardiac
not been evaluated. In antiphospholipid syndrome, lifelong anticoa- valve repair IIa C
gulation is indicated. A trial comparing rivaroxaban (a factor Xa in- b. Patients with a previous episode of IE
hibitor) and warfarin in patients with thrombotic antiphospholipid c. Patients with congenital heart disease
syndrome is currently in progress.478 However, anticoagulation is (i.e. any type of cyanotic congenital heart
disease or any type of congenital heart
associated with a risk of haemorrhagic conversion of embolic
disease repaired with a prosthetic material)
events. CT of the brain should be performed in patients with
Antibiotic prophylaxis is not recommended in
NBTE and cerebral attack before anticoagulation to rule out intra- III C
other forms of valvular or congenital heart disease
cranial haemorrhage.
Surgical intervention, valve debridement and/or reconstruction Dental procedures
are often not recommended unless the patient presents with recur- Antibiotic prophylaxis should only be considered
rent thromboembolism despite well-controlled anticoagulation. for dental procedures requiring manipulation of
IIa C
the gingival or periapical region of the teeth or
Other indications for valve surgery are the same as for IE. In the perforation of the oral mucosa
context of cancer, a multidisciplinary approach is recommended
Antibiotic prophylaxis is not recommended for
(Endocarditis Team).
local anaesthetic injections in non-infected tissues,
treatment of superficial caries, removal of sutures,
12.8.2 Infective endocarditis associated with cancer dental X-rays, placement or adjustment of
IE may be a potential marker of occult cancers. In a large, Danish, III C
removable prosthodontic or orthodontic
nationwide, population-based cohort study, 997 cancers were iden- appliances or braces, or following the shedding of
tified among 8445 IE patients with a median follow-up of 3.5 years. deciduous teeth or trauma to the lips and oral
mucosa
The risk of abdominal and haematological cancers was high soon
after IE diagnosis (within the first 3 months) and remained higher Other procedures
than expected in the long-term follow-up (.12 months) for ab- Antibiotic prophylaxis is not recommended for
dominal cancer.479 respiratory tract procedures, including
Several bacteria have been reported in association with colonic bronchoscopy or laryngoscopy, transnasal or
III C
endotracheal intubation, gastroscopy,
cancer, with the strongest and best-documented relationship with colonoscopy, cystoscopy, vaginal or caesarean
S. bovis infection, specifically the S. gallolyticus subspecies; S. bovis in- delivery, TOE or skin and soft tissue procedures
fection has been related to the presence of gastrointestinal neopla-
2. Recommendations for referring patients to the
sia, which in most cases is colonic adenoma or carcinoma.480 Reference Centre
However, it is still a source of debate whether the association of
Patients with complicated IE should be evaluated
S. bovis/S. gallolyticus IE with colorectal tumours is merely a conse- and managed at an early stage in a reference
quence of the gastrointestinal lesion or could trigger or promote centre with immediate surgical facilities and the
colorectal cancer.481 presence of a multidisciplinary Endocarditis Team, IIa B
In the setting of S. bovis IE, there is a need for proper microbiologic- including an ID specialist, a microbiologist, a
cardiologist, imaging specialists, a cardiac surgeon
al classification. In case of S. bovis/S. gallolyticus IE, it is recommended to
and, if needed, a specialist in CHD
rule out occult colon cancer during hospitalization. In the absence of
For patients with non-complicated IE managed in
any tumour, scheduling an annual colonoscopy is highly suggested.482
a non-reference centre, there should be early and
As for other tests (i.e. faecal occult blood), the serology-based regular communication with the reference centre IIa B
detection of colorectal cancer—serum IgG concentrations against and, when needed, visits to the reference centre,
S. bovis antigens—is neither sensitive (not all colorectal tumours should be made
are colonized by S. bovis) nor specific.483 3. Diagnosis
FDG PET/CT is increasingly used in the diagnostic workup of IE. It
TTE is recommended as the first-line imaging
may play an interesting role in detecting gastrointestinal pathological I B
modality in suspected IE
activity and guide colonoscopy. However, negative PET/CT does
TOE is recommended in all patients with clinical
not rule out significant colonic pathology. No study has examined suspicion of IE and a negative or non-diagnostic I B
its clinical value for the detection of occult colorectal cancer in pa- TTE
tients with S. bovis/S. gallolyticus IE.
3116 ESC Guidelines
Recommendations Classa Levelb Recommendations Classa Levelb

TOE is recommended in patients with clinical 7. Recommendations for the use of antithrombotic
suspicion of IE when a prosthetic heart valve or an I B therapy
intracardiac device is present
Interruption of antiplatelet therapy is
I B
Repeat TTE and/or TOE within 5–7 days is recommended in the presence of major bleeding
recommended in case of initially negative
I C In intracranial haemorrhage, interruption of all
examination when clinical suspicion of IE remains I C
anticoagulation is recommended
high
Thrombolytic therapy is not recommended in
Repeat TTE and/or TOE are recommended as III C
patients with IE

soon as a new complication of IE is suspected
I B
(new murmur, embolism, persisting fever, HF,
abscess, atrioventricular block)
Intra-operative echocardiography is
I B
recommended in all cases of IE requiring surgery
4. Treatment
14. Appendix
Aortic or mitral NVE or PVE with severe
regurgitation or obstruction causing symptoms of ESC Committee for Practice Guidelines (CPG): Jose Luis Za-
HF or echocardiographic signs of poor I B morano (Chairperson) (Spain), Victor Aboyans (France), Stephan
haemodynamic tolerance must by treated by
Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon
urgent surgery
(Spain), Gonzalo Barón-Esquivias (Spain), Helmut Baumgartner
Locally uncontrolled infection (abscess, false (Germany), Jeroen J. Bax (The Netherlands), Héctor Bueno (Spain),
aneurysm, fistula, enlarging vegetation) must by I B
treated by urgent surgery
Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey),
Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Paulus
Infection caused by fungi or multiresistant
I C Kirchhof (UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellotti
organisms must by treated by urgent surgery
(Belgium), Gregory Y.H. Lip (UK), Petros Nihoyannopoulos (UK),
Aortic or mitral NVE or PVE with persistent
Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marco Roffi
vegetations .10 mm after ≥1 embolic episodes
I B (Switzerland), Adam Torbicki (Poland), Antonio Vaz Carneiro (Por-
despite appropriate antibiotic therapy must by
treated by urgent surgery tugal), Stephan Windecker (Switzerland).
5. Neurological complications ESC National Cardiac Societies actively involved in the re-
view process of the 2015 ESC Guidelines on the management of in-
After a silent embolism or transient ischaemic
attack, cardiac surgery, if indicated, is I B
fective endocarditis:
recommended without delay Austria: Austrian Society of Cardiology, Bernhard Metzler;
Azerbaijan: Azerbaijan Society of Cardiology, Tofig Jahangirov;
Neurosurgery or endovascular therapy are
indicated for very large, enlarging or ruptured I C Belarus: Belarusian Scientific Society of Cardiologists, Svetlana
intracranial infectious aneurysms Sudzhaeva; Belgium: Belgian Society of Cardiology, Jean-Louis Va-
Following intracranial haemorrhage, surgery noverschelde; Bosnia & Herzegovina: Association of Cardiolo-
IIa B
should generally be postponed for ≥1 month gists of Bosnia & Herzegovina, Amra Macić-Džanković; Bulgaria:
6. Cardiac device-related infective endocarditis Bulgarian Society of Cardiology, Temenuga Donova; Croatia: Cro-
atian Cardiac Society, Boško Skorić; Cyprus: Cyprus Society of
Prolonged (i.e. before and after extraction)
antibiotic therapy and complete hardware (device
Cardiology, Georgios C. Georgiou; Czech Republic: Czech Soci-
and leads) removal are recommended in definite I C ety of Cardiology, Katerina Linhartova; Denmark: Danish Society
CDRIE, as well as in presumably isolated pocket of Cardiology, Niels Eske Bruun; Egypt: Egyptian Society of Cardi-
infection ology, Hussein Rizk; Estonia: Estonian Society of Cardiology, Sirje
Percutaneous extraction is recommended in most Kõvask; Finland: Finnish Cardiac Society, Anu Turpeinen, Former
patients with CDRIE, even those with vegetations I B Yugoslav Republic of Macedonia: Macedonian Society of Cardi-
.10 mm ology, Silvana Jovanova; France: French Society of Cardiology,
After device extraction, reassessment of the need François Delahaye; Georgia: Georgian Society of Cardiology, Shal-
I C
for reimplantation is recommended va Petriashvili; Germany: German Cardiac Society, Christoph
Temporary pacing is not routinely recommended III C K. Naber; Greece: Hellenic Cardiological Society, Georgios Haha-
Routine antibiotic prophylaxis is recommended lis; Hungary: Hungarian Society of Cardiology, Albert Varga; Ice-
I B
before device implantation land: Icelandic Society of Cardiology, Thórdı́s J. Hrafnkelsdóttir;
Israel: Israel Heart Society, Yaron Shapira; Italy: Italian Federation
ESC Guidelines 3117
of Cardiology, Enrico Cecchi; Kyrgyzstan: Kyrgyz Society of Car- Cardiology, Filipp Paleev; Serbia: Cardiology Society of Serbia, Bilja-
diology, Alina Kerimkulova; Latvia: Latvian Society of Cardiology, na Obrenovic-Kircanski; Slovakia: Slovak Society of Cardiology, Va-
Ginta Kamzola; Lithuania: Lithuanian Society of Cardiology, Regina sil Hricák; Spain: Spanish Society of Cardiology, Alberto San Roman,
Jonkaitiene; Luxembourg: Luxembourg Society of Cardiology, Sweden: Swedish Society of Cardiology, Ulf Thilén; Switzerland:
Kerstin Wagner; Malta: Maltese Cardiac Society, Daniela Cassar De- Swiss Society of Cardiology, Beat Kaufmann; The Netherlands:
marco; Morocco: Moroccan Society of Cardiology, Jamila Zarzur; Netherlands Society of Cardiology, Berto J. Bouma; Tunisia: Tunis-
Norway: Norwegian Society of Cardiology, Svend Aakhus; Poland: ian Society of Cardiology and Cardio-Vascular Surgery, Hedi Baccar;
Polish Cardiac Society, Janina Stepinska; Portugal: Portuguese Turkey: Turkish Society of Cardiology, Necla Ozer; United King-
Society of Cardiology, Cristina Gavina; Romania: Romanian Society dom: British Cardiovascular Society, Chris P. Gale; Ukraine: Ukrain-
of Cardiology, Dragos Vinereanu; Russia: Russian Society of ian Association of Cardiology, Elena Nesukay.

The CME text ‘2015 ESC Guidelines for the Management of Infective Endocarditis is accredited by the European Board for Accreditation in Cardiology (EBAC). EBAC works according
to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists
(UEMS). In compliance with EBAC/EACCME Guidelines, all authors participating in this programme have disclosed any potential conflicts of interest that might cause a bias in the
article. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the programme are declared to the participants prior to the CME
activities.
CME questions for this article are available at: European Heart Journal http://www.oxforde-learning.com/eurheartj and European Society of Cardiology http://www.escardio.org/
guidelines
15. References Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009;30:
1. Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endo- 2369 – 2413.
carditis: challenges and perspectives. Lancet 2012;379:965 – 975. 9. Kang DH, Kim YJ, Kim SH, Sun BJ, Kim DH, Yun SC, Song JM, Choo SJ, Chung CH,
2. Habib G. Management of infective endocarditis. Heart 2006;92:124 –130. Song JK, Lee JW, Sohn DW. Early surgery versus conventional treatment for infect-
3. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, Soler-Soler J, ive endocarditis. N Engl J Med 2012;366:2466 –2473.
Thiene G, von Graevenitz A, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, 10. Bruun NE, Habib G, Thuny F, Sogaard P. Cardiac imaging in infectious endocardi-
Dean V, Deckers J, Fernandez BE, Lekakis J, Lindahl B, Mazzotta G, Morais J, tis. Eur Heart J 2014;35:624 – 632.
Oto A, Smiseth OA, Lekakis J, Vahanian A, Delahaye F, Parkhomenko A, 11. Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, Donal E,
Filipatos G, Aldershvile J, Vardas P. Guidelines on prevention, diagnosis and treat- Prendergast B, Magne J, La Canna G, Pierard LA, Maurer G. ESC Working Group
ment of infective endocarditis executive summary: the Task Force on Infective on Valvular Heart Disease position paper—heart valve clinics: organization, struc-
Endocarditis of the European Society of Cardiology. Eur Heart J 2004;25: ture, and experiences. Eur Heart J 2013;34:1597 –1606.
267 –276. 12. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, Riberi A,
4. Naber CK, Erbel R, Baddour LM, Horstkotte D. New guidelines for infective Habib G, Raoult D. Dramatic reduction in infective endocarditis-related mortality
endocarditis: a call for collaborative research. Int J Antimicrob Agents 2007;29: with a management-based approach. Arch Intern Med 2009;169:1290 –1298.
615 –616. 13. Duval X, Leport C. Prophylaxis of infective endocarditis: current tendencies, con-
5. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, tinuing controversies. Lancet Infect Dis 2008;8:225 –232.
Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, 14. Danchin N, Duval X, Leport C. Prophylaxis of infective endocarditis: French re-
Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, commendations 2002. Heart 2005;91:715 –718.
Gardner T, Goff D, Durack DT. Prevention of infective endocarditis: guidelines 15. Lockhart PB, Brennan MT, Sasser HC, Fox PC, Paster BJ, Bahrani-Mougeot FK.
from the American Heart Association: a guideline from the American Heart Asso- Bacteremia associated with toothbrushing and dental extraction. Circulation
ciation Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council 2008;117:3118 –3125.
on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, 16. Veloso TR, Amiguet M, Rousson V, Giddey M, Vouillamoz J, Moreillon P,
Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Entenza JM. Induction of experimental endocarditis by continuous low-grade bac-
Outcomes Research Interdisciplinary Working Group. Circulation 2007;116: teremia mimicking spontaneous bacteremia in humans. Infect Immun 2011;79:
1736– 1754. 2006 –2011.
6. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, 17. Van der Meer JT, Van Wijk W, Thompson J, Vandenbroucke JP, Valkenburg HA,
Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Michel MF. Efficacy of antibiotic prophylaxis for prevention of native-valve endo-
Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, carditis. Lancet 1992;339:135–139.
Takahashi M, Taubert KA. Infective endocarditis: diagnosis, antimicrobial therapy, 18. Lacassin F, Hoen B, Leport C, Selton-Suty C, Delahaye F, Goulet V, Etienne J,
and management of complications: a statement for healthcare professionals from Briancon S. Procedures associated with infective endocarditis in adults. A case con-
the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council trol study. Eur Heart J 1995;16:1968 – 1974.
on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, 19. Strom BL, Abrutyn E, Berlin JA, Kinman JL, Feldman RS, Stolley PD, Levison ME,
Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Korzeniowski OM, Kaye D. Dental and cardiac risk factors for infective
endorsed by the Infectious Diseases Society of America. Circulation 2005;111: endocarditis. A population-based, case-control study. Ann Intern Med 1998;129:
e394 –e434. 761 –769.
7. Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, O’Gara PT, 20. Duval X, Alla F, Hoen B, Danielou F, Larrieu S, Delahaye F, Leport C, Briancon S.
O’Rourke RA, Shah PM. ACC/AHA 2008 guideline update on valvular heart dis- Estimated risk of endocarditis in adults with predisposing cardiac conditions
ease: focused update on infective endocarditis: a report of the American College undergoing dental procedures with or without antibiotic prophylaxis. Clin Infect
of Cardiology/American Heart Association Task Force on Practice Guidelines: en- Dis 2006;42:e102 –e107.
dorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovas- 21. Lee P, Shanson D. Results of a UK survey of fatal anaphylaxis after oral amoxicillin.
cular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation J Antimicrob Chemother 2007;60:1172 –1173.
2008;118:887 –896. 22. Glenny AM, Oliver R, Roberts GJ, Hooper L, Worthington HV. Antibiotics for the
8. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, Moreillon P, prophylaxis of bacterial endocarditis in dentistry. Cochrane Database Syst Rev 2013;
de Jesus AM, Thilen U, Lekakis J, Lengyel M, Muller L, Naber CK, 10:CD003813.
Nihoyannopoulos P, Moritz A, Zamorano JL. Guidelines on the prevention, diag- 23. Gould FK, Elliott TS, Foweraker J, Fulford M, Perry JD, Roberts GJ, Sandoe JA,
nosis, and treatment of infective endocarditis (new version 2009): the Task Watkin RW, Working Party of the British Society for Antimicrobial Chemother-
Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis apy. Guidelines for the prevention of endocarditis: report of the Working Party of
of the European Society of Cardiology (ESC). Endorsed by the European Society the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2006;
of Clinical Microbiology and Infectious Diseases (ESCMID) and the International 57:1035 –1042.
3118 ESC Guidelines
24. Daly CG, Currie BJ, Jeyasingham MS, Moulds RF, Smith JA, Strathmore NF, of cardiovascular diseases during pregnancy: the Task Force on the Management
Street AC, Goss AN. A change of heart: the new infective endocarditis prophy- of Cardiovascular Diseases during Pregnancy of the European Society of Cardi-
laxis guidelines. Aust Dent J 2008;53:196 –200. ology (ESC). Eur Heart J 2011;32:3147 –3197.
25. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, 44. Yu CH, Minnema BJ, Gold WL. Bacterial infections complicating tongue piercing.
O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD. 2014 AHA/ Can J Infect Dis Med Microbiol 2010;21:e70 –e74.
ACC guideline for the management of patients with valvular heart disease: execu- 45. de Oliveira JC, Martinelli M, Nishioka SA, Varejao T, Uipe D, Pedrosa AA, Costa R,
tive summary: a report of the American College of Cardiology/American Heart D’Avila A, Danik SB. Efficacy of antibiotic prophylaxis before the implantation of
Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63: pacemakers and cardioverter-defibrillators: results of a large, prospective, rando-
2438–2488. mized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;
26. Naber C, Al Nawas B, Baumgartner H, Becker H, Block M, Erbel R, Ertl G, 2:29– 34.
Fluckiger U, Franzen D, Gohlke-Barwolf C. Prophylaxe der infektiösen Endokar- 46. van Rijen MM, Bode LG, Baak DA, Kluytmans JA, Vos MC. Reduced costs for
ditis. Der Kardiologe 2007;1:243 –250. Staphylococcus aureus carriers treated prophylactically with mupirocin and chlor-
27. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infect- hexidine in cardiothoracic and orthopaedic surgery. PLoS One 2012;7:e43065.
ive endocarditis in adults and children undergoing interventional procedures 47. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM,
(CG64). National Institute for Health and Care Excellence (NICE). http Roosendaal R, Troelstra A, Box AT, Voss A, van der Tweel I, van Belkum A,

://www.nice.org.uk/guidance/CG64. Verbrugh HA, Vos MC. Preventing surgical-site infections in nasal carriers of
28. Mohindra RK. A case of insufficient evidence equipoise: the NICE guidance on Staphylococcus aureus. N Engl J Med 2010;362:9 –17.
antibiotic prophylaxis for the prevention of infective endocarditis. J Med Ethics 48. Recommendations on the management of oral dental foci of infection. French So-
2010;36:567 –570. ciety of Oral Surgery. http://www.societechirorale.com/documents/
29. Chambers JB, Shanson D, Hall R, Pepper J, Venn G, McGurk M. Antibiotic prophy- Recommandations/foyers_infectieux_argument-EN.pdf.
laxis of endocarditis: the rest of the world and NICE. J R Soc Med 2011;104: 49. Goldmann DA, Hopkins CC, Karchmer AW, Abel RM, McEnany MT, Akins C,
138 –140. Buckley MJ, Moellering RC Jr. Cephalothin prophylaxis in cardiac valve surgery.
30. Thornhill M, Dayer M, Forde J, Corey G, Chu V, Couper D, Lockhart P. Impact of A prospective, double-blind comparison of two-day and six-day regimens.
the NICE guideline recommending cessation of antibiotic prophylaxis for preven- J Thorac Cardiovasc Surg 1977;73:470 –479.
tion of infective endocarditis: before and after study. BMJ 2011;342:d2392. 50. Fernandez-Hidalgo N, Almirante B, Tornos P, Pigrau C, Sambola A, Igual A,
31. Dayer MJ, Chambers JB, Prendergast B, Sandoe JA, Thornhill MH. NICE guidance Pahissa A. Contemporary epidemiology and prognosis of health care-associated in-
on antibiotic prophylaxis to prevent infective endocarditis: a survey of clinicians’ fective endocarditis. Clin Infect Dis 2008;47:1287 –1297.
attitudes. QJM 2013;106:237 –243. 51. Selton-Suty C, Celard M, Le MV, Doco-Lecompte T, Chirouze C, Iung B, Strady C,
32. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Inci- Revest M, Vandenesch F, Bouvet A, Delahaye F, Alla F, Duval X, Hoen B. Pre-
dence of infective endocarditis in England, 2000 –13: a secular trend, interrupted eminence of Staphylococcus aureus in infective endocarditis: a 1-year population-
time-series analysis. Lancet 2015;385:1219 –1228.
based survey. Clin Infect Dis 2012;54:1230 – 1239.
33. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le MV, Doco-Lecompte T,
52. Benito N, Miro JM, de Lazzari E, Cabell CH, del Rio A, Altclas J, Commerford P,
Celard M, Poyart C, Strady C, Chirouze C, Bes M, Cambau E, Iung B,
Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS,
Selton-Suty C, Hoen B. Temporal trends in infective endocarditis in the context
Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr.
of prophylaxis guideline modifications: three successive population-based sur-
Health care-associated native valve endocarditis: importance of non-nosocomial
veys. J Am Coll Cardiol 2012;59:1968 –1976.
acquisition. Ann Intern Med 2009;150:586 –594.
34. Desimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR,
53. Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS,
Steckelberg JM, Wilson WR, Baddour LM. Incidence of infective endocarditis
Figueredo VM. Infective endocarditis epidemiology over five decades: a systematic
caused by viridans group streptococci before and after publication of the 2007
review. PLoS One 2013;8:e82665.
American Heart Association’s endocarditis prevention guidelines. Circulation
54. Tornos P, Iung B, Permanyer-Miralda G, Baron G, Delahaye F, Gohlke-Barwolf C,
2012;126:60 –64.
Butchart EG, Ravaud P, Vahanian A. Infective endocarditis in Europe: lessons from
35. Pasquali SK, He X, Mohamad Z, McCrindle BW, Newburger JW, Li JS, Shah SS.
the Euro heart survey. Heart 2005;91:571–575.
Trends in endocarditis hospitalizations at US children’s hospitals: impact of the
55. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H,
2007 American Heart Association Antibiotic Prophylaxis Guidelines. Am Heart J
Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P,
2012;163:894–899.
Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J,
36. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, Hirsch GA,
von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the man-
Mehta JL. Trends in infective endocarditis incidence, microbiology, and valve re-
agement of valvular heart disease (version 2012). Eur Heart J 2012;33:2451 – 2496.
placement in the United States from 2000 to 2011. J Am Coll Cardiol 2015;65:
2070–2076. 56. Chirillo F, Scotton P, Rocco F, Rigoli R, Borsatto F, Pedrocco A, De Leo A,
37. Lalani T, Chu VH, Park LP, Cecchi E, Corey GR, Durante-Mangoni E, Fowler VG Minniti G, Polesel E, Olivari Z. Impact of a multidisciplinary management strategy
Jr., Gordon D, Grossi P, Hannan M, Hoen B, Munoz P, Rizk H, Kanj SS, on the outcome of patients with native valve infective endocarditis. Am J Cardiol
Selton-Suty C, Sexton DJ, Spelman D, Ravasio V, Tripodi MF, Wang A. In-hospital 2013;112:1171 – 1176.
and 1-year mortality in patients undergoing early surgery for prosthetic valve 57. Thuny F, Giorgi R, Habachi R, Ansaldi S, Le Dolley Y, Casalta JP, Avierinos JF,
endocarditis. JAMA Intern Med 2013;173:1495 –1504. Riberi A, Renard S, Collart F, Raoult D, Habib G. Excess mortality and morbidity
38. Chu VH, Sexton DJ, Cabell CH, Reller LB, Pappas PA, Singh RK, Fowler VG Jr., in patients surviving infective endocarditis. Am Heart J 2012;164:94 –101.
Corey GR, Aksoy O, Woods CW. Repeat infective endocarditis: differentiating 58. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, Casalta JP,
relapse from reinfection. Clin Infect Dis 2005;41:406 –409. Gouvernet J, Derumeaux G, Iarussi D, Ambrosi P, Calabro R, Riberi A, Collart F,
39. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Metras D, Lepidi H, Raoult D, Harle JR, Weiller PJ, Cohen A, Habib G. Risk of em-
Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, bolism and death in infective endocarditis: prognostic value of echocardiography: a
Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, prospective multicenter study. Circulation 2005;112:69 –75.
Walma E. ESC Guidelines for the management of grown-up congenital heart dis- 59. Perez de Isla L, Zamorano J, Lennie V, Vazquez J, Ribera JM, Macaya C. Negative
ease (new version 2010). Eur Heart J 2010;31:2915 –2957. blood culture infective endocarditis in the elderly: long-term follow-up. Gerontology
40. Knirsch W, Nadal D. Infective endocarditis in congenital heart disease. Eur J Pediatr 2007;53:245–249.
2011;170:1111 – 1127. 60. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15.
41. Sherman-Weber S, Axelrod P, Suh B, Rubin S, Beltramo D, Manacchio J, 61. Yu CW, Juan LI, Hsu SC, Chen CK, Wu CW, Lee CC, Wu JY. Role of procalcitonin
Furukawa S, Weber T, Eisen H, Samuel R. Infective endocarditis following ortho- in the diagnosis of infective endocarditis: a meta-analysis. Am J Emerg Med 2013;31:
topic heart transplantation: 10 cases and a review of the literature. Transpl Infect 935 –941.
Dis 2004;6:165 –170. 62. Polewczyk A, Janion M, Podlaski R, Kutarski A. Clinical manifestations of lead-
42. Findler M, Chackartchi T, Regev E. Dental implants in patients at high risk for independent infective endocarditis: analysis of 414 cases. Eur J Clin Microbiol Infect
fective endocarditis: a preliminary study. Int J Oral Maxillofac Surg 2014;43: Dis 2014;33:1601 –1608.
1282 –1285. 63. Habib G, Avierinos JF, Thuny F. Aortic valve endocarditis: is there an optimal sur-
43. Regitz-Zagrosek V, Blomstrom LC, Borghi C, Cifkova R, Ferreira R, Foidart JM, gical timing? Curr Opin Cardiol 2007;22:77 –83.
Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, 64. Habib G, Badano L, Tribouilloy C, Vilacosta I, Zamorano JL, Galderisi M, Voigt JU,
Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Sicari R, Cosyns B, Fox K, Aakhus S. Recommendations for the practice of echocar-
Schaufelberger M, Seeland U, Torracca L. ESC Guidelines on the management diography in infective endocarditis. Eur J Echocardiogr 2010;11:202 –219.
ESC Guidelines 3119
65. Mugge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocar- 86. Okazaki S, Yoshioka D, Sakaguchi M, Sawa Y, Mochizuki H, Kitagawa K. Acute ische-
ditis: reassessment of prognostic implications of vegetation size determined by the mic brain lesions in infective endocarditis: incidence, related factors, and post-
transthoracic and the transesophageal approach. J Am Coll Cardiol 1989;14: operative outcome. Cerebrovasc Dis 2013;35:155 –162.
631 –638. 87. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR.
66. Rasmussen RV, Host U, Arpi M, Hassager C, Johansen HK, Korup E, Proposed modifications to the Duke criteria for the diagnosis of infective endocar-
Schonheyder HC, Berning J, Gill S, Rosenvinge FS, Fowler VG Jr, Moller JE, ditis. Clin Infect Dis 2000;30:633 –638.
Skov RL, Larsen CT, Hansen TF, Mard S, Smit J, Andersen PS, Bruun NE. Prevalence 88. Iung B, Tubiana S, Klein I, Messika-Zeitoun D, Brochet E, Lepage L, Al Attar N,
of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the va- Ruimy R, Leport C, Wolff M, Duval X. Determinants of cerebral lesions in endo-
lue of screening with echocardiography. Eur J Echocardiogr 2011;12:414 –420. carditis on systematic cerebral magnetic resonance imaging: a prospective study.
67. Incani A, Hair C, Purnell P, O’Brien DP, Cheng AC, Appelbe A, Athan E. Staphylo- Stroke 2013;44:3056 –3062.
coccus aureus bacteraemia: evaluation of the role of transoesophageal echocardiog- 89. Goulenok T, Klein I, Mazighi M, Messika-Zeitoun D, Alexandra JF, Mourvillier B,
raphy in identifying clinically unsuspected endocarditis. Eur J Clin Microbiol Infect Dis Laissy JP, Leport C, Iung B, Duval X. Infective endocarditis with symptomatic cere-
2013;32:1003 –1008. bral complications: contribution of cerebral magnetic resonance imaging. Cerebro-
68. Daniel WG, Mugge A, Martin RP, Lindert O, Hausmann D, Nonnast-Daniel B, vasc Dis 2013;35:327 –336.
Laas J, Lichtlen PR. Improvement in the diagnosis of abscesses associated with 90. Hess A, Klein I, Iung B, Lavallee P, Ilic-Habensus E, Dornic Q, Arnoult F, Mimoun L,

endocarditis by transesophageal echocardiography. N Engl J Med 1991;324: Wolff M, Duval X, Laissy JP. Brain MRI findings in neurologically asymptomatic pa-
795 –800. tients with infective endocarditis. AJNR Am J Neuroradiol 2013;34:1579 – 1584.
69. Sochowski RA, Chan KL. Implication of negative results on a monoplane transeso- 91. Iung B, Klein I, Mourvillier B, Olivot JM, Detaint D, Longuet P, Ruimy R, Fourchy D,
phageal echocardiographic study in patients with suspected infective endocarditis. Laurichesse JJ, Laissy JP, Escoubet B, Duval X. Respective effects of early cerebral
J Am Coll Cardiol 1993;21:216 – 221. and abdominal magnetic resonance imaging on clinical decisions in infective endo-
70. Karalis D, Chandrasekaran K, Wahl J, Ross J, Mintz G. Transesophageal echocardio- carditis. Eur Heart J Cardiovasc Imaging 2012;13:703 –710.
graphic recognition of mitral valve abnormalities associated with aortic valve endo- 92. Palestro CJ, Brown ML, Forstrom LA, Greenspan BS, McAfee JG, Royal HD,
carditis. Am Heart J 1990;119:1209 –1211. Schauwecker DS, Seabold JE, Signore A. Society of Nuclear Medicine Procedure
71. Pedersen WR, Walker M, Olson JD, Gobel F, Lange HW, Daniel JA, Rogers J, Guideline for 99mTc-exametazime (HMPAO)-labeled leukocyte scintigraphy for
Longe T, Kane M, Mooney MR. Value of transesophageal echocardiography as an suspected infection/inflammation, version 3.0, 2004. HMPAO_v3 pdf 2004.
adjunct to transthoracic echocardiography in evaluation of native and prosthetic 93. Saby L, Laas O, Habib G, Cammilleri S, Mancini J, Tessonnier L, Casalta JP,
valve endocarditis. Chest 1991;100:351 –356. Gouriet F, Riberi A, Avierinos JF, Collart F, Mundler O, Raoult D, Thuny F. Positron
72. Vilacosta I, Graupner C, San Roman JA, Sarria C, Ronderos R, Fernandez C, emission tomography/computed tomography for diagnosis of prosthetic valve
Mancini L, Sanz O, Sanmartin JV, Stoermann W. Risk of embolization after institu- endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major
tion of antibiotic therapy for infective endocarditis. J Am Coll Cardiol 2002;39: criterion. J Am Coll Cardiol 2013;61:2374 –2382.
1489 –1495. 94. Erba PA, Conti U, Lazzeri E, Sollini M, Doria R, De Tommasi SM, Bandera F,
73. Shapira Y, Weisenberg DE, Vaturi M, Sharoni E, Raanani E, Sahar G, Vidne BA, Tascini C, Menichetti F, Dierckx RA, Signore A, Mariani G. Added value of
Battler A, Sagie A. The impact of intraoperative transesophageal echocardiography 99mTc-HMPAO-labeled leukocyte SPECT/CT in the characterization and manage-
in infective endocarditis. Isr Med Assoc J 2007;9:299 –302. ment of patients with infectious endocarditis. J Nucl Med 2012;53:1235 –1243.
74. Sanchez-Enrique C, Vilacosta I, Moreno HG, Delgado-Bolton R, Perez-Alonso P, 95. Rouzet F, Chequer R, Benali K, Lepage L, Ghodbane W, Duval X, Iung B,
Martinez A, Vivas D, Ferrera C, Olmos C. Infected marantic endocarditis with leu- Vahanian A, Le Guludec D, Hyafil F. Respective performance of 18F-FDG PET
kemoid reaction. Circ J 2014;78:2325 –2327. and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endo-
75. Eudailey K, Lewey J, Hahn RT, George I. Aggressive infective endocarditis and the carditis. J Nucl Med 2014;55:1980 –1985.
importance of early repeat echocardiographic imaging. J Thorac Cardiovasc Surg 96. La Scola B, Raoult D. Direct identification of bacteria in positive blood culture bot-
2014;147:e26–e28. tles by matrix-assisted laser desorption ionisation time-of-flight mass spectrom-
76. Berdejo J, Shibayama K, Harada K, Tanaka J, Mihara H, Gurudevan SV, Siegel RJ, etry. PLoS One 2009;4:e8041.
Shiota T. Evaluation of vegetation size and its relationship with embolism in infect- 97. Raoult D, Casalta JP, Richet H, Khan M, Bernit E, Rovery C, Branger S, Gouriet F,
ive endocarditis: a real-time 3-dimensional transesophageal echocardiography Imbert G, Bothello E, Collart F, Habib G. Contribution of systematic serological
study. Circ Cardiovasc Imaging 2014;7:149 – 154. testing in diagnosis of infective endocarditis. J Clin Microbiol 2005;43:5238 –5242.
77. Liu YW, Tsai WC, Lin CC, Hsu CH, Li WT, Lin LJ, Chen JH. Usefulness of real-time 98. Fournier PE, Thuny F, Richet H, Lepidi H, Casalta JP, Arzouni JP, Maurin M,
three-dimensional echocardiography for diagnosis of infective endocarditis. Scand Celard M, Mainardi JL, Caus T, Collart F, Habib G, Raoult D. Comprehensive diag-
Cardiovasc J 2009;43:318 – 323. nostic strategy for blood culture-negative endocarditis: a prospective study of 819
78. Hekimian G, Kim M, Passefort S, Duval X, Wolff M, Leport C, Leplat C, Steg G, new cases. Clin Infect Dis 2010;51:131–140.
Iung B, Vahanian A, Messika-Zeitoun D. Preoperative use and safety of coronary 99. Loyens M, Thuny F, Grisoli D, Fournier PE, Casalta JP, Vitte J, Habib G, Raoult D.
angiography for acute aortic valve infective endocarditis. Heart 2010;96:696–700. Link between endocarditis on porcine bioprosthetic valves and allergy to pork. Int J
79. Feuchtner GM, Stolzmann P, Dichtl W, Schertler T, Bonatti J, Scheffel H, Mueller S, Cardiol 2013;167:600 –602.
Plass A, Mueller L, Bartel T, Wolf F, Alkadhi H. Multislice computed tomography in 100. Habib G, Derumeaux G, Avierinos JF, Casalta JP, Jamal F, Volot F, Garcia M,
infective endocarditis: comparison with transesophageal echocardiography and in- Lefevre J, Biou F, Maximovitch-Rodaminoff A, Fournier PE, Ambrosi P, Velut JG,
traoperative findings. J Am Coll Cardiol 2009;53:436 –444. Cribier A, Harle JR, Weiller PJ, Raoult D, Luccioni R. Value and limitations of the
80. Fagman E, Perrotta S, Bech-Hanssen O, Flinck A, Lamm C, Olaison L, Svensson G. Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol 1999;33:
ECG-gated computed tomography: a new role for patients with suspected aortic 2023– 2029.
prosthetic valve endocarditis. Eur Radiol 2012;22:2407 – 2414. 101. Hill EE, Herijgers P, Claus P, Vanderschueren S, Peetermans WE, Herregods MC.
81. Goddard AJ, Tan G, Becker J. Computed tomography angiography for the detec- Abscess in infective endocarditis: the value of transesophageal echocardiography
tion and characterization of intra-cranial aneurysms: current status. Clin Radiol 2005; and outcome: a 5-year study. Am Heart J 2007;154:923 –928.
60:1221 –1236. 102. Vieira ML, Grinberg M, Pomerantzeff PM, Andrade JL, Mansur AJ. Repeated echo-
82. Huang JS, Ho AS, Ahmed A, Bhalla S, Menias CO. Borne identity: CT imaging of cardiographic examinations of patients with suspected infective endocarditis.
vascular infections. Emerg Radiol 2011;18:335 –343. Heart 2004;90:1020 – 1024.
83. Snygg-Martin U, Gustafsson L, Rosengren L, Alsio A, Ackerholm P, Andersson R, 103. Thuny F, Gaubert JY, Jacquier A, Tessonnier L, Cammilleri S, Raoult D, Habib G.
Olaison L. Cerebrovascular complications in patients with left-sided infective endo- Imaging investigations in infective endocarditis: current approach and perspec-
carditis are common: a prospective study using magnetic resonance imaging and tives. Arch Cardiovasc Dis 2013;106:52 –62.
neurochemical brain damage markers. Clin Infect Dis 2008;47:23–30. 104. Gahide G, Bommart S, Demaria R, Sportouch C, Dambia H, Albat B,
84. Cooper HA, Thompson EC, Laureno R, Fuisz A, Mark AS, Lin M, Goldstein SA. Sub- Vernhet-Kovacsik H. Preoperative evaluation in aortic endocarditis: findings on
clinical brain embolization in left-sided infective endocarditis: results from the cardiac CT. AJR Am J Roentgenol 2010;194:574 – 578.
evaluation by MRI of the brains of patients with left-sided intracardiac solid masses 105. Thuny F, Avierinos JF, Tribouilloy C, Giorgi R, Casalta JP, Milandre L, Brahim A,
(EMBOLISM) pilot study. Circulation 2009;120:585 – 591. Nadji G, Riberi A, Collart F, Renard S, Raoult D, Habib G. Impact of cerebrovas-
85. Duval X, Iung B, Klein I, Brochet E, Thabut G, Arnoult F, Lepage L, Laissy JP, cular complications on mortality and neurologic outcome during infective endo-
Wolff M, Leport C. Effect of early cerebral magnetic resonance imaging on clinical carditis: a prospective multicentre study. Eur Heart J 2007;28:1155 –1161.
decisions in infective endocarditis: a prospective study. Ann Intern Med 2010;152: 106. Hyafil F, Rouzet F, Lepage L, Benali K, Raffoul R, Duval X, Hvass U, Iung B, Nataf P,
497 –504, W175. Lebtahi R, Vahanian A, Le Guludec D. Role of radiolabelled leucocyte scintigraphy
3120 ESC Guidelines
in patients with a suspicion of prosthetic valve endocarditis and inconclusive echo- profile of patients with infective endocarditis who need urgent surgery. Eur Heart
cardiography. Eur Heart J Cardiovasc Imaging 2013;14:586 –594. J 2007;28:65 –71.
107. Bensimhon L, Lavergne T, Hugonnet F, Mainardi JL, Latremouille C, Maunoury C, 125. Mirabel M, Sonneville R, Hajage D, Novy E, Tubach F, Vignon P, Perez P, Lavoue S,
Lepillier A, Le Heuzey JY, Faraggi M. Whole body [(18)F]fluorodeoxyglucose posi- Kouatchet A, Pajot O, Mekontso-Dessap A, Tonnelier JM, Bollaert PE, Frat JP,
tron emission tomography imaging for the diagnosis of pacemaker or implantable Navellou JC, Hyvernat H, Hssain AA, Timsit JF, Megarbane B, Wolff M,
cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Trouillet JL. Long-term outcomes and cardiac surgery in critically ill patients
Infect 2011;17:836 –844. with infective endocarditis. Eur Heart J 2014;35:1195 –1204.
108. Sarrazin JF, Philippon F, Tessier M, Guimond J, Molin F, Champagne J, Nault I, 126. Durack DT, Pelletier LL, Petersdorf RG. Chemotherapy of experimental strepto-
Blier L, Nadeau M, Charbonneau L, Trottier M, O’Hara G. Usefulness of coccal endocarditis. II. Synergism between penicillin and streptomycin against
fluorine-18 positron emission tomography/computed tomography for identifica- penicillin-sensitive streptococci. J Clin Invest 1974;53:829 –833.
tion of cardiovascular implantable electronic device infections. J Am Coll Cardiol 127. Wilson WR, Geraci JE, Wilkowske CJ, Washington JA. Short-term intramuscular
2012;59:1616 –1625. therapy with procaine penicillin plus streptomycin for infective endocarditis due
109. Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG, to viridans streptococci. Circulation 1978;57:1158 –1161.
Barzaghi N, Falcone M, Chinello P, Pasticci MB, Grossi P, Utili R, Viale P, 128. Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP,
Rizzi M, Suter F. Epidemiology, characteristics, and outcome of infective endocar- Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low-dose gentami-

ditis in Italy: the Italian Study on Endocarditis. Infection 2012;40:527 –535. cin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin
110. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS, Infect Dis 2009;48:713 –721.
Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, 129. Dahl A, Rasmussen RV, Bundgaard H, Hassager C, Bruun LE, Lauridsen TK,
Falco V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Moser C, Sogaard P, Arpi M, Bruun NE. Enterococcus faecalis infective endocar-
Utili R, Wang A, Woods CW, Cabell CH. Clinical presentation, etiology, and out- ditis: a pilot study of the relationship between duration of gentamicin treatment
come of infective endocarditis in the 21st century: the International Collaboration and outcome. Circulation 2013;127:1810 –1817.
on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169:463 –473. 130. Miro JM, Garcia-de-la-Maria C, Armero Y, Soy D, Moreno A, del Rio A, Almela M,
111. Nadji G, Rusinaru D, Remadi JP, Jeu A, Sorel C, Tribouilloy C. Heart failure in left- Sarasa M, Mestres CA, Gatell JM, Jimenez de Anta MT, Marco F. Addition of gen-
sided native valve infective endocarditis: characteristics, prognosis, and results of tamicin or rifampin does not enhance the effectiveness of daptomycin in treat-
surgical treatment. Eur J Heart Fail 2009;11:668–675. ment of experimental endocarditis due to methicillin-resistant Staphylococcus
112. Olmos C, Vilacosta I, Fernandez C, Lopez J, Sarria C, Ferrera C, Revilla A, Silva J, aureus. Antimicrob Agents Chemother 2009;53:4172 –4177.
Vivas D, Gonzalez I, San Roman JA. Contemporary epidemiology and prognosis of 131. Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, Cabo J,
septic shock in infective endocarditis. Eur Heart J 2013;34:1999 –2006. Ariza J. Fosfomycin-daptomycin and other fosfomycin combinations as alternative
113. Garcia-Cabrera E, Fernandez-Hidalgo N, Almirante B, Ivanova-Georgieva R, therapies in experimental foreign-body infection by methicillin-resistant Staphylo-
Noureddine M, Plata A, Lomas JM, Galvez-Acebal J, Hidalgo-Tenorio C,
coccus aureus. Antimicrob Agents Chemother 2013;57:606 –610.
Ruiz-Morales J, Martinez-Marcos FJ, Reguera JM, Torre-Lima J, de Alarcon GA.
132. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J,
Neurological complications of infective endocarditis: risk factors, outcome, and
Sakoulas G, Cosgrove SE, Rybak MJ. A multicentre evaluation of the effectiveness
impact of cardiac surgery: a multicenter observational study. Circulation 2013;
and safety of high-dose daptomycin for the treatment of infective endocarditis.
127:2272 – 2284.
J Antimicrob Chemother 2013;68:2921 –2926.
114. Delahaye F, Alla F, Beguinot I, Bruneval P, Doco-Lecompte T, Lacassin F,
133. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G.
Selton-Suty C, Vandenesch F, Vernet V, Hoen B. In-hospital mortality of infective
Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradi-
endocarditis: prognostic factors and evolution over an 8-year period. Scand J Infect
cating persistent bacteremia due to methicillin-resistant Staphylococcus aureus:
Dis 2007;39:849–857.
role of enhanced daptomycin binding. Clin Infect Dis 2011;53:158 –163.
115. Thuny F, Beurtheret S, Mancini J, Gariboldi V, Casalta JP, Riberi A, Giorgi R,
134. Miro JM, Entenza JM, del Rio A, Velasco M, Castaneda X, Garcia de la Maria C,
Gouriet F, Tafanelli L, Avierinos JF, Renard S, Collart F, Raoult D, Habib G. The
Giddey M, Armero Y, Pericas JM, Cervera C, Mestres CA, Almela M, Falces C,
timing of surgery influences mortality and morbidity in adults with severe compli-
Marco F, Moreillon P, Moreno A. High-dose daptomycin plus fosfomycin is safe
cated infective endocarditis: a propensity analysis. Eur Heart J 2011;32:
and effective in treating methicillin-susceptible and methicillin-resistant Staphylo-
2027– 2033.
coccus aureus endocarditis. Antimicrob Agents Chemother 2012;56:4511 –4515.
116. Chu VH, Cabell CH, Benjamin DK Jr, Kuniholm EF, Fowler VG Jr, Engemann J,
135. Gould FK, Denning DW, Elliott TS, Foweraker J, Perry JD, Prendergast BD,
Sexton DJ, Corey GR, Wang A. Early predictors of in-hospital death in infective
Sandoe JA, Spry MJ, Watkin RW, Working Party of the British Society for Anti-
endocarditis. Circulation 2004;109:1745 –1749.
microbial Chemotherapy. Guidelines for the diagnosis and antibiotic treatment
117. San Roman JA, Lopez J, Vilacosta I, Luaces M, Sarria C, Revilla A, Ronderos R,
of endocarditis in adults: a report of the Working Party of the British Society
Stoermann W, Gomez I, Fernandez-Aviles F. Prognostic stratification of patients
with left-sided endocarditis determined at admission. Am J Med 2007;120: for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012;67:269 –289.
369 –367. 136. Westling K, Aufwerber E, Ekdahl C, Friman G, Gardlund B, Julander I, Olaison L,
118. Chambers J, Sandoe J, Ray S, Prendergast B, Taggart D, Westaby S, Arden C, Olesund C, Rundstrom H, Snygg-Martin U, Thalme A, Werner M, Hogevik H.
Grothier L, Wilson J, Campbell B, Gohlke-Barwolf C, Mestres CA, Rosenhek R, Swedish guidelines for diagnosis and treatment of infective endocarditis. Scand J
Pibarot P, Otto C. The infective endocarditis team: recommendations from an Infect Dis 2007;39:929–946.
international working group. Heart 2014;100:524 –527. 137. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis
119. Duval X, Alla F, Doco-Lecompte T, Le MV, Delahaye F, Mainardi JL, Plesiat P, with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective
Celard M, Hoen B, Leport C. Diabetes mellitus and infective endocarditis: the in- multicenter study. Clin Infect Dis 1995;21:1406 –1410.
sulin factor in patient morbidity and mortality. Eur Heart J 2007;28:59– 64. 138. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal
120. Gelsomino S, Maessen JG, van der Veen F, Livi U, Renzulli A, Luca F, Carella R, endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy
Crudeli E, Rubino A, Rostagno C, Russo C, Borghetti V, Beghi C, De Bonis M, and outpatient treatment feasibility. JAMA 1992;267:264 –267.
Gensini GF, Lorusso R. Emergency surgery for native mitral valve endocarditis: 139. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D,
the impact of septic and cardiogenic shock. Ann Thorac Surg 2012;93:1469 –1476. Dismukes W, Drew RH, Durack DT. Ceftriaxone once daily for four weeks com-
121. Olmos C, Vilacosta I, Pozo E, Fernandez C, Sarria C, Lopez J, Ferrera C, Maroto L, pared with ceftriaxone plus gentamicin once daily for two weeks for treatment of
Gonzalez I, Vivas D, Palacios J, San Roman JA. Prognostic implications of diabetes endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment
in patients with left-sided endocarditis: findings from a large cohort study. Medi- Consortium Group. Clin Infect Dis 1998;27:1470 –1474.
cine (Baltimore) 2014;93:114–119. 140. Cremieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H, Bouvet A,
122. Hoen B, Alla F, Selton-Suty C, Beguinot I, Bouvet A, Briancon S, Casalta JP, Pocidalo JJ, Carbon C. Evaluation of antibiotic diffusion into cardiac vegetations by
Danchin N, Delahaye F, Etienne J, Le Moing V, Leport C, Mainardi JL, Ruimy R, quantitative autoradiography. J Infect Dis 1989;159:938 –944.
Vandenesch F. Changing profile of infective endocarditis: results of a 1-year survey 141. Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective
in France. JAMA 2002;288:75 –81. analysis of 104 cases. J Antimicrob Chemother 1996;38:507 –521.
123. Lopez J, Sevilla T, Vilacosta I, Sarria C, Revilla A, Ortiz C, Ferrera C, Olmos C, 142. Venditti M, Tarasi A, Capone A, Galie M, Menichetti F, Martino P, Serra P. Teico-
Gomez I, San Roman JA. Prognostic role of persistent positive blood cultures after planin in the treatment of enterococcal endocarditis: clinical and microbiological
initiation of antibiotic therapy in left-sided infective endocarditis. Eur Heart J 2013; study. J Antimicrob Chemother 1997;40:449–452.
34:1749 –1754. 143. Moet GJ, Dowzicky MJ, Jones RN. Tigecycline (GAR-936) activity against Strepto-
124. Revilla A, Lopez J, Vilacosta I, Villacorta E, Rollan MJ, Echevarria JR, Carrascal Y, Di coccus gallolyticus (bovis) and viridans group streptococci. Diagn Microbiol Infect Dis
Stefano S, Fulquet E, Rodriguez E, Fiz L, San Roman JA. Clinical and prognostic 2007;57:333 –336.
ESC Guidelines 3121
144. Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, Lucey DR. Endocarditis caused 166. Bae IG, Federspiel JJ, Miro JM, Woods CW, Park L, Rybak MJ, Rude TH, Bradley S,
by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Bukovski S, de la Maria CG, Kanj SS, Korman TM, Marco F, Murdoch DR, Plesiat P,
Clin Infect Dis 2001;33:577 – 579. Rodriguez-Creixems M, Reinbott P, Steed L, Tattevin P, Tripodi MF, Newton KL,
145. Knoll B, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Infective endocar- Corey GR, Fowler VG Jr. Heterogeneous vancomycin-intermediate susceptibility
ditis due to penicillin-resistant viridans group streptococci. Clin Infect Dis 2007;44: phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from
1585–1592. an international cohort of patients with infective endocarditis: prevalence, geno-
146. Hsu RB, Lin FY. Effect of penicillin resistance on presentation and outcome of type, and clinical significance. J Infect Dis 2009;200:1355 –1366.
nonenterococcal streptococcal infective endocarditis. Cardiology 2006;105: 167. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin min-
234 –239. imum inhibitory concentration in Staphylococcus aureus infections: a systematic re-
147. Shelburne SA III, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone ther- view and meta-analysis. Clin Infect Dis 2012;54:755 –771.
apy of endocarditis due to penicillin non-susceptible viridans streptococci. J Infect 168. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME,
2007;54:e99 –e101. Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I,
148. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN,
Experience with a once-daily aminoglycoside program administered to 2,184 Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin
adult patients. Antimicrob Agents Chemother 1995;39:650 –655. versus standard therapy for bacteremia and endocarditis caused by Staphylococ-

149. Martinez E, Miro JM, Almirante B, Aguado JM, Fernandez-Viladrich P, cus aureus. N Engl J Med 2006;355:653–665.
Fernandez-Guerrero ML, Villanueva JL, Dronda F, Moreno-Torrico A, 169. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective
Montejo M, Llinares P, Gatell JM. Effect of penicillin resistance of Streptococcus endocarditis: experience from a registry. Am J Med 2007;120(Suppl 1):S28 – S33.
pneumoniae on the presentation, prognosis, and treatment of pneumococcal 170. Carugati M, Bayer AS, Miro JM, Park LP, Guimaraes AC, Skoutelis A, Fortes CQ,
endocarditis in adults. Clin Infect Dis 2002;35:130 – 139. Durante-Mangoni E, Hannan MM, Nacinovich F, Fernandez-Hidalgo N, Grossi P,
150. Friedland IR, McCracken GH Jr. Management of infections caused by Tan RS, Holland T, Fowler VG Jr, Corey RG, Chu VH. High-dose daptomycin ther-
antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377 –382. apy for left-sided infective endocarditis: a prospective study from the International
151. Lefort A, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi JL. Com- Collaboration on Endocarditis. Antimicrob Agents Chemother 2013;57:6213 –6222.
parison between adult endocarditis due to beta-hemolytic streptococci (ser- 171. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Dap-
ogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. tomycin versus vancomycin for bloodstream infections due to methicillin-
Arch Intern Med 2002;162:2450 –2456. resistant Staphylococcus aureus with a high vancomycin minimum inhibitory con-
152. Sambola A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, Gurgui M, centration: a case-control study. Clin Infect Dis 2012;54:51 –58.
Martinez E, del Rio A, Azqueta M, Marco F, Gatell JM. Streptococcus agalactiae in- 172. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ. Early use of
fective endocarditis: analysis of 30 cases and review of the literature, 1962 –1998. daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bac-
Clin Infect Dis 2002;34:1576 –1584. teremia with vancomycin minimum inhibitory concentration .1 mg/L: a matched
153. Giuliano S, Caccese R, Carfagna P, Vena A, Falcone M, Venditti M. Endocarditis cohort study. Clin Infect Dis 2013;56:1562 –1569.
caused by nutritionally variant streptococci: a case report and literature review. 173. Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination
Infez Med 2012;20:67–74. therapy for Gram-positive infections. Int J Antimicrob Agents 2013;42:202 –210.
154. Adam EL, Siciliano RF, Gualandro DM, Calderaro D, Issa VS, Rossi F, Caramelli B, 174. Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, Carpenter CF,
Mansur AJ, Strabelli TM. Case series of infective endocarditis caused by Granulica- Rybak MJ. Daptomycin activity against Staphylococcus aureus following vancomycin
tella species. Int J Infect Dis 2015;31:56 –58. exposure in an in vitro pharmacodynamic model with simulated endocardial ve-
155. Anguera I, del Rio A, Miro JM, Matinez-Lacasa X, Marco F, Guma JR, Quaglio G, getations. Antimicrob Agents Chemother 2008;52:831 –836.
Claramonte X, Moreno A, Mestres CA, Mauri E, Azqueta M, Benito N, Garcia-de 175. del Rio A, Gasch O, Moreno A, Pena C, Cuquet J, Soy D, Mestres CA, Suarez C,
la Maria C, Almela M, Jimenez-Exposito MJ, Sued O, de Lazzari E, Gatell JM. Pare JC, Tubau F, Garcia de la Maria C, Marco F, Carratala J, Gatell JM, Gudiol F,
Staphylococcus lugdunensis infective endocarditis: description of 10 cases and ana- Miro JM. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for
lysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical pro- complicated bacteremia and endocarditis due to methicillin-resistant Staphylococ-
files. Heart 2005;91:e10. cus aureus: a multicenter clinical trial. Clin Infect Dis 2014;59:1105 –1112.
156. Cone LA, Sontz EM, Wilson JW, Mitruka SN. Staphylococcus capitis endocarditis 176. Tattevin P, Boutoille D, Vitrat V, Van Grunderbeeck N, Revest M, Dupont M,
due to a transvenous endocardial pacemaker infection: case report and review Alfandari S, Stahl JP. Salvage treatment of methicillin-resistant staphylococcal
of Staphylococcus capitis endocarditis. Int J Infect Dis 2005;9:335–339. endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Che-
157. Sandoe JA, Kerr KG, Reynolds GW, Jain S. Staphylococcus capitis endocarditis: two mother 2014;69:2010 –2013.
cases and review of the literature. Heart 1999;82:e1. 177. Guignard B, Entenza JM, Moreillon P. Beta-lactams against methicillin-resistant
158. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococ- Staphylococcus aureus. Curr Opin Pharmacol 2005;5:479 –489.
cus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: 178. Vouillamoz J, Entenza JM, Feger C, Glauser MP, Moreillon P. Quinupristin-
a prospective study. Ann Intern Med 1982;97:496 –503. dalfopristin combined with beta-lactams for treatment of experimental endocar-
159. Apellaniz G, Valdes M, Perez R, Martin-Luengo F, Garcia A, Soria F, Gomez J. ditis due to Staphylococcus aureus constitutively resistant to macrolide-
[Teicoplanin versus cloxacillin, cloxacillin-gentamycin and vancomycin in the lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 2000;44:
treatment of experimental endocarditis caused by methicillin-sensitive Staphylo- 1789–1795.
coccus aureus]. Enferm Infecc Microbiol Clin 1991;9:208 – 210. 179. Jang HC, Kim SH, Kim KH, Kim CJ, Lee S, Song KH, Jeon JH, Park WB, Kim HB,
160. Casalta JP, Zaratzian C, Hubert S, Thuny F, Gouriet F, Habib G, Grisoli D, Park SW, Kim NJ, Kim EC, Oh MD, Choe KW. Salvage treatment for persistent
Deharo JC, Raoult D. Treatment of Staphylococcus aureus endocarditis with high methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with
doses of trimethoprim/sulfamethoxazole and clindamycin—preliminary report. or without carbapenem. Clin Infect Dis 2009;49:395–401.
Int J Antimicrob Agents 2013;42:190 –191. 180. Perichon B, Courvalin P. Synergism between beta-lactams and glycopeptides
161. Chirouze C, Cabell CH, Fowler VG Jr, Khayat N, Olaison L, Miro JM, Habib G, against VanA-type methicillin-resistant Staphylococcus aureus and heterologous
Abrutyn E, Eykyn S, Corey GR, Selton-Suty C, Hoen B. Prognostic factors in 61 expression of the vanA operon. Antimicrob Agents Chemother 2006;50:
cases of Staphylococcus aureus prosthetic valve infective endocarditis from the 3622 –3630.
International Collaboration on Endocarditis merged database. Clin Infect Dis 181. Chirouze C, Athan E, Alla F, Chu VH, Ralph CG, Selton-Suty C, Erpelding ML,
2004;38:1323 –1327. Miro JM, Olaison L, Hoen B. Enterococcal endocarditis in the beginning of the
162. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treat- 21st century: analysis from the International Collaboration on Endocarditis-
ment of orthopedic implant-related staphylococcal infections: a randomized con- Prospective Cohort Study. Clin Microbiol Infect 2013;19:1140 –1147.
trolled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279:1537 – 1541. 182. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A. Anti-
163. O’Connor S, Andrew P, Batt M, Becquemin JP. A systematic review and microbial susceptibility of the pathogens of bacteraemia in the UK and Ireland
meta-analysis of treatments for aortic graft infection. J Vasc Surg 2006;44:38 –45. 2001 – 2002: the BSAC Bacteraemia Resistance Surveillance Programme.
164. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for J Antimicrob Chemother 2004;53:1018 –1032.
treatment of native valve infective endocarditis caused by Staphylococcus aureus. 183. Gavalda J, Len O, Miro JM, Munoz P, Montejo M, Alarcon A, Torre-Cisneros J,
Antimicrob Agents Chemother 2008;52:2463 –2467. Pena C, Martinez-Lacasa X, Sarria C, Bou G, Aguado JM, Navas E, Romeu J,
165. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level Marco F, Torres C, Tornos P, Planes A, Falco V, Almirante B, Pahissa A. Brief com-
vancomycin resistance associated with persistent methicillin-resistant Staphylococ- munication: treatment of Enterococcus faecalis endocarditis with ampicillin plus
cus aureus bacteremia. Antimicrob Agents Chemother 2006;50:3039 –3047. ceftriaxone. Ann Intern Med 2007;146:574 –579.
3122 ESC Guidelines
184. Fernandez-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Pena C, de Alarcon A, 208. Hasbun R, Vikram HR, Barakat LA, Buenconsejo J, Quagliarello VJ. Complicated
Ruiz J, Vilacosta I, Montejo M, Vallejo N, Lopez-Medrano F, Plata A, Lopez J, left-sided native valve endocarditis in adults: risk classification for mortality.
Hidalgo-Tenorio C, Galvez J, Saez C, Lomas JM, Falcone M, de la Torre J, JAMA 2003;289:1933 –1940.
Martinez-Lacasa X, Pahissa A. Ampicillin plus ceftriaxone is as effective as ampicil- 209. Aksoy O, Sexton DJ, Wang A, Pappas PA, Kourany W, Chu V, Fowler VG Jr,
lin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin In- Woods CW, Engemann JJ, Corey GR, Harding T, Cabell CH. Early surgery in pa-
fect Dis 2013;56:1261 – 1268. tients with infective endocarditis: a propensity score analysis. Clin Infect Dis 2007;
185. Pericas JM, Cervera C, del Rio A, Moreno A, Garcia de la Maria C, Almela M, 44:364 –372.
Falces C, Ninot S, Castaneda X, Armero Y, Soy D, Gatell JM, Marco F, 210. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on
Mestres CA, Miro JM. Changes in the treatment of Enterococcus faecalis infective 6-month mortality in adults with complicated, left-sided native valve endocarditis:
endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampi- a propensity analysis. JAMA 2003;290:3207 –3214.
cillin plus ceftriaxone. Clin Microbiol Infect 2014;20:O1075 –O1083. 211. Di Salvo G, Thuny F, Rosenberg V, Pergola V, Belliard O, Derumeaux G, Cohen A,
186. Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995– 1999: can Iarussi D, Giorgi R, Casalta JP, Caso P, Habib G. Endocarditis in the elderly: clinical,
shorter therapy with aminoglycosides be used? Clin Infect Dis 2002;34:159 –166. echocardiographic, and prognostic features. Eur Heart J 2003;24:1576 –1583.
187. Miro JM, Pericas JM, del Rio A. A new era for treating Enterococcus faecalis endo- 212. Olmos C, Vilacosta I, Fernandez C, Sarria C, Lopez J, Del Trigo M, Ferrera C,
carditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that Vivas D, Maroto L, Hernandez M, Rodriguez E, San Roman JA. Comparison of clin-

is the question! Circulation 2013;127:1763 –1766. ical features of left-sided infective endocarditis involving previously normal versus
188. Das M, Badley AD, Cockerill FR, Steckelberg JM, Wilson WR. Infective endocar- previously abnormal valves. Am J Cardiol 2014;114:278 –283.
ditis caused by HACEK microorganisms. Annu Rev Med 1997;48:25 –33. 213. Anguera I, Miro JM, Vilacosta I, Almirante B, Anguita M, Munoz P, Roman JA, de
189. Paturel L, Casalta JP, Habib G, Nezri M, Raoult D. Actinobacillus actinomycetemco- Alarcon A, Ripoll T, Navas E, Gonzalez-Juanatey C, Cabell CH, Sarria C,
mitans endocarditis. Clin Microbiol Infect 2004;10:98 –118. Garcia-Bolao I, Farinas MC, Leta R, Rufi G, Miralles F, Pare C, Evangelista A,
190. Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, Fowler VG Jr, Mestres CA, de Lazzari E, Guma JR. Aorto-cavitary fistulous tract
Nacinovich F, Tattevin P, Fernandez-Hidalgo N, Dickerman S, Bouza E, del formation in infective endocarditis: clinical and echocardiographic features of 76
Rio A, Lejko-Zupanc T, de Oliveira RA, Iarussi D, Klein J, Chirouze C, cases and risk factors for mortality. Eur Heart J 2005;26:288 – 297.
Bedimo R, Corey GR, Fowler VG Jr. Non-HACEK Gram-negative bacillus endo- 214. Piper C, Hetzer R, Korfer R, Bergemann R, Horstkotte D. The importance of sec-
carditis. Ann Intern Med 2007;147:829 –835. ondary mitral valve involvement in primary aortic valve endocarditis; the mitral
191. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: kissing vegetation. Eur Heart J 2002;23:79 –86.
etiologic diagnosis of 348 cases. Medicine (Baltimore) 2005;84:162 –173. 215. Vilacosta I, San Roman JA, Sarria C, Iturralde E, Graupner C, Batlle E, Peral V,
192. Tattevin P, Watt G, Revest M, Arvieux C, Fournier PE. Update on blood culture- Aragoncillo P, Stoermann W. Clinical, anatomic, and echocardiographic charac-
negative endocarditis. Med Mal Infect 2015;45:1 –8. teristics of aneurysms of the mitral valve. Am J Cardiol 1999;84:110 –113, A9.
193. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol 216. Kiefer T, Park L, Tribouilloy C, Cortes C, Casillo R, Chu V, Delahaye F,
Rev 2001;14:177 – 207. Durante-Mangoni E, Edathodu J, Falces C, Logar M, Miro JM, Naber C,
194. Ghigo E, Capo C, Aurouze M, Tung CH, Gorvel JP, Raoult D, Mege JL. Survival of Tripodi MF, Murdoch DR, Moreillon P, Utili R, Wang A. Association between
Tropheryma whipplei, the agent of Whipple’s disease, requires phagosome acidifi- valvular surgery and mortality among patients with infective endocarditis compli-
cation. Infect Immun 2002;70:1501 –1506. cated by heart failure. JAMA 2011;306:2239 –2247.
195. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommenda- 217. Kahveci G, Bayrak F, Mutlu B, Bitigen A, Karaahmet T, Sonmez K, Izgi A,
tions for treatment of human infections caused by Bartonella species. Antimicrob Degertekin M, Basaran Y. Prognostic value of N-terminal pro-B-type natriuretic pep-
Agents Chemother 2004;48:1921 – 1933. tide in patients with active infective endocarditis. Am J Cardiol 2007;99:1429–1433.
196. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, 218. Purcell JB, Patel M, Khera A, De Lemos JA, Forbess LW, Baker S, Cabell CH,
Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Peterson GE. Relation of troponin elevation to outcome in patients with infective
Levison ME, Peter G, Zuccaro G Jr. Prevention of bacterial endocarditis. Recom- endocarditis. Am J Cardiol 2008;101:1479 –1481.
mendations by the American Heart Association. Circulation 1997;96:358 –366. 219. Shiue AB, Stancoven AB, Purcell JB, Pinkston K, Wang A, Khera A, De Lemos JA,
197. Raoult D, Fournier PE, Vandenesch F, Mainardi JL, Eykyn SJ, Nash J, James E, Peterson GE. Relation of level of B-type natriuretic peptide with outcomes in pa-
Benoit-Lemercier C, Marrie TJ. Outcome and treatment of Bartonella endocardi- tients with infective endocarditis. Am J Cardiol 2010;106:1011 –1015.
tis. Arch Intern Med 2003;163:226 –230. 220. Lopez J, Sevilla T, Vilacosta I, Garcia H, Sarria C, Pozo E, Silva J, Revilla A,
198. Tattevin P, Revest M, Lefort A, Michelet C, Lortholary O. Fungal endocarditis: cur- Varvaro G, del Palacio M, Gomez I, San Roman JA. Clinical significance of congest-
rent challenges. Int J Antimicrob Agents 2014;44:290 –294. ive heart failure in prosthetic valve endocarditis. A multicenter study with 257
199. Kalokhe AS, Rouphael N, El Chami MF, Workowski KA, Ganesh G, Jacob JT. As- patients. Rev Esp Cardiol (Engl Ed) 2013;66:384 – 390.
pergillus endocarditis: a review of the literature. Int J Infect Dis 2010;14: 221. Habib G, Tribouilloy C, Thuny F, Giorgi R, Brahim A, Amazouz M, Remadi JP,
e1040 –e1047. Nadji G, Casalta JP, Coviaux F, Avierinos JF, Lescure X, Riberi A, Weiller PJ,
200. Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endo- Metras D, Raoult D. Prosthetic valve endocarditis: who needs surgery? A multi-
carditis: a meta-analysis. Medicine (Baltimore) 2011;90:237 –249. centre study of 104 cases. Heart 2005;91:954 –959.
201. Lye DC, Hughes A, O’Brien D, Athan E. Candida glabrata prosthetic valve endo- 222. Hubert S, Thuny F, Resseguier N, Giorgi R, Tribouilloy C, Le Dolley Y, Casalta JP,
carditis treated successfully with fluconazole plus caspofungin without surgery: a Riberi A, Chevalier F, Rusinaru D, Malaquin D, Remadi JP, Ammar AB, Avierinos JF,
case report and literature review. Eur J Clin Microbiol Infect Dis 2005;24:753 –755. Collart F, Raoult D, Habib G. Prediction of symptomatic embolism in infective
202. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in endocarditis: construction and validation of a risk calculator in a multicenter co-
adults: how many blood cultures are needed? J Clin Microbiol 2007;45:3546 –3548. hort. J Am Coll Cardiol 2013;62:1384 –1392.
203. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, Leibovici L, 223. Anguera I, Miro JM, Evangelista A, Cabell CH, San Roman JA, Vilacosta I,
Bishara J. Are all beta-lactams similarly effective in the treatment of methicillin- Almirante B, Ripoll T, Farinas MC, Anguita M, Navas E, Gonzalez-Juanatey C,
sensitive Staphylococcus aureus bacteraemia?. Clin Microbiol Infect 2011;17: Garcia-Bolao I, Munoz P, de Alarcon A, Sarria C, Rufi G, Miralles F, Pare C,
1581 –1586. Fowler VG Jr, Mestres CA, de Lazzari E, Guma JR, Moreno A, Corey GR. Perian-
204. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer RB, nular complications in infective endocarditis involving native aortic valves. Am J
Kunkel MJ, Yancey RW, Williams DN. Practice guidelines for outpatient paren- Cardiol 2006;98:1254 –1260.
teral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004;38:1651 – 1672. 224. Anguera I, Miro JM, San Roman JA, de Alarcon A, Anguita M, Almirante B,
205. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines Evangelista A, Cabell CH, Vilacosta I, Ripoll T, Munoz P, Navas E,
for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Gonzalez-Juanatey C, Sarria C, Garcia-Bolao I, Farinas MC, Rufi G, Miralles F,
Clin Infect Dis 2001;33:203 –209. Pare C, Fowler VG Jr, Mestres CA, de Lazzari E, Guma JR, del Rio A,
206. Cervera C, del Rio A, Garcia L, Sala M, Almela M, Moreno A, Falces C, Corey GR. Periannular complications in infective endocarditis involving prosthet-
Mestres CA, Marco F, Robau M, Gatell JM, Miro JM. Efficacy and safety of out- ic aortic valves. Am J Cardiol 2006;98:1261 –1268.
patient parenteral antibiotic therapy for infective endocarditis: a ten-year pro- 225. Daniel W, Flaschkampf F. Infective endocarditis. In: Camm A, Luscher T, Serruys P,
spective study. Enferm Infecc Microbiol Clin 2011;29:587–592. eds. The ESC textbook of cardiovascular medicine. Oxford: Blackwell, 2006.
207. Duncan CJ, Barr DA, Ho A, Sharp E, Semple L, Seaton RA. Risk factors for failure 226. Leung DY, Cranney GB, Hopkins AP, Walsh WF. Role of transoesophageal echo-
of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. cardiography in the diagnosis and management of aortic root abscess. Br Heart J
J Antimicrob Chemother 2013;68:1650 –1654. 1994;72:175 –181.
ESC Guidelines 3123
227. Graupner C, Vilacosta I, San Roman J, Ronderos R, Sarria C, Fernandez C, Verhagen DW, Cabell CH. The relationship between the initiation of antimicro-
Mujica R, Sanz O, Sanmartin JV, Pinto AG. Periannular extension of infective bial therapy and the incidence of stroke in infective endocarditis: an analysis from
endocarditis. J Am Coll Cardiol 2002;39:1204 – 1211. the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 2007;154:1086 –1094.
228. Lengyel M. The impact of transesophageal echocardiography on the management 251. Cabell CH, Pond KK, Peterson GE, Durack DT, Corey GR, Anderson DJ, Ryan T,
of prosthetic valve endocarditis: experience of 31 cases and review of the litera- Lukes AS, Sexton DJ. The risk of stroke and death in patients with aortic and mitral
ture. J Heart Valve Dis 1997;6:204 –211. valve endocarditis. Am Heart J 2001;142:75 –80.
229. Forteza A, Centeno J, Ospina V, Lunar IG, Sanchez V, Perez E, Lopez MJ, Cortina J. 252. Tischler MD, Vaitkus PT. The ability of vegetation size on echocardiography to
Outcomes in aortic and mitral valve replacement with intervalvular fibrous body predict clinical complications: a meta-analysis. J Am Soc Echocardiogr 1997;10:
reconstruction. Ann Thorac Surg 2015;99:838 –845. 562– 568.
230. Chan KL. Early clinical course and long-term outcome of patients with infective 253. Rohmann S, Erbel R, Darius H, Gorge G, Makowski T, Zotz R, Mohr-Kahaly S,
endocarditis complicated by perivalvular abscess. CMAJ 2002;167:19 –24. Nixdorff U, Drexler M, Meyer J. Prediction of rapid versus prolonged healing of
231. Tingleff J, Egeblad H, Gotzsche CO, Baandrup U, Kristensen BO, Pilegaard H, infective endocarditis by monitoring vegetation size. J Am Soc Echocardiogr 1991;4:
Pettersson G. Perivalvular cavities in endocarditis: abscesses versus pseudoaneur- 465 –474.
ysms? A transesophageal Doppler echocardiographic study in 118 patients with 254. Pergola V, Di Salvo G, Habib G, Avierinos JF, Philip E, Vailloud JM, Thuny F,
endocarditis. Am Heart J 1995;130:93– 100. Casalta JP, Ambrosi P, Lambert M, Riberi A, Ferracci A, Mesana T, Metras D,

232. Jenkins NP, Habib G, Prendergast BD. Aorto-cavitary fistulae in infective endocar- Harle JR, Weiller PJ, Raoult D, Luccioni R. Comparison of clinical and echocardio-
ditis: understanding a rare complication through collaboration. Eur Heart J 2005; graphic characteristics of Streptococcus bovis endocarditis with that caused by
26:213 –214. other pathogens. Am J Cardiol 2001;88:871 –875.
233. Bashore TM, Cabell C, Fowler V Jr. Update on infective endocarditis. Curr Probl 255. Durante ME, Adinolfi LE, Tripodi MF, Andreana A, Gambardella M, Ragone E,
Cardiol 2006;31:274 –352. Precone DF, Utili R, Ruggiero G. Risk factors for "major" embolic events in hospi-
234. Manzano MC, Vilacosta I, San Roman JA, Aragoncillo P, Sarria C, Lopez D, Lopez J, talized patients with infective endocarditis. Am Heart J 2003;146:311 –316.
Revilla A, Manchado R, Hernandez R, Rodriguez E. [Acute coronary syndrome in 256. Kupferwasser LI, Hafner G, Mohr-Kahaly S, Erbel R, Meyer J, Darius H. The pres-
infective endocarditis]. Rev Esp Cardiol 2007;60:24 –31. ence of infection-related antiphospholipid antibodies in infective endocarditis de-
235. Manne MB, Shrestha NK, Lytle BW, Nowicki ER, Blackstone E, Gordon SM, termines a major risk factor for embolic events. J Am Coll Cardiol 1999;33:
Pettersson G, Fraser TG. Outcomes after surgical treatment of native and pros- 1365 –1371.
thetic valve infective endocarditis. Ann Thorac Surg 2012;93:489 –493. 257. Anavekar NS, Tleyjeh IM, Anavekar NS, Mirzoyev Z, Steckelberg JM, Haddad C,
236. Glazier JJ, Verwilghen J, Donaldson RM, Ross DN. Treatment of complicated Khandaker MH, Wilson WR, Chandrasekaran K, Baddour LM. Impact of prior
prosthetic aortic valve endocarditis with annular abscess formation by homograft antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis
aortic root replacement. J Am Coll Cardiol 1991;17:1177 –1182. 2007;44:1180 –1186.
237. Knosalla C, Weng Y, Yankah AC, Siniawski H, Hofmeister J, Hammerschmidt R, 258. Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, Robinson TI,
Loebe M, Hetzer R. Surgical treatment of active infective aortic valve endocarditis Moher D. A randomized trial of aspirin on the risk of embolic events in patients
with associated periannular abscess—11 year results. Eur Heart J 2000;21:490–497. with infective endocarditis. J Am Coll Cardiol 2003;42:775–780.
238. Ellis ME, Al Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evi- 259. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neuro-
dence in the world literature, 1965 –1995. Clin Infect Dis 2001;32:50 –62. logic manifestations of infective endocarditis: a 17-year experience in a teaching
239. Baddley JW, Benjamin DK Jr, Patel M, Miro J, Athan E, Barsic B, Bouza E, Clara L, hospital in Finland. Arch Intern Med 2000;160:2781 –2787.
Elliott T, Kanafani Z, Klein J, Lerakis S, Levine D, Spelman D, Rubinstein E, 260. Tleyjeh IM, Steckelberg JM, Georgescu G, Ghomrawi HM, Hoskin TL, Enders FB,
Tornos P, Morris AJ, Pappas P, Fowler VG Jr, Chu VH, Cabell C. Candida infective Mookadam F, Huskins WC, Wilson WR, Baddour LM. The association between
endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:519 – 529. the timing of valve surgery and 6-month mortality in left-sided infective endocar-
240. Bishara J, Leibovici L, Gartman-Israel D, Sagie A, Kazakov A, Miroshnik E, ditis. Heart 2008;94:892 –896.
Ashkenazi S, Pitlik S. Long-term outcome of infective endocarditis: the impact 261. Barsic B, Dickerman S, Krajinovic V, Pappas P, Altclas J, Carosi G, Casabe JH,
of early surgical intervention. Clin Infect Dis 2001;33:1636 –1643. Chu VH, Delahaye F, Edathodu J, Fortes CQ, Olaison L, Pangercic A, Patel M,
241. Remadi JP, Habib G, Nadji G, Brahim A, Thuny F, Casalta JP, Peltier M, Rudez I, Tamin SS, Vincelj J, Bayer AS, Wang A. Influence of the timing of cardiac
Tribouilloy C. Predictors of death and impact of surgery in Staphylococcus aureus surgery on the outcome of patients with infective endocarditis and stroke. Clin In-
infective endocarditis. Ann Thorac Surg 2007;83:1295 –1302. fect Dis 2013;56:209–217.
242. Di SalvoG, Habib G, Pergola V, Avierinos JF, Philip E, Casalta JP, Vailloud JM, 262. Bannay A, Hoen B, Duval X, Obadia JF, Selton-Suty C, Le MV, Tattevin P, Iung B,
Derumeaux G, Gouvernet J, Ambrosi P, Lambert M, Ferracci A, Raoult D, Delahaye F, Alla F. The impact of valve surgery on short- and long-term mortality
Luccioni R. Echocardiography predicts embolic events in infective endocarditis. in left-sided infective endocarditis: do differences in methodological approaches
J Am Coll Cardiol 2001;37:1069 –1076. explain previous conflicting results? Eur Heart J 2011;32:2003 –2015.
243. Steckelberg JM, Murphy JG, Ballard D, Bailey K, Tajik AJ, Taliercio CP, Giuliani ER, 263. Ruttmann E, Willeit J, Ulmer H, Chevtchik O, Hofer D, Poewe W, Laufer G,
Wilson WR. Emboli in infective endocarditis: the prognostic value of echocardi- Muller LC. Neurological outcome of septic cardioembolic stroke after infective
ography. Ann Intern Med 1991;114:635 – 640. endocarditis. Stroke 2006;37:2094 – 2099.
244. De Castro S, Magni G, Beni S, Cartoni D, Fiorelli M, Venditti M, Schwartz SL, 264. Yoshioka D, Sakaguchi T, Yamauchi T, Okazaki S, Miyagawa S, Nishi H,
Fedele F, Pandian NG. Role of transthoracic and transesophageal echocardiog- Yoshikawa Y, Fukushima S, Saito S, Sawa Y. Impact of early surgical treatment
raphy in predicting embolic events in patients with active infective endocarditis on postoperative neurologic outcome for active infective endocarditis compli-
involving native cardiac valves. Am J Cardiol 1997;80:1030 –1034. cated by cerebral infarction. Ann Thorac Surg 2012;94:489 –495.
245. Heinle S, Wilderman N, Harrison JK, Waugh R, Bashore T, Nicely LM, Durack D, 265. Eishi K, Kawazoe K, Kuriyama Y, Kitoh Y, Kawashima Y, Omae T. Surgical manage-
Kisslo J. Value of transthoracic echocardiography in predicting embolic events in ment of infective endocarditis associated with cerebral complications. Multi-
active infective endocarditis. Duke Endocarditis Service. Am J Cardiol 1994;74: center retrospective study in Japan. J Thorac Cardiovasc Surg 1995;110:1745 –1755.
799– 801. 266. Wilbring M, Irmscher L, Alexiou K, Matschke K, Tugtekin SM. The impact of pre-
246. Rohmann S, Erbel R, Gorge G, Makowski T, Mohr-Kahaly S, Nixdorff U, operative neurological events in patients suffering from native infective valve
Drexler M, Meyer J. Clinical relevance of vegetation localization by transoesopha- endocarditis. Interact Cardiovasc Thorac Surg 2014;18:740 –747.
geal echocardiography in infective endocarditis. Eur Heart J 1992;13:446 –452. 267. Hui FK, Bain M, Obuchowski NA, Gordon S, Spiotta AM, Moskowitz S, Toth G,
247. Erbel R, Liu F, Ge J, Rohmann S, Kupferwasser I. Identification of high-risk sub- Hussain S. Mycotic aneurysm detection rates with cerebral angiography in pa-
groups in infective endocarditis and the role of echocardiography. Eur Heart J tients with infective endocarditis. J Neurointerv Surg 2015;7:449 –452.
1995;16:588 –602. 268. Ducruet AF, Hickman ZL, Zacharia BE, Narula R, Grobelny BT, Gorski J,
248. Sanfilippo AJ, Picard MH, Newell JB, Rosas E, Davidoff R, Thomas JD, Weyman AE. Connolly ES Jr. Intracranial infectious aneurysms: a comprehensive review. Neuro-
Echocardiographic assessment of patients with infectious endocarditis: prediction surg Rev 2010;33:37– 46.
of risk for complications. J Am Coll Cardiol 1991;18:1191 –1199. 269. Peters PJ, Harrison T, Lennox JL. A dangerous dilemma: management of infectious
249. Mugge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endo- intracranial aneurysms complicating endocarditis. Lancet Infect Dis 2006;6:
carditis: reassessment of prognostic implications of vegetation size determined by 742 –748.
the transthoracic and the transesophageal approach. J Am Coll Cardiol 1989;14: 270. Corr P, Wright M, Handler LC. Endocarditis-related cerebral aneurysms: radio-
631– 638. logic changes with treatment. AJNR Am J Neuroradiol 1995;16:745 –748.
250. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, 271. White PM, Teasdale EM, Wardlaw JM, Easton V. Intracranial aneurysms: CT angi-
Doco-Lecompte T, Eisen DP, Fortes CQ, Fowler VG Jr, Lerakis S, Miro JM, ography and MR angiography for detection prospective blinded comparison in a
Pappas P, Peterson GE, Rubinstein E, Sexton DJ, Suter F, Tornos P, large patient cohort. Radiology 2001;219:739 –749.
3123a ESC Guidelines
272. Gonzalez I, Sarria C, Lopez J, Vilacosta I, San Roman A, Olmos C, Saez C, Revilla A, 297. Mahr A, Batteux F, Tubiana S, Goulvestre C, Wolff M, Papo T, Vrtovsnik F, Klein I,
Hernandez M, Caniego JL, Fernandez C. Symptomatic peripheral mycotic aneur- Iung B, Duval X. Brief report: prevalence of antineutrophil cytoplasmic antibodies
ysms due to infective endocarditis: a contemporary profile. Medicine (Baltimore) in infective endocarditis. Arthritis Rheumatol 2014;66:1672 –1677.
2014;93:42 –52. 298. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR,
273. Bonfiglioli R, Nanni C, Morigi JJ, Graziosi M, Trapani F, Bartoletti M, Tumietto F, Lockowandt U. EuroSCORE II. Eur J Cardiothorac Surg 2012;41:734 –744.
Ambrosini V, Ferretti A, Rubello D, Rapezzi C, Viale PL, Fanti S. 18F-FDG PET/CT 299. Gaca JG, Sheng S, Daneshmand MA, O’Brien S, Rankin JS, Brennan JM, Hughes GC,
diagnosis of unexpected extracardiac septic embolisms in patients with suspected Glower DD, Gammie JS, Smith PK. Outcomes for endocarditis surgery in North
cardiac endocarditis. Eur J Nucl Med Mol Imaging 2013;40:1190 –1196. America: a simplified risk scoring system. J Thorac Cardiovasc Surg 2011;141:
274. Akhyari P, Mehrabi A, Adhiwana A, Kamiya H, Nimptsch K, Minol JP, 98 –106.
Tochtermann U, Godehardt E, Weitz J, Lichtenberg A, Karck M, Ruhparwar A. 300. De Feo M, Cotrufo M, Carozza A, De Santo LS, Amendolara F, Giordano S, Della
Is simultaneous splenectomy an additive risk factor in surgical treatment for active Ratta EE, Nappi G, Della CA. The need for a specific risk prediction system in na-
endocarditis? Langenbecks Arch Surg 2012;397:1261 –1266. tive valve infective endocarditis surgery. ScientificWorldJournal 2012;2012:307571.
275. Chou YH, Hsu CC, Tiu CM, Chang T. Splenic abscess: sonographic diagnosis and 301. Wang J, Liu H, Sun J, Xue H, Xie L, Yu S, Liang C, Han X, Guan Z, Wei L, Yuan C,
percutaneous drainage or aspiration. Gastrointest Radiol 1992;17:262–266. Zhao X, Chen H. Varying correlation between 18F-fluorodeoxyglucose positron
276. Katz LH, Pitlik S, Porat E, Biderman P, Bishara J. Pericarditis as a presenting sign of emission tomography and dynamic contrast-enhanced MRI in carotid atheroscler-

infective endocarditis: two case reports and review of the literature. Scand J Infect osis: implications for plaque inflammation. Stroke 2014;45:1842 –1845.
Dis 2008;40:785 – 791. 302. de Kerchove L, Vanoverschelde JL, Poncelet A, Glineur D, Rubay J, Zech F,
277. Regueiro A, Falces C, Cervera C, del Rio A, Pare JC, Mestres CA, Castaneda X, Noirhomme P, El Khoury G. Reconstructive surgery in active mitral valve endo-
Pericas JM, Azqueta M, Marco F, Ninot S, Almela M, Moreno A, Miro JM. Risk fac- carditis: feasibility, safety and durability. Eur J Cardiothorac Surg 2007;31:592 –599.
tors for pericardial effusion in native valve infective endocarditis and its influence 303. de Kerchove L, Price J, Tamer S, Glineur D, Momeni M, Noirhomme P, El
on outcome. Am J Cardiol 2013;112:1646 –1651. Khoury G. Extending the scope of mitral valve repair in active endocarditis.
278. DiNubile MJ, Calderwood SB, Steinhaus DM, Karchmer AW. Cardiac conduction J Thorac Cardiovasc Surg 2012;143(Suppl):S91– S95.
abnormalities complicating native valve active infective endocarditis. Am J Cardiol 304. Meszaros K, Nujic S, Sodeck GH, Englberger L, Konig T, Schonhoff F, Reineke D,
1986;58:1213 – 1217. Roost-Krahenbuhl E, Schmidli J, Czerny M, Carrel TP. Long-term results after op-
279. Ryu HM, Bae MH, Lee SH, Lee JH, Lee JH, Kwon YS, Yang DH, Park HS, Cho Y, erations for active infective endocarditis in native and prosthetic valves. Ann Thorac
Chae SC, Jun JE, Park WH. Presence of conduction abnormalities as a predictor of Surg 2012;94:1204 –1210.
clinical outcomes in patients with infective endocarditis. Heart Vessels 2011;26: 305. Edwards MB, Ratnatunga CP, Dore CJ, Taylor KM. Thirty-day mortality and long-
298 –305. term survival following surgery for prosthetic endocarditis: a study from the UK
280. Kitkungvan D, Denktas AE. Cardiac arrest and ventricular tachycardia from cor- heart valve registry. Eur J Cardiothorac Surg 1998;14:156 –164.
onary embolism: an unusual presentation of infective endocarditis. Anadolu Kar- 306. Dreyfus G, Serraf A, Jebara VA, Deloche A, Chauvaud S, Couetil JP, Carpentier A.
diyol Derg 2014;14:204 –205. Valve repair in acute endocarditis. Ann Thorac Surg 1990;49:706 – 711.
281. Eisinger AJ. Atrial fibrillation in bacterial endocarditis. Br Heart J 1971;33:739 –741. 307. Shang E, Forrest GN, Chizmar T, Chim J, Brown JM, Zhan M, Zoarski GH,
282. Gonzalez-Juanatey C, Gonzalez-Gay MA, Llorca J, Crespo F, Garcia-Porrua C, Griffith BP, Gammie JS. Mitral valve infective endocarditis: benefit of early oper-
Corredoira J, Vidan J, Gonzalez-Juanatey JR. Rheumatic manifestations of infective ation and aggressive use of repair. Ann Thorac Surg 2009;87:1728 –1733.
endocarditis in non-addicts. A 12-year study. Medicine (Baltimore) 2001;80:9– 19. 308. David TE, Regesta T, Gavra G, Armstrong S, Maganti MD. Surgical treatment of
paravalvular abscess: long-term results. Eur J Cardiothorac Surg 2007;31:43–48.
283. Pigrau C, Almirante B, Flores X, Falco V, Rodriguez D, Gasser I, Villanueva C,
309. Nataf P, Jault F, Dorent R, Vaissier E, Bors V, Pavie A, Cabrol C, Gandjbakhch I.
Pahissa A. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: inci-
Extra-annular procedures in the surgical management of prosthetic valve endo-
dence, risk factors, and outcome. Am J Med 2005;118:1287.
carditis. Eur Heart J 1995;16(Suppl B):99 –102.
284. Bojalil R, Mazon-Gonzalez B, Carrillo-Cordova JR, Springall R, Amezcua-
310. Vistarini N, d’Alessandro C, Aubert S, Jault F, Acar C, Pavie A, Gandjbakhch I. Sur-
Guerra LM. Frequency and clinical significance of a variety of autoantibodies in
gery for infective endocarditis on mitral annulus calcification. J Heart Valve Dis
patients with definite infective endocarditis. J Clin Rheumatol 2012;18:67– 70.
2007;16:611 –616.
285. Ying CM, Yao DT, Ding HH, Yang CD. Infective endocarditis with antineutrophil
311. Ali M, Iung B, Lansac E, Bruneval P, Acar C. Homograft replacement of the mitral
cytoplasmic antibody: report of 13 cases and literature review. PLoS One 2014;9:
valve: eight-year results. J Thorac Cardiovasc Surg 2004;128:529 –534.
e89777.
312. Kabbani S, Jamil H, Nabhani F, Hamoud A, Katan K, Sabbagh N, Koudsi A,
286. Nunes MC, Gelape CL, Ferrari TC. Profile of infective endocarditis at a tertiary
Kabbani L, Hamed G. Analysis of 92 mitral pulmonary autograft replacement
care center in Brazil during a seven-year period: prognostic factors and in-hospital
(Ross II) operations. J Thorac Cardiovasc Surg 2007;134:902 – 908.
outcome. Int J Infect Dis 2010;14:e394 –e398.
313. David TE. Aortic valve repair for active infective endocarditis. Eur J Cardiothorac
287. Tamura K. Clinical characteristics of infective endocarditis with vertebral osteo-
Surg 2012;42:127 –128.
myelitis. J Infect Chemother 2010;16:260 – 265.
314. Mayer K, Aicher D, Feldner S, Kunihara T, Schafers HJ. Repair versus replacement
288. Koslow M, Kuperstein R, Eshed I, Perelman M, Maor E, Sidi Y. The unique clinical
of the aortic valve in active infective endocarditis. Eur J Cardiothorac Surg 2012;42:
features and outcome of infectious endocarditis and vertebral osteomyelitis co-
122 –127.
infection. Am J Med 2014;127:669.e9 –669.e15.
315. Lopes S, Calvinho P, de Oliveira F, Antunes M. Allograft aortic root replacement in
289. Ojeda J, Lopez-Lopez L, Gonzalez A, Vila LM. Infective endocarditis initially pre-
complex prosthetic endocarditis. Eur J Cardiothorac Surg 2007;32:126 –130.
senting with a dermatomyositis-like syndrome. BMJ Case Rep 2014 Jan 10;2014. pii:
316. Musci M, Weng Y, Hubler M, Amiri A, Pasic M, Kosky S, Stein J, Siniawski H,
bcr2013200865. doi:10.1136/bcr-2013-200865.
Hetzer R. Homograft aortic root replacement in native or prosthetic active infect-
290. Vind SH, Hess S. Possible role of PET/CT in infective endocarditis. J Nucl Cardiol
ive endocarditis: twenty-year single-center experience. J Thorac Cardiovasc Surg
2010;17:516 – 519.
2010;139:665 –673.
291. Ferraris L, Milazzo L, Ricaboni D, Mazzali C, Orlando G, Rizzardini G, Cicardi M, 317. Klieverik LM, Yacoub MH, Edwards S, Bekkers JA, Roos-Hesselink JW,
Raimondi F, Tocalli L, Cialfi A, Vanelli P, Galli M, Antona C, Antinori S. Profile of Kappetein AP, Takkenberg JJ, Bogers AJ. Surgical treatment of active native aortic
infective endocarditis observed from 2. BMC Infect Dis 2013;13:545. valve endocarditis with allografts and mechanical prostheses. Ann Thorac Surg
292. Le V, Gill S. Serious complications after infective endocarditis. Dan Med Bull 2010; 2009;88:1814 – 1821.
57:A4192. 318. Avierinos JF, Thuny F, Chalvignac V, Giorgi R, Tafanelli L, Casalta JP, Raoult D,
293. Tamura K, Arai H, Yoshizaki T. Long-term outcome of active infective endocardi- Mesana T, Collart F, Metras D, Habib G, Riberi A. Surgical treatment of active aor-
tis with renal insufficiency in cardiac surgery. Ann Thorac Cardiovasc Surg 2012;18: tic endocarditis: homografts are not the cornerstone of outcome. Ann Thorac Surg
216 –221. 2007;84:1935 –1942.
294. Conlon PJ, Jefferies F, Krigman HR, Corey GR, Sexton DJ, Abramson MA. Predic- 319. Takkenberg JJ, Klieverik LM, Bekkers JA, Kappetein AP, Roos JW, Eijkemans MJ,
tors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin Ne- Bogers AJ. Allografts for aortic valve or root replacement: insights from an
phrol 1998;49:96 –101. 18-year single-center prospective follow-up study. Eur J Cardiothorac Surg 2007;
295. Majumdar A, Chowdhary S, Ferreira MA, Hammond LA, Howie AJ, Lipkin GW, 31:851 –859.
Littler WA. Renal pathological findings in infective endocarditis. Nephrol Dial Trans- 320. Obadia JF, Henaine R, Bergerot C, Ginon I, Nataf P, Chavanis N, Robin J,
plant 2000;15:1782 – 1787. Andre-Fouet X, Ninet J, Raisky O. Monobloc aorto-mitral homograft or mechan-
296. Colen TW, Gunn M, Cook E, Dubinsky T. Radiologic manifestations of extra- ical valve replacement: a new surgical option for extensive bivalvular endocarditis.
cardiac complications of infective endocarditis. Eur Radiol 2008;18:2433 –2445. J Thorac Cardiovasc Surg 2006;131:243 –245.
ESC Guidelines 3123b
321. Prat A, Fabre OH, Vincentelli A, Doisy V, Shaaban G. Ross operation and mitral 344. Mahesh B, Angelini G, Caputo M, Jin XY, Bryan A. Prosthetic valve endocarditis.
homograft for aortic and tricuspid valve endocarditis. Ann Thorac Surg 1998;65: Ann Thorac Surg 2005;80:1151 –1158.
1450–1452. 345. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, Kapadia S, Lerakis S, Cheema A,
322. Schmidtke C, Dahmen G, Sievers HH. Subcoronary Ross procedure in patients Gutierrez-Ibanes E, Munoz-Garcia A, Pan M, Webb JG, Herrmann H, Kodali S,
with active endocarditis. Ann Thorac Surg 2007;83:36–39. Nombela-Franco L, Tamburino C, Jilaihawi H, Masson JB, Sandoli dB,
323. Aymami M, Revest M, Piau C, Chabanne C, Le Gall F, Lelong B, Verhoye JP, Ferreira MC, Correa LV, Mangione JA, Iung B, Durand E, Vahanian A, Tuzcu M,
Michelet C, Tattevin P, Flecher E. Heart transplantation as salvage treatment of Hayek SS, Angulo-Llanos R, Gomez-Doblas JJ, Castillo JC, Dvir D, Leon MB,
intractable infective endocarditis. Clin Microbiol Infect 2015;21:371.e1 –371.e4. Garcia E, Cobiella J, Vilacosta I, Barbanti M, Makkar R, Barbosa RH, Urena M,
324. Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Dumont E, Pibarot P, Lopez J, San Roman A, Rodes-Cabau J. Infective endocarditis
Cormier B, Prendergast B, Iung B, Bjornstad H, Leport C, Hall RJ, Vahanian A. Re- following transcatheter aortic valve implantation: results from a large multicenter
commendations for the management of patients after heart valve surgery. Eur registry. Circulation 2015;131:1566–1574.
Heart J 26:2463 –2471. 346. Pericas JM, Llopis J, Cervera C, Sacanella E, Falces C, Andrea R, Garcia de la
325. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical Maria C, Ninot S, Vidal B, Almela M, Pare JC, Sabate M, Moreno A, Marco F,
treatment of active infective endocarditis: a continued challenge. J Thorac Cardio- Mestres CA, Miro JM. Infective endocarditis in patients with an implanted trans-
vasc Surg 2007;133:144–149. catheter aortic valve: Clinical characteristics and outcome of a new entity. J Infect

326. Heiro M, Helenius H, Hurme S, Savunen T, Metsarinne K, Engblom E, 2015;70:565 –576.
Nikoskelainen J, Kotilainen P. Long-term outcome of infective endocarditis: a 347. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocar-
study on patients surviving over one year after the initial episode treated in a Finn- ditis: utilization of specific echocardiographic findings. Duke Endocarditis Service.
ish teaching hospital during 25 years. BMC Infect Dis 2008;8:49. Am J Med 1994;96:200 –209.
327. Martinez-Selles M, Munoz P, Estevez A, del Castillo R, Garcia-Fernandez MA, 348. Lamas CC, Eykyn SJ. Suggested modifications to the Duke criteria for the clinical
Rodriguez-Creixems M, Moreno M, Bouza E. Long-term outcome of infective diagnosis of native valve and prosthetic valve endocarditis: analysis of 118 patho-
endocarditis in non-intravenous drug users. Mayo Clin Proc 2008;83:1213 –1217. logically proven cases. Clin Infect Dis 1997;25:713 – 719.
328. Fernandez-Hidalgo N, Almirante B, Tornos P, Gonzalez-Alujas MT, Planes AM, 349. Perez-Vazquez A, Farinas MC, Garcia-Palomo JD, Bernal JM, Revuelta JM,
Galinanes M, Pahissa A. Immediate and long-term outcome of left-sided infective Gonzalez-Macias J. Evaluation of the Duke criteria in 93 episodes of prosthetic valve
endocarditis. A 12-year prospective study from a contemporary cohort in a refer- endocarditis: could sensitivity be improved? Arch Intern Med 2000;160:1185–1191.
ral hospital. Clin Microbiol Infect 2012;18:E522 – E530. 350. Tornos P, Almirante B, Olona M, Permanyer G, Gonzalez T, Carballo J, Pahissa A,
329. Ternhag A, Cederstrom A, Torner A, Westling K. A nationwide cohort study of Soler-Soler J. Clinical outcome and long-term prognosis of late prosthetic valve
mortality risk and long-term prognosis in infective endocarditis in Sweden. PLoS endocarditis: a 20-year experience. Clin Infect Dis 1997;24:381 – 386.
One 2013;8:e67519. 351. Akowuah EF, Davies W, Oliver S, Stephens J, Riaz I, Zadik P, Cooper G. Prosthetic
330. Mokhles MM, Ciampichetti I, Head SJ, Takkenberg JJ, Bogers AJ. Survival of surgi- valve endocarditis: early and late outcome following medical or surgical treat-
cally treated infective endocarditis: a comparison with the general Dutch popula- ment. Heart 2003;89:269 –272.
tion. Ann Thorac Surg 2011;91:1407 – 1412. 352. John MD, Hibberd PL, Karchmer AW, Sleeper LA, Calderwood SB. Staphylococcus
331. Fedoruk LM, Jamieson WR, Ling H, MacNab JS, Germann E, Karim SS, aureus prosthetic valve endocarditis: optimal management and risk factors for
Lichtenstein SV. Predictors of recurrence and reoperation for prosthetic valve death. Clin Infect Dis 1998;26:1302 –1309.
endocarditis after valve replacement surgery for native valve endocarditis. 353. Wolff M, Witchitz S, Chastang C, Regnier B, Vachon F. Prosthetic valve endocar-
J Thorac Cardiovasc Surg 2009;137:326 –333. ditis in the ICU. Prognostic factors of overall survival in a series of 122 cases and con-
332. Alagna L, Park LP, Nicholson BP, Keiger AJ, Strahilevitz J, Morris A, Wray D, sequences for treatment decision. Chest 1995;108:688–694.
Gordon D, Delahaye F, Edathodu J, Miro JM, Fernandez-Hidalgo N, 354. Gordon SM, Serkey JM, Longworth DL, Lytle BW, Cosgrove DM III. Early onset
Nacinovich FM, Shahid R, Woods CW, Joyce MJ, Sexton DJ, Chu VH. Repeat prosthetic valve endocarditis: the Cleveland Clinic experience 1992 –1997. Ann
endocarditis: analysis of risk factors based on the International Collaboration Thorac Surg 2000;69:1388 –1392.
on Endocarditis – Prospective Cohort Study. Clin Microbiol Infect 2014;20: 355. Sohail MR, Martin KR, Wilson WR, Baddour LM, Harmsen WS, Steckelberg JM.
566 – 575. Medical versus surgical management of Staphylococcus aureus prosthetic valve
333. Kaiser SP, Melby SJ, Zierer A, Schuessler RB, Moon MR, Moazami N, Pasque MK, endocarditis. Am J Med 2006;119:147 –154.
Huddleston C, Damiano RJ Jr, Lawton JS. Long-term outcomes in valve replace- 356. Wang A, Pappas P, Anstrom KJ, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM,
ment surgery for infective endocarditis. Ann Thorac Surg 2007;83:30 –35. Corey GR, Olaison L, Stafford JA, Mestres CA, Cabell CH. The use and effect
334. Heiro M, Helenius H, Makila S, Hohenthal U, Savunen T, Engblom E, of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis
Nikoskelainen J, Kotilainen P. Infective endocarditis in a Finnish teaching hospital: of a multicenter, international cohort. Am Heart J 2005;150:1086 –1091.
a study on 326 episodes treated during 1980 –2004. Heart 2006;92:1457 –1462. 357. Truninger K, AttenhoferJost CH, Seifert B, Vogt PR, Follath F, Schaffner A, Jenni R.
335. Sabik JF, Lytle BW, Blackstone EH, Marullo AG, Pettersson GB, Cosgrove DM. Long term follow up of prosthetic valve endocarditis: what characteristics identify
Aortic root replacement with cryopreserved allograft for prosthetic valve endo- patients who were treated successfully with antibiotics alone? Heart 1999;82:
carditis. Ann Thorac Surg 2002;74:650 –659. 714 –720.
336. Hagl C, Galla JD, Lansman SL, Fink D, Bodian CA, Spielvogel D, Griepp RB. Re- 358. Hill EE, Herregods MC, Vanderschueren S, Claus P, Peetermans WE, Herijgers P.
placing the ascending aorta and aortic valve for acute prosthetic valve endocardi- Management of prosthetic valve infective endocarditis. Am J Cardiol 2008;101:
tis: is using prosthetic material contraindicated? Ann Thorac Surg 2002;74: 1174 –1178.
S1781 –S1785. 359. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD,
337. Chambers JB, Ray S, Prendergast B, Taggart D, Westaby S, Grothier L, Arden C, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM,
Wilson J, Campbell B, Sandoe J, Gohlke-Barwolf C, Mestres CA, Rosenhek R, Shah PM, Shanewise JS. 2008 focused update incorporated into the ACC/AHA
Otto C. Specialist valve clinics: recommendations from the British Heart Valve So- 2006 guidelines for the management of patients with valvular heart disease: a re-
ciety working group on improving quality in the delivery of care for patients with port of the American College of Cardiology/American Heart Association Task
heart valve disease. Heart 2013;99:1714 –1716. Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines
338. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996; for the management of patients with valvular heart disease). Endorsed by the So-
335:407 –416. ciety of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiog-
339. Moreillon P, Que YA. Infective endocarditis. Lancet 2004;363:139 – 149. raphy and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol
340. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Pare C, Almirante B, 2008;52:e523–e661.
Munoz P, Rizzi M, Naber C, Logar M, Tattevin P, Iarussi DL, Selton-Suty C, 360. Rundstrom H, Kennergren C, Andersson R, Alestig K, Hogevik H. Pacemaker
Jones SB, Casabe J, Morris A, Corey GR, Cabell CH. Contemporary clinical profile endocarditis during 18 years in Goteborg. Scand J Infect Dis 2004;36:674 –679.
and outcome of prosthetic valve endocarditis. JAMA 2007;297:1354 – 1361. 361. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, Pavri BB, Kurtz SM.
341. Habib G, Thuny F, Avierinos JF. Prosthetic valve endocarditis: current approach 16-year trends in the infection burden for pacemakers and implantable
and therapeutic options. Prog Cardiovasc Dis 2008;50:274 – 281. cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol
342. Lopez J, Revilla A, Vilacosta I, Villacorta E, Gonzalez-Juanatey C, Gomez I, 2011;58:1001 –1006.
Rollan MJ, San Roman JA. Definition, clinical profile, microbiological spectrum, 362. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB,
and prognostic factors of early-onset prosthetic valve endocarditis. Eur Heart J Masoudi FA, Okum EJ, Wilson WR, Beerman LB, Bolger AF, Estes NA III,
2007;28:760 –765. Gewitz M, Newburger JW, Schron EB, Taubert KA. Update on cardiovascular im-
343. Piper C, Korfer R, Horstkotte D. Prosthetic valve endocarditis. Heart 2001;85: plantable electronic device infections and their management: a scientific state-
590– 593. ment from the American Heart Association. Circulation 2010;121:458 –477.
3123c ESC Guidelines
363. Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferrieri P, Gerber MA, 386. Bongiorni MG, Di Cori A, Soldati E, Zucchelli G, Arena G, Segreti L, De Lucia R,
Gewitz MH, Jacobs AK, Levison ME, Newburger JW, Pallasch TJ, Wilson WR, Marzilli M. Intracardiac echocardiography in patients with pacing and defibrillating
Baltimore RS, Falace DA, Shulman ST, Tani LY, Taubert KA. Nonvalvular cardio- leads: a feasibility study. Echocardiography 2008;25:632–638.
vascular device-related infections. Circulation 2003;108:2015 –2031. 387. Narducci ML, Pelargonio G, Russo E, Marinaccio L, Di Monaco A, Perna F,
364. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, Bencardino G, Casella M, Di Biase L, Santangeli P, Palmieri R, Lauria C, Al
Wilson WR, Steckelberg JM, Baddour LM. Permanent pacemaker and implantable Mohani G, Di Clemente F, Tondo C, Pennestri F, Ierardi C, Rebuzzi AG,
cardioverter defibrillator infection: a population-based study. Arch Intern Med Crea F, Bellocci F, Natale A, Dello RA. Usefulness of intracardiac echocardiog-
2007;167:669–675. raphy for the diagnosis of cardiovascular implantable electronic device-related
365. Nof E, Epstein LM. Complications of cardiac implants: handling device infections. endocarditis. J Am Coll Cardiol 2013;61:1398 –1405.
Eur Heart J 2013;34:229 –236. 388. Dalal A, Asirvatham SJ, Chandrasekaran K, Seward JB, Tajik AJ. Intracardiac echo-
366. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, cardiography in the detection of pacemaker lead endocarditis. J Am Soc Echocar-
Steckelberg JM, Stoner S, Baddour LM. Management and outcome of permanent diogr 2002;15:1027 –1028.
pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 389. Erba PA, Sollini M, Conti U, Bandera F, Tascini C, De Tommasi SM, Zucchelli G,
2007;49:1851 –1859. Doria R, Menichetti F, Bongiorni MG, Lazzeri E, Mariani G. Radiolabeled WBC
367. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, Rey JL, Lande G, scintigraphy in the diagnostic workup of patients with suspected device-related

Lazarus A, Victor J, Barnay C, Grandbastien B, Kacet S. Risk factors related to in- infections. JACC Cardiovasc Imaging 2013;6:1075 –1086.
fections of implanted pacemakers and cardioverter-defibrillators: results of a large 390. Ploux S, Riviere A, Amraoui S, Whinnett Z, Barandon L, Lafitte S, Ritter P,
prospective study. Circulation 2007;116:1349 –1355. Papaioannou G, Clementy J, Jais P, Bordenave L, Haissaguerre M, Bordachar P.
368. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Positron emission tomography in patients with suspected pacing system infec-
Steckelberg JM, Stoner SM, Baddour LM. Risk factor analysis of permanent pace- tions may play a critical role in difficult cases. Heart Rhythm 2011;8:1478 –1481.
maker infection. Clin Infect Dis 2007;45:166 –173. 391. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR,
369. Bloom H, Heeke B, Leon A, Mera F, Delurgio D, Beshai J, Langberg J. Renal insuf- Steckelberg JM, Jenkins SM, Baddour LM. Infective endocarditis complicating per-
ficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing manent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin
Clin Electrophysiol 2006;29:142–145. Proc 2008;83:46 –53.
370. Lekkerkerker JC, van Nieuwkoop C, Trines SA, van der Bom JG, Bernards A, van 392. Jan E, Camou F, Texier-Maugein J, Whinnett Z, Caubet O, Ploux S, Pellegrin JL,
de Velde ET, Bootsma M, Zeppenfeld K, Jukema JW, Borleffs JW, Schalij MJ, van Ritter P, Metayer PL, Roudaut R, Haissaguerre M, Bordachar P. Microbiologic
Erven L. Risk factors and time delay associated with cardiac device infections: Lei- characteristics and in vitro susceptibility to antimicrobials in a large population
den device registry. Heart 2009;95:715 –720. of patients with cardiovascular implantable electronic device infection.
371. Johansen J, Nielsen J, Arnsbo P, Moller M, Pedersen A, Mortensen P. Higher inci- J Cardiovasc Electrophysiol 2012;23:375 – 381.
dence of pacemaker infection after replacement than after implantation: experi- 393. Tumbarello M, Pelargonio G, Trecarichi EM, Narducci ML, Fiori B, Bellocci F,
ences from 36,076 consecutive patients. 2006. p. 102 –103. Spanu T. High-dose daptomycin for cardiac implantable electronic device-related
372. Gould PA, Krahn AD. Complications associated with implantable cardioverter- infective endocarditis caused by staphylococcal small-colony variants. Clin Infect
defibrillator replacement in response to device advisories. JAMA 2006;295: Dis 2012;54:1516 –1517.
1907 –1911. 394. Tascini C, Bongiorni MG, Di Cori A, Di Paolo A, Polidori M, Tagliaferri E,
373. Da Costa A, Kirkorian G, Cucherat M, Delahaye F, Chevalier P, Cerisier A, Isaaz K, Fondelli S, Soldati E, Ciullo I, Leonildi A, Danesi R, Coluccia G, Menichetti F. Car-
Touboul P. Antibiotic prophylaxis for permanent pacemaker implantation: a diovascular implantable electronic device endocarditis treated with daptomycin
meta-analysis. Circulation 1998;97:1796 – 1801. with or without transvenous removal. Heart Lung 2012;41:e24 –e30.
374. Al Khatib SM, Lucas FL, Jollis JG, Malenka DJ, Wennberg DE. The relation between 395. Durante-Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D,
patients’ outcomes and the volume of cardioverter-defibrillator implantation pro- Agrusta F, Caprioli R, Albisinni R, Ragone E, Utili R. High-dose daptomycin for car-
cedures performed by physicians treating Medicare beneficiaries. J Am Coll Cardiol diac implantable electronic device-related infective endocarditis. Clin Infect Dis
2005;46:1536 – 1540. 2012;54:347 –354.
375. Villamil CI, Rodriguez FM, Van den Eynde CA, Jose V, Canedo RC. Permanent 396. Wilkoff BL, Love CJ, Byrd CL, Bongiorni MG, Carrillo RG, Crossley GH III,
transvenous pacemaker infections: An analysis of 59 cases. Eur J Intern Med Epstein LM, Friedman RA, Kennergren CE, Mitkowski P, Schaerf RH,
2007;18:484–488. Wazni OM. Transvenous lead extraction: Heart Rhythm Society expert consen-
376. Bongiorni MG, Tascini C, Tagliaferri E, Di Cori A, Soldati E, Leonildi A, sus on facilities, training, indications, and patient management: this document was
Zucchelli G, Ciullo I, Menichetti F. Microbiology of cardiac implantable electronic endorsed by the American Heart Association (AHA). Heart Rhythm 2009;6:
device infections. Europace 2012;14:1334 –1339. 1085 –1104.
377. Tarakji KG, Chan EJ, Cantillon DJ, Doonan AL, Hu T, Schmitt S, Fraser TG, Kim A, 397. Pichlmaier M, Knigina L, Kutschka I, Bara C, Oswald H, Klein G, Bisdas T,
Gordon SM, Wilkoff BL. Cardiac implantable electronic device infections: presen- Haverich A. Complete removal as a routine treatment for any cardiovascular im-
tation, management, and patient outcomes. Heart Rhythm 2010;7:1043 –1047. plantable electronic device-associated infection. J Thorac Cardiovasc Surg 2011;
378. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative 142:1482 – 1490.
staphylococci. Antimicrob Agents Chemother 1994;38:2231 – 2237. 398. Grammes JA, Schulze CM, Al Bataineh M, Yesenosky GA, Saari CS, Vrabel MJ,
379. Abraham J, Mansour C, Veledar E, Khan B, Lerakis S. Staphylococcus aureus bacter- Horrow J, Chowdhury M, Fontaine JM, Kutalek SP. Percutaneous pacemaker
emia and endocarditis: the Grady Memorial Hospital experience with methicillin- and implantable cardioverter-defibrillator lead extraction in 100 patients with in-
sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J 2004; tracardiac vegetations defined by transesophageal echocardiogram. J Am Coll Car-
147:536 –539. diol 2010;55:886 –894.
380. del Rio A, Anguera I, Miro JM, Mont L, Fowler VG Jr, Azqueta M, Mestres CA. Sur- 399. Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead ex-
gical treatment of pacemaker and defibrillator lead endocarditis: the impact of traction. Circ Arrhythm Electrophysiol 2012;5:252 –257.
electrode lead extraction on outcome. Chest 2003;124:1451 –1459. 400. Di Cori A, Bongiorni MG, Zucchelli G, Segreti L, Viani S, Paperini L, Soldati E.
381. Cacoub P, Leprince P, Nataf P, Hausfater P, Dorent R, Wechsler B, Bors V, Pavie A, Transvenous extraction performance of expanded polytetrafluoroethylene cov-
Piette JC, Gandjbakhch I. Pacemaker infective endocarditis. Am J Cardiol 1998;82: ered ICD leads in comparison to traditional ICD leads in humans. Pacing Clin Elec-
480 –484. trophysiol 2010;33:1376 –1381.
382. Klug D, Lacroix D, Savoye C, Goullard L, Grandmougin D, Hennequin JL, Kacet S, 401. Di Cori A, Bongiorni MG, Zucchelli G, Segreti L, Viani S, De Lucia R, Paperini L,
Lekieffre J. Systemic infection related to endocarditis on pacemaker leads: clinical Soldati E. Large, single-center experience in transvenous coronary sinus lead ex-
presentation and management. Circulation 1997;95:2098 –2107. traction: procedural outcomes and predictors for mechanical dilatation. Pacing
383. Vilacosta I, Sarria C, San Roman JA, Jimenez J, Castillo JA, Iturralde E, Rollan MJ, Clin Electrophysiol 2012;35:215 –222.
Martinez EL. Usefulness of transesophageal echocardiography for diagnosis of in- 402. Maytin M, Carrillo RG, Baltodano P, Schaerf RH, Bongiorni MG, Di Cori A,
fected transvenous permanent pacemakers. Circulation 1994;89:2684 –2687. Curnis A, Cooper JM, Kennergren C, Epstein LM. Multicenter experience with
384. Victor F, de Place C, Camus C, Le Breton H, Leclercq C, Pavin D, Mabo P, transvenous lead extraction of active fixation coronary sinus leads. Pacing Clin
Daubert C. Pacemaker lead infection: echocardiographic features, management, Electrophysiol 2012;35:641 –647.
and outcome. Heart 1999;81:82 –87. 403. Deharo JC, Bongiorni MG, Rozkovec A, Bracke F, Defaye P, Fernandez-Lozano I,
385. Golzio PG, Fanelli AL, Vinci M, Pelissero E, Morello M, Grosso MW, Gaita F. Lead Golzio PG, Hansky B, Kennergren C, Manolis AS, Mitkowski P, Platou ES. Path-
vegetations in patients with local and systemic cardiac device infections: preva- ways for training and accreditation for transvenous lead extraction: a European
lence, risk factors, and therapeutic effects. Europace 2013;15:89– 100. Heart Rhythm Association position paper. Europace 2012;14:124 – 134.
ESC Guidelines 3123d
404. Meier-Ewert HK, Gray ME, John RM. Endocardial pacemaker or defibrillator leads patterns of presentation and long-term outcomes of surgical treatment. J Heart
with infected vegetations: a single-center experience and consequences of trans- Valve Dis 2006;15:125 –131.
venous extraction. Am Heart J 2003;146:339 –344. 426. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic
405. Ruttmann E, Hangler HB, Kilo J, Hofer D, Muller LC, Hintringer F, Muller S, features in 102 episodes. Ann Intern Med 1992;117:560 –566.
Laufer G, Antretter H. Transvenous pacemaker lead removal is safe and effective 427. Moss R, Munt B. Injection drug use and right sided endocarditis. Heart 2003;89:
even in large vegetations: an analysis of 53 cases of pacemaker lead endocarditis. 577 –581.
Pacing Clin Electrophysiol 2006;29:231 –236. 428. Gottardi R, Bialy J, Devyatko E, Tschernich H, Czerny M, Wolner E,
406. Gaynor SL, Zierer A, Lawton JS, Gleva MJ, Damiano RJ Jr., Moon MR. Laser assist- Seitelberger R. Midterm follow-up of tricuspid valve reconstruction due to active
ance for extraction of chronically implanted endocardial leads: infectious versus infective endocarditis. Ann Thorac Surg 2007;84:1943 –1948.
noninfectious indications. Pacing Clin Electrophysiol 2006;29:1352 –1358. 429. Gaca JG, Sheng S, Daneshmand M, Rankin JS, Williams ML, O’Brien SM,
407. Braun MU, Rauwolf T, Bock M, Kappert U, Boscheri A, Schnabel A, Strasser RH. Gammie JS. Current outcomes for tricuspid valve infective endocarditis surgery
Percutaneous lead implantation connected to an external device in stimulation- in North America. Ann Thorac Surg 2013;96:1374 –1381.
dependent patients with systemic infection—a prospective and controlled study. 430. San Roman JA, Vilacosta I, Lopez J, Revilla A, Arnold R, Sevilla T, Rollan MJ. Role of
Pacing Clin Electrophysiol 2006;29:875 –879. transthoracic and transesophageal echocardiography in right-sided endocarditis:
408. Kornberger A, Schmid E, Kalender G, Stock UA, Doernberger V, Khalil M, Lisy M. one echocardiographic modality does not fit all. J Am Soc Echocardiogr 2012;25:

Bridge to recovery or permanent system implantation: an eight-year single-center 807 –814.
experience in transvenous semipermanent pacing. Pacing Clin Electrophysiol 2013; 431. San Roman JA, Vilacosta I, Zamorano JL, Almeria C, Sanchez-Harguindey L. Trans-
36:1096 –1103. esophageal echocardiography in right-sided endocarditis. J Am Coll Cardiol 1993;
409. Kawata H, Pretorius V, Phan H, Mulpuru S, Gadiyaram V, Patel J, Steltzner D, 21:1226 – 1230.
Krummen D, Feld G, Birgersdotter-Green U. Utility and safety of temporary pa- 432. Winslow T, Foster E, Adams JR, Schiller NB. Pulmonary valve endocarditis: im-
cing using active fixation leads and externalized re-usable permanent pacemakers proved diagnosis with biplane transesophageal echocardiography. J Am Soc Echo-
after lead extraction. Europace 2013;15:1287 –1291. cardiogr 1992;5:206 –210.
410. Pecha S, Aydin MA, Yildirim Y, Sill B, Reiter B, Wilke I, Reichenspurner H, 433. Botsford KB, Weinstein RA, Nathan CR, Kabins SA. Selective survival in pentazo-
Treede H. Transcutaneous lead implantation connected to an externalized pace- cine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug ad-
maker in patients with implantable cardiac defibrillator/pacemaker infection and dicts. J Infect Dis 1985;151:209 –216.
pacemaker dependency. Europace 2013;15:1205 – 1209. 434. Martin-Davila P, Navas E, Fortun J, Moya JL, Cobo J, Pintado V, Quereda C,
411. Mourvillier B, Trouillet JL, Timsit JF, Baudot J, Chastre J, Regnier B, Gibert C, Jimenez-Mena M, Moreno S. Analysis of mortality and risk factors associated
Wolff M. Infective endocarditis in the intensive care unit: clinical spectrum and with native valve endocarditis in drug users: the importance of vegetation size.
prognostic factors in 228 consecutive patients. Intensive Care Med 2004;30: Am Heart J 2005;150:1099 – 1106.
2046 –2052. 435. Bisbe J, Miro JM, Latorre X, Moreno A, Mallolas J, Gatell JM, de la Bellacasa JP,
412. Sonneville R, Mirabel M, Hajage D, Tubach F, Vignon P, Perez P, Lavoue S, Soriano E. Disseminated candidiasis in addicts who use brown heroin: report of
Kouatchet A, Pajot O, Mekontso DA, Tonnelier JM, Bollaert PE, Frat JP, 83 cases and review. Clin Infect Dis 1992;15:910 –923.
Navellou JC, Hyvernat H, Hssain AA, Tabah A, Trouillet JL, Wolff M. Neurologic 436. Ribera E, Gomez-Jimenez J, Cortes E, del Valle O, Planes A, Gonzalez-Alujas T,
complications and outcomes of infective endocarditis in critically ill patients: the Almirante B, Ocana I, Pahissa A. Effectiveness of cloxacillin with and without gen-
ENDOcardite en REAnimation prospective multicenter study. Crit Care Med tamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A
2011;39:1474 –1481. randomized, controlled trial. Ann Intern Med 1996;125:969 – 974.
413. Fernandez Guerrero ML, Alvarez B, Manzarbeitia F, Renedo G. Infective endocar- 437. Fortun J, Perez-Molina JA, Anon MT, Martinez-Beltran J, Loza E, Guerrero A.
ditis at autopsy: a review of pathologic manifestations and clinical correlates. Medi- Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimi-
cine (Baltimore) 2012;91:152 –164. crob Agents Chemother 1995;39:525 – 528.
414. Saydain G, Singh J, Dalal B, Yoo W, Levine DP. Outcome of patients with injection 438. Pulvirenti JJ, Kerns E, Benson C, Lisowski J, Demarais P, Weinstein RA. Infective
drug use-associated endocarditis admitted to an intensive care unit. J Crit Care endocarditis in injection drug users: importance of human immunodeficiency
2010;25:248–253. virus serostatus and degree of immunosuppression. Clin Infect Dis 1996;22:40–45.
415. McDonald JR. Acute infective endocarditis. Infect Dis Clin North Am 2009;23: 439. Al Omari A, Cameron DW, Lee C, Corrales-Medina VF. Oral antibiotic therapy
643– 664. for the treatment of infective endocarditis: a systematic review. BMC Infect Dis
416. Karth G, Koreny M, Binder T, Knapp S, Zauner C, Valentin A, Honninger R, 2014;14:140.
Heinz G, Siostrzonek P. Complicated infective endocarditis necessitating ICU ad- 440. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr.,
mission: clinical course and prognosis. Crit Care 2002;6:149 –154. Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vanco-
417. Glockner A, Cornely OA. [Invasive candidiasis in non-neutropenic adults: mycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin
guideline-based management in the intensive care unit]. Anaesthetist 2013;62: Microbiol 2004;42:2398 –2402.
1003 –1009. 441. Akinosoglou K, Apostolakis E, Koutsogiannis N, Leivaditis V, Gogos CA. Right-
418. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, sided infective endocarditis: surgical management. Eur J Cardiothorac Surg 2012;
Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, 42:470 –479.
Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, 442. Moller JH, Anderson RC. 1,000 consecutive children with a cardiac malformation
Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Cam- with 26- to 37-year follow-up. Am J Cardiol 1992;70:661 – 667.
paign: international guidelines for management of severe sepsis and septic shock, 443. Niwa K, Nakazawa M, Tateno S, Yoshinaga M, Terai M. Infective endocarditis in
2012. Intensive Care Med 2013;39:165 –228. congenital heart disease: Japanese national collaboration study. Heart 2005;91:
419. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of 795 –800.
proposed mechanisms of pathogenesis. Clin Infect Dis 2000;30:374 –379. 444. Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, Veen G,
420. Wilson LE, Thomas DL, Astemborski J, Freedman TL, Vlahov D. Prospective study Stappers JL, Grobbee DE, Mulder BJ. Turning 18 with congenital heart disease:
of infective endocarditis among injection drug users. J Infect Dis 2002;185: prediction of infective endocarditis based on a large population. Eur Heart J
1761–1766. 2011;32:1926 –1934.
421. Gebo KA, Burkey MD, Lucas GM, Moore RD, Wilson LE. Incidence of, risk factors 445. Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.
for, clinical presentation, and 1-year outcomes of infective endocarditis in an ur- Infective endocarditis in children with congenital heart disease: cumulative inci-
ban HIV cohort. J Acquir Immune Defic Syndr 2006;43:426–432. dence and predictors. Circulation 2013;128:1412 –1419.
422. Cooper HL, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Na- 446. Michel PL, Acar J. Native cardiac disease predisposing to infective endocarditis. Eur
tionwide increase in the number of hospitalizations for illicit injection drug Heart J 1995;16(Suppl B):2 –6.
use-related infective endocarditis. Clin Infect Dis 2007;45:1200 –1203. 447. De Gevigney G, Pop C, Delahaye JP. The risk of infective endocarditis after cardiac
423. Miro JM, del Rio A, Mestres CA. Infective endocarditis and cardiac surgery in intra- surgical and interventional procedures. Eur Heart J 1995;16(Suppl B):7 –14.
venous drug abusers and HIV-1 infected patients. Cardiol Clin 2003;21:167–184. 448. Roder BL, Wandall DA, Espersen F, Frimodt-Moller N, Skinhoj P, Rosdahl VT.
424. Sousa C, Botelho C, Rodrigues D, Azeredo J, Oliveira R. Infective endocarditis in Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260
intravenous drug abusers: an update. Eur J Clin Microbiol Infect Dis 2012;31: bacteremic cases in nondrug addicts. Am J Med 1997;102:379 –386.
2905–2910. 449. Baek JE, Park SJ, Woo SB, Choi JY, Jung JW, Kim NK. Changes in patient character-
425. Carozza A, De Santo LS, Romano G, Della CA, Ursomando F, Scardone M, istics of infective endocarditis with congenital heart disease: 25 years experience
Caianiello G, Cotrufo M. Infective endocarditis in intravenous drug abusers: in a single institution. Korean Circ J 2014;44:37 –41.
3123e ESC Guidelines
450. Webb R, Voss L, Roberts S, Hornung T, Rumball E, Lennon D. Infective endocar- 466. Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective
ditis in New Zealand children 1994 –2012. Pediatr Infect Dis J 2014;33:437–442. endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant ther-
451. Di Filippo S, Delahaye F, Semiond B, Celard M, Henaine R, Ninet J, Sassolas F, apy. Arch Intern Med 1999;159:473 –475.
Bozio A. Current patterns of infective endocarditis in congenital heart disease. 467. Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison L.
Heart 2006;92:1490 –1495. Warfarin therapy and incidence of cerebrovascular complications in left-sided na-
452. Li W, Somerville J. Infective endocarditis in the grown-up congenital heart tive valve endocarditis. Eur J Clin Microbiol Infect Dis 2011;30:151 –157.
(GUCH) population. Eur Heart J 1998;19:166 –173. 468. Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Sullam PM, Filler SG,
453. Gabriel HM, Heger M, Innerhofer P, Zehetgruber M, Mundigler G, Wimmer M, Bayer AS. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous
Maurer G, Baumgartner H. Long-term outcome of patients with ventricular septal bacterial dissemination, and frequency of embolic events in experimental
defect considered not to require surgical closure during childhood. J Am Coll Car- Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects.
diol 2002;39:1066 –1071. Circulation 1999;99:2791 –2797.
454. Yoshinaga M, Niwa K, Niwa A, Ishiwada N, Takahashi H, Echigo S, Nakazawa M. 469. Habib A, Irfan M, Baddour LM, Le KY, Anavekar NS, Lohse CM, Friedman PA,
Risk factors for in-hospital mortality during infective endocarditis in patients with
Hayes DL, Wilson WR, Steckelberg JM, Sohail MR. Impact of prior aspirin therapy
congenital heart disease. Am J Cardiol 2008;101:114 –118.
on clinical manifestations of cardiovascular implantable electronic device infec-
455. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del
tions. Europace 2013;15:227–235.

Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ,
470. Chan KL, Tam J, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek M, Robinson T,
Miner PD, Radford MJ, Walsh EP, Webb GD, Smith SC Jr, Jacobs AK,
Williams K. Effect of long-term aspirin use on embolic events in infective endocar-
Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM,
ditis. Clin Infect Dis 2008;46:37 –41.
Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA,
Page RL, Riegel B, Tarkington LG, Yancy CW. ACC/AHA 2008 guidelines for the 471. Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison L.
management of adults with congenital heart disease: a report of the American Col- The relationship between cerebrovascular complications and previously estab-
lege of Cardiology/American Heart Association Task Force on Practice Guidelines lished use of antiplatelet therapy in left-sided infective endocarditis. Scand J Infect
(Writing Committee to Develop Guidelines on the Management of Adults With Dis 2011;43:899 –904.
Congenital Heart Disease). Developed in Collaboration with the American Society 472. Silbiger JJ. The valvulopathy of non-bacterial thrombotic endocarditis. J Heart Valve
of Echocardiography, Heart Rhythm Society, International Society for Adult Con- Dis 2009;18:159 –166.
genital Heart Disease, Society for Cardiovascular Angiography and Interventions, 473. Zamorano J, Sanz J, Almeria C, Rodrigo JL, Samedi M, Herrera D, Aubele A,
and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;52:e143–e263. Mataix L, Serra V, Moreno R, Sanchez-Harguindei L. Differences between endo-
456. Moons P, De Volder E, Budts W, De Geest S, Elen J, Waeytens K, Gewillig M. carditis with true negative blood cultures and those with previous antibiotic treat-
What do adult patients with congenital heart disease know about their disease, ment. J Heart Valve Dis 2003;12:256 –260.
treatment, and prevention of complications? A call for structured patient educa- 474. Mazokopakis EE, Syros PK, Starakis IK. Nonbacterial thrombotic endocarditis
tion. Heart 2001;86:74–80. (marantic endocarditis) in cancer patients. Cardiovasc Hematol Disord Drug Targets
457. Gersony WM, Hayes CJ, Driscoll DJ, Keane JF, Kidd L, O’Fallon WM, Pieroni DR, 2010;10:84– 86.
Wolfe RR, Weidman WH. Bacterial endocarditis in patients with aortic stenosis, 475. Dutta T, Karas MG, Segal AZ, Kizer JR. Yield of transesophageal echocardiography
pulmonary stenosis, or ventricular septal defect. Circulation 1993;87:I121 –I126. for nonbacterial thrombotic endocarditis and other cardiac sources of embolism
458. Thilen U, Astrom-Olsson K. Does the risk of infective endarteritis justify routine in cancer patients with cerebral ischemia. Am J Cardiol 2006;97:894 –898.
patent ductus arteriosus closure? Eur Heart J 1997;18:503 –506. 476. Zamorano J, de Isla LP, Moura L, Almeria C, Rodrigo JL, Aubele A, Macaya C. Im-
459. Foley M. Cardiac disease. In: Dildy G, Belfort M, Saade G, Phelan J, Hankins G, pact of echocardiography in the short- and long-term prognosis of patients with
Clark S, eds. Critical care obstetrics, 4th ed. Oxford: Blackwell, 2004:252 –274. infective endocarditis and negative blood cultures. J Heart Valve Dis 2004;13:
460. Montoya ME, Karnath BM, Ahmad M. Endocarditis during pregnancy. South Med J 997 –1004.
2003;96:1156 – 1157. 477. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014;
461. Roos-Hesselink JW, Ruys TP, Stein JI, Thilen U, Webb GD, Niwa K, Kaemmerer H,
384:1878 –1888.
Baumgartner H, Budts W, Maggioni AP, Tavazzi L, Taha N, Johnson MR, Hall R. Out-
478. Giles I, Khamashta M, D’Cruz D, Cohen H. A new dawn of anticoagulation for pa-
come of pregnancy in patients with structural or ischaemic heart disease: results of a
tients with antiphospholipid syndrome? Lupus 2012;21:1263 – 1265.
registry of the European Society of Cardiology. Eur Heart J 2013;34:657–665.
479. Thomsen RW, Farkas DK, Friis S, Svaerke C, Ording AG, Norgaard M,
462. Morissens M, Viart P, Tecco L, Wauthy P, Michiels S, Dessy H, Malekzadeh MS,
Sorensen HT. Endocarditis and risk of cancer: a Danish nationwide cohort study.
Verbeet T, Castro RJ. Does congenital heart disease severely jeopardise family
Am J Med 2013;126:58 –67.
life and pregnancies? Obstetrical history of women with congenital heart disease
in a single tertiary centre. Cardiol Young 2013;23:41–46. 480. Gupta A, Madani R, Mukhtar H. Streptococcus bovis endocarditis, a silent sign for
463. Aggarwal N, Suri V, Kaur H, Chopra S, Rohila M, Vijayvergiya R. Retrospective ana- colonic tumour. Colorectal Dis 2010;12:164 –171.
lysis of outcome of pregnancy in women with congenital heart disease: single- 481. Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Strepto-
centre experience from North India. Aust N Z J Obstet Gynaecol 2009;49:376 –381. coccus gallolyticus infection among colorectal cancer patients: systematic review
464. Mazibuko B, Ramnarain H, Moodley J. An audit of pregnant women with prosthet- and meta-analysis. Clin Infect Dis 2011;53:870 – 878.
ic heart valves at a tertiary hospital in South Africa: a five-year experience. Cardi- 482. Ferrari A, Botrugno I, Bombelli E, Dominioni T, Cavazzi E, Dionigi P. Colonoscopy
ovasc J Afr 2012;23:216 –221. is mandatory after Streptococcus bovis endocarditis: a lesson still not learned. Case
465. Ong E, Mechtouff L, Bernard E, Cho TH, Diallo LL, Nighoghossian N, Derex L. report. World J Surg Oncol 2008;6:49.
Thrombolysis for stroke caused by infective endocarditis: an illustrative case 483. Darjee R, Gibb AP. Serological investigation into the association between Strepto-
and review of the literature. J Neurol 2013;260:1339 – 1342. coccus bovis and colonic cancer. J Clin Pathol 1993;46:1116 – 1119.

Ie Esc Guideline

Uploaded by

Document Informationclick to expand document information

Copyright:

Available Formats

Ie Esc Guideline

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ie Esc Guideline

Uploaded by

Copyright:

Available Formats

European Heart Journal (2015) 36, 3075–3123 ESC GUIDELINES

2015 ESC Guidelines for the management

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Online publish-ahead-of-print 29 August 2015

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

management options were weighed and graded according to prede-

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Table 1 Classes of recommendations

Classes of Suggested wording to use

Class I Evidence and/or general Is recommended/is

Class II Conflicting evidence and/or a

Class IIa Weight of evidence/opinion is in Should be considered

Class IIb Usefulness/efficacy is less well May be considered

Class III Evidence or general agreement Is not recommended

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

† The remaining uncertainties regarding estimations of the risk of

Table 4 Non-specific prevention measures to be Table 5 Continued

Recommendations Classa Levelb

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

3.3 Situations and procedures at risk

Recommendations Classa Levelb

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

key role in the management and monitoring of these patients.64,65

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Surgery/necropsy Echocardiography 5.3.2 Multislice computed tomography

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

least three sets are taken at 30-min intervals, each containing 10 mL of

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Identification by mass spectrometry

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Microbiological identification Blood PCRa Specific PCRa

Figure 2 Microbiological diagnostic algorithm in culture-positive and culture-negative IE.

5.5 Diagnostic criteria

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Modified Duke criteria (Li)

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Antibiotic Dosage and route Duration Classb Levelc Ref.d Comments

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Table 17 Antibiotic treatment of infective endocarditis due to Staphylococcus spp.

Antibiotic Dosage and route Duration Classi Levelj Ref.k Comments

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Table 18 Antibiotic treatment of infective endocarditis due to Enterococcus spp.

Antibiotic Dosage and route Duration, Classg Levelh Ref.i Comments

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

Pathogens Proposed therapy a Treatment outcome

ID ¼ infectious disease; IE ¼ infective endocarditis; Ig ¼ immunoglobulin; i.v. ¼ intravenous; U ¼ units.

Antibiotic Dosage and route Classb Levelc Comments

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020

amoxicillin/clavulanic acid or ampicillin/sulbactam, 203 and

Suggested regimens for empirical treatment in acute patients Phase of

Downloaded from https://academic.oup.com/eurheartj/article-abstract/36/44/3075/2293384 by guest on 31 July 2020